Document:

EX-10.10

 Exhibit 10.10 

 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

 LICENSE AGREEMENT 

This License Agreement (“Agreement”), made as of January 29, 2018 (“Effective Date”), is by and between
Novartis International Pharmaceutical Ltd., a for-profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland
(“Novartis”) and QED Therapeutics, Inc., a Delaware corporation located at 421 Kipling Street, Palo Alto, CA 94301 USA (“QED”). Novartis and QED are each referred to individually as a “Party” and
together as the “Parties.” 
 Background 

Novartis Controls (as defined below) the Novartis Patents and Know-How (each as defined below)
relating to the Compound (as defined below). BridgeBio (as defined below) has caused QED to be incorporated under the laws of the State of Delaware. QED wishes to obtain, and Novartis wishes to grant, rights under the Novartis Technology (as defined
below) to develop, make, use and sell Products (as defined below) incorporating the Compound. 
 For good and valuable consideration, the
Parties agree as follows: 
  

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 Definitions. Unless the context otherwise requires, the terms in this Agreement with initial letters
capitalized, will have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. 

“Accounting Standards” means, with respect to QED, US GAAP (United States Generally Accepted Accounting Principles) and
means, with respect to Novartis, IFRS (International Financial Reporting Standards), in each case as generally and consistently applied throughout the Party’s organization. Each Party will promptly notify the other Party in the event that it
changes the Accounting Standards pursuant to which its records relating to this Agreement are maintained; provided, however, that each Party may only use internationally recognized accounting principles (e.g., IFRS or US GAAP). 

“Affiliate” means, with respect to a particular entity or Person, any Person that controls, is controlled by, or is under
common control with that Party. For the purpose of this definition, “control” will mean, direct or indirect ownership of 50% or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or
50% or more of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby the entity or Person controls or has the right to control the board of directors or
equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a 

  
 CONFIDENTIAL - 1 

 
corporation or other entity. In the case of entities organized under the laws of certain countries, the maximum percentage ownership permitted by law for a foreign investor may be less than 50%,
and in such case such lower percentage will be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity. For the avoidance of doubt, BridgeBio and QED shall
be deemed to be Affiliates of each other, but any portfolio company in which BridgeBio is an investor shall not be deemed to be an Affiliate of QED. 

“Alliance Manager” will have the meaning set forth in Section 3.1. 

“Ancillary Agreement” has the meaning set forth in Section 2.5. 

“Applicable Law” means any federal, state, local or foreign law (including, common law), statute or ordinance, or any rule,
regulation, judgment, order, writ or decree of or from any court, or other Regulatory Authority having jurisdiction over or related to the subject item that may be in effect from time to time, including GCP, GLP and GMP. 

“Array” has the meaning set forth in Section 2.4(a). 

“Array Combination Therapies” has the meaning set forth in Section 2.4(a). 

“[***]” means the compound described as [***] in Exhibit A-2 to this Agreement,
whether produced by chemical synthesis or otherwise, and [***]. 
 “BridgeBio” means BridgeBio Pharma, LLC, a Delaware
limited liability company with its principal place of business at 421 Kipling St, Palo Alto, CA 94301 USA. 
 “Calendar
Quarter” means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

“Calendar Year” means a period of twelve consecutive calendar months ending on December 31.     

“Claims” means all Third Party demands, claims, actions, proceedings and liability (whether criminal or civil, in contract,
tort or otherwise) for losses, damages, reasonable legal costs, and other reasonable expenses of any nature whatsoever. 
 “Clinical
Site Agreements” means the agreements set forth on Schedule A to the Ancillary Agreement. 
 “CMO” has the meaning
set forth in Section 2.5. 
 “Code” means Title 11 of the U.S. Code. 

“Commercialize” means to market, promote, distribute, import, export, offer to sell and/or sell Product, and
“Commercialization” means commercialization activities relating to Product, including activities relating to marketing, promoting, distributing, importing, exporting, offering for sale and/or selling Product. 

“Commercially Reasonable Efforts” means, with respect to a Party, [***]. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 2 

 “Compound” means the compound described as BGJ398 in Exhibit A-1 to this Agreement, whether produced by chemical synthesis or otherwise, which is owned or Controlled by Novartis or its Affiliates, and any radioisomer, stereoisomer, racemates, solvates, salt forms, bases,
anhydrides, hydrates, polymorphs, ester forms or pro drugs of such compound. 
 “Control” or “Controlled”
means, with respect to any Know-How, Patent Rights, other intellectual property rights, or any proprietary or trade secret information, the legal authority or right (whether by ownership, license or otherwise,
other than by a license granted under this Agreement) of a Party or its Affiliates, to grant a license or a sublicense of or under such Know-How, Patent Rights, or intellectual property rights to another
Person, or to otherwise disclose such proprietary or trade secret information to another Person, without breaching the terms of any agreement with a Third Party or misappropriating the proprietary or trade secret information of a Third Party. 

“Develop” or “Development” means drug development activities, including, without limitation, test method
development and stability testing, assay development and audit development, toxicology, formulation, quality assurance/quality control development, statistical analysis, clinical studies, packaging development, regulatory affairs, and the
preparation, filing and prosecution of INDs, NDAs, and MAAs. 
 “Development Plan” has the meaning set forth in
Section 3.2. 
 “Effective Date” has the meaning in the preamble (i.e., in the first paragraph of this
Agreement). 
 “Encumbrance” means any claim, charge, equitable interest, hypothecation, lien, mortgage, pledge, option,
license, assignment, power of sale, retention of title, right of pre-emption, right of first refusal or security interest of any kind. 

“European Regulatory and Reimbursement Approval” means, with respect to a Product, (a) MAA approval from the
European Commission (i.e., European Union-wide) and pricing and reimbursement approval in three of the Major European Countries, or (b) marketing, pricing, and reimbursement approvals in three of the Major European Countries. 

“FDA” means the United States Food and Drug Administration or any successor entity thereto. 

“Field” means all fields of use. 

“First Commercial Sale” means, with respect to a Product in a particular country, the first arm’s length sale to a Third
Party for value for use or consumption of any such Product following receipt of Regulatory Approval and Pricing Reimbursement Approval (to the extent commercially applicable) of such Product in such country. 

“GCP” means the ethical, scientific, and quality standards required by FDA or European Commission for designing,
conducting, recording, and reporting trials that involve the participation of human subjects, as set forth in FDA regulations in 21 C.F.R. Parts 11, 50, 54, 56, and 312 and related FDA guidance documents, and by the International Conference on
Harmonization E6: Good Clinical Practices Consolidated Guideline (the “ICH Guidelines”), or as otherwise required by Applicable Laws. 

  
 CONFIDENTIAL - 3 

 “Generic Equivalent” means, with respect to a particular Product in a
country, any product that (a) has Regulatory Approval for use in such country pursuant to a regulatory process governing approval of generic, interchangeable, or biosimilar pharmaceutical or biological product based on the then-current
standards for Regulatory Approval in such country, where such Regulatory Approval relied on or incorporated clinical data generated by either Party to this Agreement or their Affiliates or licensees, or was obtained using an abbreviated, expedited,
or other similar process; (b) during the Royalty Term, is not owned or licensed by QED under this Agreement; and (c) is sold in the same country as the relevant Product by a Third Party that is not a sublicensee or
Affiliate of QED, and that did not purchase such product in a chain of distribution that included QED, or its Affiliates or its or their sublicensees. 

“GLP” means good laboratory practice as required by the FDA under 21 C.F.R. part 58 and all applicable FDA rules,
regulations, orders and guidances, and the requirements with respect to current good laboratory practices prescribed by the European Community, the OECD (Organization for Economic Cooperation and Development Council) and the ICH Guidelines, or as
otherwise required by Applicable Laws. 
 “GMP” means good manufacturing practices and regulations as required by the FDA
under provisions of 21 C.F.R. parts 210 and 211 and all applicable FDA rules, regulations, orders and guidances, and the requirements with respect to current good manufacturing practices prescribed by the European Community under provisions of
“The Rules Governing Medicinal Products in the European Community, Volume 4, Good Manufacturing Practices, Annex 13, Manufacture of Investigational Medicinal Products, July 2003,” or as otherwise required by Applicable Laws. 

“Inserm Transfert” means Inserm Transfert SA, a limited company (société anonyme à directoire et
conseil de surveillance) organized under the laws of France, [***]. 
 “IIT” has the meaning set forth in
Section 5.1(d). 
 “IIT Agreements” means the Investigator Initiated Trial Agreements identified on Exhibit F.

 “IND/CTA” means an Investigational New Drug application in the US filed with the FDA or the corresponding application
(e.g., a clinical trial authorisation) for the investigation of Products in any other country or group of countries, as defined in the Applicable Laws and filed with the Regulatory Authority of a given country or group of countries. 

“Indication” means a specific disease, impairment, medical condition, or symptom thereof that is the intended subject of a
Product.    For purposes of the Milestones set forth in Section 8.2, a “Second Indication” shall mean an intended subject of a Product that is a different disease, impairment, medical condition, or symptom
thereof than the subject of the first Indication for a Product and for which a separate NDA/MAA or a supplement (or other addition) to an existing NDA/MAA is required for the purpose of obtaining Regulatory Approval in a country. 

“Information” means all Know-How and other confidential or proprietary information and
data of a financial, commercial or technical nature which the disclosing Party, its Affiliates, or its or their licensors has supplied or otherwise made available to the other Party or its Affiliates, prior to or during the Term, whether made
available orally, in writing or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae in relation to this Agreement. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 4 

 “Insolvency Event” means (a) QED ceases to function as a going
concern by suspending or discontinuing its business; (b) QED is the subject of voluntary or involuntary bankruptcy proceedings instituted on behalf of or against QED (except for involuntary bankruptcy proceedings that are dismissed
within 90 days); (c) an administrative receiver, receiver and manager, interim receiver, custodian, sequestrator, or similar officer is appointed for QED; (d) a resolution to wind up QED is passed at a meeting of the directors or
shareholders of QED; (e) a resolution shall have been passed by QED or QED’s directors to make an application for an administration order or to appoint an administrator for all of QED’s assets; or (f) QED makes any
general assignment for the benefit of all of its creditors. 
 “Invoice” means an invoice in a form reasonably acceptable to
QED and to Novartis. 
 “Know-How” means all proprietary or confidential technical
information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology
applicable to the Compound or Products or to its or their manufacture, Regulatory Approval, Pricing Reimbursement Approval, Development, or Commercialization, or methods of assaying or testing the Compound or Products, compositions incorporating or
comprising the Compound, formulation of any Product, and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data,
instructions, processes, formulae, expertise and information, regulatory filings and copies thereof. 
 “MAA” means an
application for the authorization to market the Product in any country or group of countries outside the United States, as defined in the Applicable Laws and filed with the Regulatory Authority of a given country or group of countries. 

“Major European Countries” means France, Germany, Italy, Spain, and the United Kingdom. 

“Milestones” means the milestones relating to the Product as set forth in Sections 8.2 and 8.3. 

“Milestone Payments” means the payments to be made by QED to Novartis upon the achievement of the corresponding Milestones as
set forth in Sections 8.2 and 8.3. 
 “NDA” means a New Drug Application, as described in the FDA regulations, 21 CFR
Section 314.50, submitted to the FDA. 
 “Net Sales” means [***]. 

“Novartis Know-How” means the Know-How
Controlled by Novartis or any of its Affiliates as of the Effective Date that is identified on Exhibit C. 
 “Novartis
Patents” means the Patent Rights Controlled by Novartis or any of its Affiliates as of the Effective Date that are set forth on Exhibit B-1 and Exhibit B-2. 
 “Novartis Additional Patents” means Patent Rights Controlled by Novartis or
any of its Affiliates after the Effective Date, but during the Term, to the extent that such Patent Rights 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 5 

 
are necessary to make use, sell, offer for sale, or import the Compound or Products in the Field. For this purpose, a Patent Right will be deemed “necessary” if, but for a license to
the relevant Patent Right, QED cannot manufacture, use, sell, offer for sale, or import the Compound or the Products without infringement. For the avoidance of doubt, Novartis Additional Patents do not include Novartis Patents. 

“Novartis Technology” means the Novartis Know-How and Novartis Patents. 

“Patent Rights” means (a) all patent applications, including any provisional patent applications, in any country;
(b) any patent application claiming priority from such patent application or provisional application, including all divisionals, continuations, substitutions,
continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (c) any patent that has issued or in the future issues
from any of the foregoing patent applications, ((a) and (b)), including any utility model, petty patent, design patent and certificate of invention; (d) any re-examinations, reissues, additions,
renewals, extensions, registrations, supplemental protection certificates of any of the foregoing patents or patent applications ((a), (b), and (c)); and (e) any similar rights, including so-called
pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent application or patent. 

“Party” or “Parties” has the meaning set forth in the preamble. 

“Person” means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated
organization or other entity. 
 “Pharmacovigilance Agreement” has the meaning set forth in Section 5.2. 

“Phase III Clinical Trial” means a controlled clinical study of a Product in patients designed to establish efficacy and
safety of such Product for the purpose of preparing and submitting an NDA/MAA or supplement to an MAA/NDA for Regulatory Approval of a Product for use in a clinical indication that satisfies the requirements of 21 C.F.R. § 312.21(c) or its
foreign equivalent. For clarity, a Phase II/III shall not be considered a Phase III unless it satisfies or will satisfy the requirements of 21 C.F.R. § 312.21(c) or its foreign equivalent. 

“Pricing Reimbursement Approval” means the authorization or approval of reimbursement in a country or jurisdiction by the
relevant Regulatory Authority, government agency, or other body responsible for such activities in such jurisdiction(s) under Applicable Law. 

“Prior Confidentiality Agreement” means the [***]. 

“Product” means a therapeutic product incorporating or comprising the Compound, (i) the Development, manufacture,
preparation, use or Commercialization of which would, but for the license granted hereunder, infringe a Valid Claim of the Novartis Patents; and/or (ii) that is Developed using, incorporates, or embodies Novartis Know-How. 
 “Regulatory Approval” means, with respect to a product in any country or
jurisdiction, any approval, registration, license or authorization from a Regulatory Authority in a country or other jurisdiction that is reasonably necessary to market and sell a Product in such country or jurisdiction. 

“Regulatory Authority” means any governmental authority or agency responsible for authorizing or approving the marketing
and/or sale of products in a jurisdiction (e.g., the FDA, European Commission, the Japanese Ministry of Health, Labour and Welfare, and corresponding national or regional regulatory agencies or organizations). 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 6 

 “Regulatory Exclusivity” means with respect to a Product in a country, the
period of time during which (a) a Party or its Affiliate or sublicensee has been granted the exclusive legal right by a Regulatory Authority (or is otherwise entitled to the exclusive legal right by operation of Applicable Law) in such
country to market and sell the Product; or (b) the data and information submitted by a Party or its Affiliate or sublicensee to the relevant Regulatory Authority in such country for purposes of obtaining Regulatory Approval and Pricing
Reimbursement Approval may not be disclosed, referenced, or relied upon in any way by a Third Party or such Regulatory Authority (including by relying upon the Regulatory Authority’s previous findings regarding the safety or effectiveness of
the Product) to support the Regulatory Approval and Pricing Reimbursement Approval or marketing of any product by a Third Party in such country. 

“Regulatory Filings” means, with respect to the Compound or a Product, any submission to a Regulatory Authority of any
appropriate regulatory application, and will include, without limitation, any submission to a regulatory advisory board, marketing authorization application, and any supplement or amendment thereto. For the avoidance of doubt, Regulatory Filings
will include any IND/CTA, NDA, MAA or the corresponding application in any other country or group of countries. 
 “Royalty
Term” means the period commencing on the First Commercial Sale of a Product in a specified country until the latest of (a) the expiration of the last to expire Valid Claim of the Novartis Patents that, but for the licenses
granted in this Agreement, would be infringed by the Development, manufacture, use, importation or other Commercialization of such Product in such country; (b) the expiration of any Regulatory Exclusivity for such Product in such
country; or (c) the ten year anniversary of the First Commercial Sale of the Product in the relevant country. 

“Sales & Royalty Report” means a written report or reports showing each of: (a) the gross
and Net Sales of each Product, on a country-by-country basis, during the reporting period by QED and its Affiliates and sublicensees (in all cases itemizing the various
deductions taken from gross to compute Net Sales as set forth in the definition of Net Sales, above); and (b) the royalties payable, in USD, which will have accrued hereunder with respect to such Net Sales;. 

“Senior Officers” means, for Novartis, the Global Head, Business Development & Licensing of Novartis Institutes for
BioMedical Research, or his or her designee, and for QED, its Chief Executive Officer or his or her designee. 
 “Term” with
reference to this Agreement shall mean the period of time beginning on the Effective Date and ending upon the expiration of the Royalty Term for the last Product with a Royalty Term. 

“Territory” means worldwide. 

“Third Party” means any Person other than a Party or an Affiliate of a Party. 

“United States” or “US” means the United States of America, its territories and possessions. 

  
 CONFIDENTIAL - 7 

 “Valid Claim” means (a) claim of an issued and unexpired patent
included within the Novartis Patents that (i) covers the practice of the relevant Compound or Product in the relevant jurisdiction; (ii) has not been irrevocably or unappealably disclaimed or abandoned, or been held
unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction; and (iii) has not been admitted to be invalid or unenforceable through reissue, disclaimer, or otherwise; or
(b) a claim included in a patent application included within the Novartis Patents that (i) would cover the practices of the relevant Product in the relevant jurisdiction if such claim was to issue; and
(ii) has not been cancelled, withdrawn or abandoned, nor been pending for more than [***] from the earliest filing date to which such patent application or claim is entitled. 

“Vendors” has the meaning set forth in Section 2.5. 

 

	1.2	 Interpretation. In this agreement unless otherwise specified: 

 

	 	(a)	 “includes” and “including” will mean respectively includes and including without
limitation; 

  

	 	(b)	 a Party includes its permitted assignees and/or the respective successors in title to substantially the
whole of its undertaking; 

  

	 	(c)	 a statute or statutory instrument or any of their provisions is to be construed as a reference to that
statute or statutory instrument or such provision as the same may have been or may from time to time hereafter be amended or re-enacted; 

 

	 	(d)	 words denoting the singular will include the plural and vice versa and words denoting any gender will
include all genders; 

  

	 	(e)	 the Exhibits and other attachments form part of the operative provision of this Agreement and references
to this Agreement shall, unless the context otherwise requires, include references to the Exhibits and attachments; 

  

	 	(f)	 the headings in this Agreement are for information only and will not be considered in the interpretation
of this Agreement; 

  

	 	(g)	 general words will not be given a restrictive interpretation by reason of their being preceded or
followed by words indicating a particular class of acts, matters or things; 

  

	 	(h)	 references to “days” will mean calendar days unless otherwise indicated; and

  

	 	(i)	 the terms and conditions of this Agreement are the result of negotiations between the Parties and that
this Agreement will not be construed in favor of or against any Party by reason of the extent to which any Party participated in the preparation of this Agreement. 

 

	2.	 LICENSE; SUBLICENSES; GRANT BACKS 

 

	2.1	 License Grant. 

 

	 	(a)	 Subject to the terms and conditions of this Agreement, Novartis hereby grants to QED a sub-licensable (pursuant to Section 2.2) license, under Novartis’ and its 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 8 

	 	
Affiliates’ interest in the Novartis Technology, to research, Develop, make, have made, use, import, offer for sale, sell, have sold and otherwise Commercialize the Compound and Products in
the Field in the Territory; provided, however, that for the avoidance of doubt, this license does not include the right to Develop or Commercialize the compound referred to as [***], and Novartis will retain all such rights with respect to
[***]. 

  

	 	(b)	 Subject to the retained supply right and contingent reversionary right set forth in Section 2.4,
the license set forth in Section 2.1(a) shall be exclusive (even as to Novartis and its Affiliates) to QED with respect to the Development and Commercialization of the Compound and the Product, it being understood that Novartis and its
Affiliates will retain the right (with no ability to sublicense such right) to continue to make and use Compound solely in connection with its and their internal research (but not Development or Commercialization) activities. 

 

	 	(c)	 Subject to the terms and conditions of this Agreement, effective upon QED’s written request,
Novartis hereby grants to QED a sub-licensable (pursuant to Section 2.2) non-exclusive license, under Novartis’ and its Affiliates’ interest in the
Novartis Additional Patents, to research, Develop, make, have made, use, import, offer for sale, sell, have sold and otherwise Commercialize the Compound or Products; [***]. To the extent that any such license would require any payment to a Third
Party as a result of QED’s, its Affiliates’, or their sublicensees’ practice of the Novartis Additional Patents (e.g., with respect to Novartis Additional Patents that have been licensed by Novartis or its Affiliates from a
Third Party), Novartis will inform QED of any financial or other applicable restrictions, limitations, and obligations arising from the practice of the relevant Novartis Additional Patents. The grant described in this Section 2.1(c) is
conditioned on (i) the assumption and continued prompt payment of obligations to such Third Party licensors (to the extent the such obligations arise from QED’s, its Affiliates’, or their sublicensees’ practice of the
Novartis Additional Patents with respect to the Compound or Products); and (ii) compliance with any applicable restrictions, limitations, and obligations included in the relevant license agreement between Novartis (or its Affiliates, as
applicable) and the relevant Third Party licensors. 

  

	 	(d)	 The Parties acknowledge that Novartis’ Affiliate, Novartis Pharma AG, has rights and an option to
patent rights, know-how, data, findings, results and any other intellectual property rights concerning the Compound that are generated by or on behalf [***] pursuant to that certain Materials Transfer
Agreement by and between [***]. Novartis hereby acknowledges and agrees that that any and all rights that Novartis or its Affiliates have in and to any Discoveries (as defined in the [***]) are licensed to QED as part of the Novartis Technology
hereunder and such Patent Rights covering such Discoveries will be deemed to be listed in Exhibit B-1. Within thirty (30) days of the Effective Date, QED and Novartis Pharma AG will execute an
agreement by and among QED, Novartis Pharma AG and [***] confirming such rights, including confirmation that [***]. 

  

	2.2	 Sublicense Rights. QED may sublicense (through multiple tiers) the rights granted to it by Novartis
under this Agreement at any time at its sole discretion, but subject to the applicable terms of this Agreement. QED may exercise its rights and perform its rights and obligations under this Agreement itself or through any of its Affiliates. In
addition, QED 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 9 

	 	
may subcontract to Third Parties the performance of any Development or Commercialization of the Compounds or Products as it deems appropriate. QED shall provide Novartis with a copy of any
sublicense agreement it enters into with a Third Party with respect to the Novartis Technology or Novartis Additional Patents, as applicable, [***], provided that such copy may be subject to redaction as QED reasonably believes appropriate to
protect confidential business information, including financial provisions and other sensitive information as applicable. Each such sublicense agreement shall be considered confidential Information of QED and subject to Article 10 of this Agreement
and the Ancillary Agreement. Each sublicense of the Novartis Technology or Novartis Additional Patents, as applicable, shall be consistent with the terms and conditions of this Agreement. Upon the termination of this Agreement, at the written
request of any sublicensee who is not then in breach of its sublicense agreement, Novartis agrees to enter into a direct license agreement with such sublicensee under the same terms and conditions of this agreement (except for Section 8.1),
effective upon the date that notice of such written request. QED will remain liable for the acts and omissions of its sublicensees and Affiliates as if such sublicensees and Affiliates were QED hereunder. Further, QED will use Commercially
Reasonable Efforts to include in each such sublicense a requirement that upon any termination of such sublicense agreement, such sublicensee will grant rights to QED (or directly to Novartis) that are substantially similar to the rights granted by
QED to Novartis under Sections 12.2(b), to the extent applicable. 

  

	2.3	 Non-Assertion. During the Term of this Agreement (and with
respect to a sublicensee, during the term of its sublicense surviving pursuant to Section 2.2), Novartis covenants that it and its Affiliates (a) will not assert rights to the Novartis Technology or any Patent Rights covering [***]
against QED, its Affiliates, (sub)licensees, or any of their respective distributors, resellers or customers; (b) will not otherwise participate in any such action or proceeding against QED, its Affiliates and (sub)licensees, or any of
their respective distributors, resellers or customers; and (c) will not support or encourage any Third Party to sue for infringement or misappropriation of any Patent Rights covering [***], in each case ((a), (b), and (c)), [***].
Novartis will cause its (sub)licensees to be bound by the terms of this Section 2.3. 

  

	2.4	 Obligations to [***]. 

 

	 	(a)	 The Parties acknowledge that Novartis has certain obligations to manufacture and supply Compound to a
Third Party, [***], and notwithstanding the provisions this Article II, (i) Novartis, its Affiliates, and their agents will retain the right to manufacture and supply Compound to [***] and to otherwise [***]; and (ii) [***], and
nothing in this Agreement will restrict or conflict with Novartis’ obligations with respect to such matters. 

  

	 	(b)	 The Parties also acknowledge that [***] under certain specified circumstances. Accordingly, from time to
time during the Term, Novartis may request QED and/or its sublicensees to inform Novartis if QED and/or its sublicensees intends to seek Regulatory Approval for and Commercialize and pursue Commercialization of the Compound for various Indications,
including to the extent that such indications are the subject of [***], and QED and/or its sublicensees shall, within [***] after receipt of Novartis’ inquiry, inform Novartis whether it intends to seek such Regulatory Approval for and
Commercialize and pursue Commercialization of the Compound for such Indication and provide its anticipated plan for such activities; provided,  

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 10 

	 	
however, that if QED and/or its sublicensees notifies Novartis of its intent to seek Regulatory Approval and Commercialize and pursue Commercialization of the Compound and/or Product for
such Indication, but thereafter makes a determination not to Commercialize such Compound and/or Product for such Indication, then prior to ceasing to pursue the Development of the Compound it will provide at least [***] prior notice to Novartis of
such determination. If QED and/or its sublicensees does not intend to seek Regulatory Approval for and Commercialize and pursue Commercialization of the Compound for the relevant Indication, does not provide to Novartis a plan that Novartis
determines is a commercially reasonable plan for such activity within such [***] period, Novartis determines in its sole discretion that QED has failed to sufficiently pursue such plan (including pursuing Regulatory Approval and Commercializing the
Compound and/or Product for such Indication), or thereafter makes a determination not to Commercialize or pursue Commercialization for such Compound and/or Product for such Indication, then notwithstanding any provision of this Agreement to the
contrary, [***]. 

  

	2.5	 Authorization; Ancillary Agreement. 

 

	 	(a)	 Within [***] of the Effective Date, Novartis will provide a notice of authorization to Third Party
contract manufacturing organizations (“CMOs”) and Third Party vendors, including contract research organizations (“Vendors”) selected by QED, which will authorize such CMOs and Vendors to conduct work on the
Compound with QED under separate agreements to be negotiated between QED and such CMOs and Vendors. 

  

	 	(b)	 Within [***] of the Effective Date, the Parties will execute an ancillary agreement regarding the
transfer of the Clinical Site Agreements and Investigator Initiated Trial Agreements to the extent relating to the Compound or the Products (the “Ancillary Agreement”). If, after the effective date of the Ancillary Agreement, the
Parties, through their Alliance Managers, mutually agree that additional related agreements should be transferred to QED and obligations of cooperation relating to [***], the Parties shall amend the Ancillary Agreement to include such additional
agreements. 

  

	3.	 GOVERNANCE 

  

	3.1	 Alliance Managers. Within [***] after the Effective Date, each Party will appoint (and notify the other
Party of the identity of) a senior representative having a general understanding of pharmaceutical development and commercialization issues to act as its alliance manager under this Agreement (“Alliance Manager”). The Alliance
Managers will (a) serve as the contact point between the Parties for the purpose of providing Novartis with information on the progress of QED’s Development and Commercialization of Products; (b) be primarily responsible
for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties, including in particular the transfer of information and Know-How from
Novartis to QED; (c) provide a single point of communication for seeking consensus both internally within the respective Party’s organization and facilitating review of external corporate communications; and (d) raise
cross-Party and/or cross-functional disputes in a timely manner. Each Party may replace its Alliance Manager on written notice to the other Party. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 11 

	3.2	 Development Information. Within [***] after the Effective Date, QED will provide Novartis with a high
level summary development plan setting forth the anticipated Development activities to be conducted by QED and its Affiliates and sublicensees related to the Compound and Products during the following 18 month period (the “Development
Plan”). No later than [***] after each anniversary of the Effective Date, until the approval of the first NDA or MAA for a Product, QED will provide Novartis an updated Development Plan providing, in reasonable detail, the Development
activities conducted by QED and its Affiliates and sublicensees related to the Compound and Products during the immediately preceding year and its anticipated plans for Development of the Compound and Products for next 18 month period. In addition
to this annual report, QED will provide to Novartis a high level summary of all Development activities that QED, its agents, or their sublicensees have conducted in the prior six month period until the approval of the first NDA or MAA for a Product.
QED may revise the Development Plan or any update thereto in its sole discretion, subject to satisfaction of its obligations under Section 5.2. All such reports shall include sufficient detail to permit Novartis to determine QED’s
compliance with its obligations set forth in Section 5.2. 

  

	3.3	 Meetings. During the period from the Effective Date until the first NDA or MAA filing for a Product, the
Alliance Managers will meet (either in person or by teleconference) at least twice per year, to review and discuss progress made under, and any changes to, the Development, Plan, including the Development work performed, clinical trials, Milestones,
any key issues and the overall status of Development. 

  

	4.	 DISCLOSURE OF LICENSOR KNOW-HOW & COOPERATION

  

	4.1	 Technology Transfer. Novartis shall provide to QED, on or before [***] following the Effective Date,
with a copy (in electronic format if available, or a hard copy if not available in electronic format) of the documentation as listed in Exhibit C. For clarity, any other documentation, to the extent such documentation is related to the
Compound and/or any drug substance or drug product manufactured therefrom, including the BGJ398 Material, for use in the Field owned or Controlled by Novartis or its Affiliates in its global databases and archives will be transferred by Novartis or
its Affiliates upon QED’s request, but only to the extent that such information and data would be accessible by Novartis using Commercially Reasonable Efforts. In addition, any additional information that is maintained by Novartis on a
country-level may be transferred by Novartis or its Affiliates to the extent such effort is commercially reasonable for Novartis upon QED’s written request and [***] as soon as reasonably possible. Any request for transfer of local data
must be submitted not later than six months after the Effective Date. Notwithstanding the forgoing, if the Alliance Managers both agree that the provision of additional documentation or information is necessary or reasonable useful after such six-month period, Novartis will transfer or make accessible to QED such additional documentation and information. 

  

	4.2	 Know-How Transfer Assistance. For [***] after the Effective Date
of this Agreement and upon QED’s reasonable request, Novartis shall use Commercially Reasonable Efforts to answer questions and provide clarifications to QED related to the Know-How to be transferred to
QED pursuant to Section 4.1. Such assistance will be provided [***] to QED for (a) one (1) weekly hour-long transition meeting for each function set forth on Exhibit C, including clinical operations, regulatory operations,
data, quality and any other required function, for the first two (2) months following the Effective Date, and bi-weekly (i.e., every other week) calls for each such function thereafter, in
both cases (clauses (a) and (b)) 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 12 

	 	
not to exceed a total of [***] hours; (b) one (1) transition meeting for each active clinical site (in the form of a co-monitoring visit or
remote monitoring visit), and (c) a total of three visits by QED to Novartis’ Basel and/or East Hanover facility. With respect to any additional assistance (in excess of the amounts set forth in clauses (a), (b), and (c)) that is
requested by QED, (i) the relevant activities must be agreed upon by the Parties in a written task order describing the scope of the agreed upon activities; and (ii) Novartis will charge QED at the rate of [***] for such
services. For clarity, except as set forth herein and as otherwise agreed to by the Parties, all assistance pursuant to this Section 4.2 will be provided remotely (e.g., e-mail, telephone or video
conferences) and shall not require travel by Novartis personnel 

  

	4.3	 Database Transfer. Notwithstanding anything in this Agreement to the contrary, the Parties acknowledge
that the transfer by Novartis of data from its relevant databases will include data residing in such databases, but not any database architecture. QED shall be solely responsible for establishing appropriate database structures for receipt of the
relevant data, which it shall complete not later than [***] after QED’s receipt of the trial master file for the Compound. With respect to any clinical trial for the Compound that is ongoing as of the Effective Date, until the transfer by
Novartis of data from its relevant databases is complete, Novartis will use reasonable efforts to provide QED with access to information in Novartis’ relevant databases for such clinical trial, related documentation, data validation tools and
SAS datasets. The Alliance Managers shall mutually agree on the appropriate scope of such access and shall coordinate QED’s access thereof. 

  

	5.	 DEVELOPMENT AND REGULATORY; PHARMACOVIGILENCE 

 

	5.1	 Transfer of Sponsorship of INDs; Array. 

 

	 	(a)	 Except as otherwise noted in Exhibit F and as set forth in Section 5.1(c) of this Agreement,
within [***] after the later of (i) the execution of the Pharmacovigilance Agreement; or (ii) the completion of clinical data transfer (which, for clarity, will not include the Novartis’ safety database architecture)
(the “Transfer Deadline”), Novartis and its Affiliates shall assign and transfer to QED the sponsorship of Regulatory Filings identified in Exhibit F (the “Transferred IND/CTAs”). 

 

	 	(b)	 Upon the transfer described in Section 5.1(a), Novartis shall file with relevant Regulatory
Authorities a notification that the sponsorship of the Transferred IND/CTAs are being transferred from Novartis to QED. QED will submit to the relevant Regulatory Authorities a notification that it is assuming the sponsorship of the Transferred
IND/CTAs. These notifications shall be filed simultaneously by the Parties unless otherwise required by local Applicable Law. Thereafter, QED shall be responsible for all future communications with the relevant Regulatory Authorities regarding the
Transferred IND/CTAs and any and all subsequent Regulatory Filings relating to the Compound under those Transferred IND/CTAs. If, at any time after the Transferred IND/CTAs are transferred to QED, a Regulatory Authority requests information, data,
or documentation Controlled by Novartis or its Affiliates, Novartis will provide such information, data, or documentation, to the extent that such information, data and documentation is accessible by Novartis using Commercially Reasonable Efforts,
and shall reasonably cooperate with QED with respect to responding to requests from Regulatory Authorities. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 13 

	 	(c)	 Notwithstanding the foregoing, (i) it is understood that QED is in the process of
identifying appropriate CROs to manage the (ex-US) CTAs, and that transfer of the ex-US CTAs might take place in a staggered fashion, on a country by country basis;
(ii) QED will use Commercially Reasonable Efforts to assume sponsorship of the (ex-US) CTAs on or before the “Transfer Deadline” as defined in Section 5.1(a); and
(iii) QED hereby grants to Novartis all the necessary rights to remain the sponsor of such trials, including the right to take any action in consultation with QED that might be necessary to comply with its regulatory and legal
obligations as sponsor of such CTAs, solely until QED is able to assume the sponsorship of such CTAs. 

  

	 	(d)	 The Parties also acknowledge that Novartis has certain obligations regarding clinical studies for the
[***]. In order to allow for Novartis to comply with these contractual obligations, without limiting any additional obligations under the Ancillary Agreement: 

 

	 	(i)	 QED will, simultaneous with the filings described in Section 5.1(b) by which QED will assume the
sponsorship of [***]; and 

  

	 	(ii)	 [***]. 

  

	 	(e)	 In order to allow for continuation of on-going clinical
investigations sponsored by other institutions and/or investigators which were previously authorized by Novartis (“IITs”), simultaneously with the filings described in Section 5.1(b) by which QED will assume the sponsorship for
[***], QED will provide the sponsors of such IITs with a written authorization to cross-reference the data contained in such IND/CTA, in part or in its totality (as necessary) for the purpose of allowing the continuation of those studies. As of the
date of transfer of [***] and for as long as such investigations are not terminated by the respective sponsors, QED will (A) promptly provide any future updated version of the BGJ398 investigator brochure to those IIT sponsors;
(B) respond to requests and questions received by those IIT sponsors from any Regulatory Authority in any country which requires BGJ398 information transferred to and in the possession of QED, in a timeframe commensurate with the
preparation and timely submission of responses; (C) promptly and directly inform those IIT sponsors upon becoming aware of any material issue that might warrant disclosure to Regulatory Authorities, including but not limited to
safety measures, aggregate safety findings or quality defects (if applicable); and (D) inform the IIT sponsors of any change in quality aspects of the drug substance or drug product utilized in the clinical supplies provided by QED to
such sponsors, should this be the case. QED will also provide those Sponsors with any necessary CMC documentation in QED’s Control that might be required to allow for continuation of the clinical investigations, as per Applicable Law.

  

	5.2	 Adverse Event Reporting and Safety Data Exchange. QED and Novartis shall cooperate with regard to the
reporting and handling of safety information involving or relating to the Compound and/or the Products at least to the extent required by Applicable Laws. Subject to the Ancillary Agreement, in time to ensure that all regulatory requirements are
met, and at least to the extent required by Applicable Laws or any Regulatory Authority, QED will enter into written agreements containing customary terms that will govern the exchange of adverse event and other safety information reporting
obligations relating to the Compound 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 14 

	 	
or the Products (the “Pharmacovigilance Agreement(s)”) with Novartis and its Affiliates, and where requested by Novartis [***], to ensure that adverse events and other safety
information is exchanged and reported to the relevant Regulatory Authorities in compliance with the Applicable Laws and requirements of Regulatory Authorities in the Territory. The Pharmacovigilance Agreement to be entered into with Novartis or its
Affiliates, will govern the exchange of adverse event and other safety information until completion of the transfer of Regulatory Filings, transfer of sponsorship or Novartis completion of the clinical trials/programs, transfer of or completion of
Novartis supported IIT agreements in accordance with Exhibit F, whichever is later, [***]. Additionally, without limiting the foregoing, the Novartis Alliance Manager shall promptly inform QED if at any time during the Term, any of the
following occur: (a) Novartis terminates its development program for [***] for safety reasons, (b) Novartis receives notice from any Regulatory Authority of a clinical hold on the development program for [***], or
(c) a data safety monitor board terminates a clinical trial for [***]. 

  

	5.3	 Obligation to Develop and Obtain Regulatory Approval. Subject to the obligations set forth in this
Agreement, following the date of transfer of the INDs, QED will be solely responsible for all regulatory matters arising in connection with the Development of the Compound and Product(s) at its own cost and expense. QED will itself, or through its
Affiliates or sublicensees, use Commercially Reasonable Efforts to Develop the Compound and Product(s) in the Field and shall use Commercially Reasonable Efforts to obtain Regulatory Approval (and, if applicable, Pricing Reimbursement Approval) for
at least one Product in the United States and the European Union. 

  

	6.	 MATERIAL TRANSFER; MANUFACTURING. 

 

	6.1	 Transfer of BGJ398. Within [***] after the written request of QED (or as may be otherwise set forth in
Exhibit D), but in no event earlier than the later of (i) the execution of the Pharmacovigilance Agreement; or (ii) the completion of database transfer, and subject to the reservation described in
Section 6.4, Novartis will make available for pick-up (ex works, Incoterms 2010) the material identified on Exhibit D (the “BGJ398 Material”), in the form as currently exists, from
Novartis’ facilities where BGJ398 Material is currently stored, at no additional cost to QED. The pick-up of the BGJ398 Material must be completed within [***] after the date that Novartis notifies such
BGJ398 Material is available for pick up. Any BGJ398 Material not picked up by the end of that [***] period may be disposed of by Novartis in its sole discretion. 

 

	6.2	 Description of Material. BGJ398 Material is divided into three categories: reference samples, non-GMP technical batches, and previously released GMP clinical batches (see Exhibit D). Novartis represents and warrants that released clinical study BGJ398 Material (and not the non-GMP technical batches or reference samples) was manufactured in accordance with Applicable Laws (including GMP) where the relevant study was to be conducted at the time of release and QED shall be provided with
documentation signed by an authorized representative of Novartis, certifying that such BGJ398 Material was manufactured in accordance with its specifications and all Applicable Law, including GMP; no such representation or warranty is given with
respect to the Applicable Law of any other country or jurisdiction or to any changes to Applicable Law following the release date. Except as provided above, the BGJ398 Material is provided “as is” and “where is”, and without
representation or warranty of any kind. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 15 

	6.3	 Documentation and Transfer Process. In connection with the transfer of the BGJ398 Material as described
in Section 6.1, the following shall apply: 

  

	 	(a)	 Novartis will share with QED any MSDSs and customs value information that is readily available to
Novartis (and not otherwise available to QED), in particular Compound-specific information, as is reasonably necessary to permit QED to pick up the BGJ398 Material; 

 

	 	(b)	 QED will be solely responsible for any re-testing associated
with the BGJ398 Material prior to use; 

  

	 	(c)	 with respect to the released clinical study BGJ398 Material, Novartis will provide the certificate of
analysis associated with its release; 

  

	 	(d)	 QED will be responsible for all documentation, licenses, customs clearance, costs, etc. that are
needed for and related to the pick-up, transport, and subsequent delivery of the BGJ398 Material to the first destination as designated by QED; 

 

	 	(e)	 the BGJ398 Material will be picked up in not more than one installment; 

 

	 	(f)	 the BGJ398 Material made available by Novartis will only be used according to its specifications,
especially release specifications, and in accordance with Applicable Laws, and Novartis will have no further obligation with respect to the BGJ398 Material, except with respect to providing any documentation relating to the BGJ398 pursuant to
Section 4.1 and as otherwise set forth in this Section 6.3; 

  

	 	(g)	 prior to the BGJ398 Material being made available by Novartis, Novartis will provide QED with copies of
any GMP certificates issued by Regulatory Authorities for the Novartis manufacturing facilities used for manufacturing the BGJ398 Material; and 

  

	 	(h)	 Novartis shall promptly notify QED of any notice received by a Regulatory Authority regarding regulatory
actions of Novartis manufacturing facilities used for manufacturing the BGJ398 Material, where such action is related to the BGJ398 Material. Novartis shall provide QED with copies of specific correspondence relating to such regulatory action
pertaining to BGJ398 and shall cooperate with the applicable Regulatory Authority, including by providing any requested documentation related to the BGJ398 Material directly to such Regulatory Authority. 

 

	6.4	 Drug Product Supply; Reservation for Novartis Obligations. Within [***] after the Effective Date,
the Parties will agree upon a transfer plan for the transfer of Compound drug product inventory controlled or owned by Novartis or its Affiliates as of the Effective Date and the stability programs related to the Compound conducted by or on
behalf of Novartis or its Affiliates as of the Effective Date, in each case, as identified on Exhibit D. This transfer plan shall take into account Novartis’ obligations to manufacture and supply Compound to Array as described in
Section 2.4 and reserve a reasonable portion of the material described in Exhibit D to satisfy such obligations. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 16 

	6.5	 Manufacturing. Subject to Novartis’ obligations set forth in Section 4, QED will be solely
responsible for and shall, subject to the terms of this Agreement, have final decision-making authority with respect to the manufacturing of the Compound or the Products in the Field in the Territory, at its sole cost and expense.

  

	7.	 COMMERCIALIZATION 

 

	7.1	 Commercialization. Unless the contingent reversionary rights set forth in Section 2.4(b) are
invoked, QED will be solely responsible for all aspects of Commercialization of the Products, including planning and implementation, distribution, booking of sales, pricing, and reimbursement. QED will itself, or through its Affiliates or
sublicensees, use Commercially Reasonable Efforts to Commercialize at least one Product in the United States and the European Union. Notwithstanding the foregoing, QED’s application of Commercially Reasonable Efforts will not require QED to
Commercialize a Product in any particular country or territory if QED reasonably determines that it is not commercially reasonable to do so for such Product. Subject to compliance with the foregoing, the Commercialization of the Product will be in
QED’s sole discretion. 

  

	8.	 FINANCIAL PROVISIONS 

 

	8.1	 Upfront and Equity in QED. In consideration of the licenses and rights granted to QED hereunder,

  

	 	(a)	 QED will make a one-time payment to Novartis in the amount of USD
$15,000,000 via wire transfer within 15 days after the Effective Date; an 

  

	 	(b)	 Novartis will be granted a number of shares of Series A Preferred Stock of QED upon the initial closing
of QED’s issuance and sale of Series A Preferred Stock, representing a fully-diluted (i.e., the total number of shares that would be outstanding if all possible sources of conversion, such as convertible debt, preferred stock, and stock
options (taking into account unallocated shares reserved for issuance under an equity incentive plan), are exercised or converted into common stock) ownership percentage of [***] of QED immediately following the funding of the initial tranche of
preferred stock financing of QED from BridgeBio, which shall be in the amount of [***]. The shares issued to Novartis will be subject to the terms and conditions of the documents attached as Exhibits E-1
and E-2. 

  

	8.2	 Milestone Payments. 

 

	 	(a)	 In further consideration of the licenses and rights granted to QED hereunder, upon achievement of each
of the following Milestones set forth below for a Product by QED, its Affiliates, or its sublicensees (as applicable), the corresponding Milestone Payments will be payable to Novartis: 

 

					
	 Milestone
	  	Milestone Payment
(in US Dollars)	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 17 

	 	(b)	 Each Milestone Payment will be deemed earned as of the first achievement of the corresponding Milestone,
and will be paid within [***] after the relevant Milestone is achieved. QED will provide Novartis with written notice of the achievement of each Milestone within 15 days after such Milestone is determined to have been achieved.

  

	 	(c)	 Each Milestone in the table above will be paid only once. The total potential Milestone Payments that
may be paid under this Section 8.2 is $60,000,000. For the avoidance of doubt, no additional Milestone Payments will be due for Milestones completed for the Development and Commercialization of Products that were previously achieved by a
different Product for the same Indication, or for any Product intended to treat any additional Indications (by the same Product) (after the first two indications). 

 

	8.3	 Sales Milestones. 

 

	 	(a)	 QED will make each of the following one time payments when worldwide Annual Net Sales of all Products in
a given Calendar Year by it, its Affiliates, or their sublicensees first meet the corresponding thresholds: 

  

					
	
Aggregate Net Sales of Products in any Calendar 
Year
during the Royalty Term (in US Dollars)
	  	Sales Milestone
Payment
(in US Dollars)	 
	 Annual Net Sales equal to or greater than [***]
	  	 	[***	] 
	 Annual Net Sales equal to or greater than [***]
	  	 	[***	] 
	 Annual Net Sales equal to or greater than [***]
	  	 	[***	] 

  

	 	(b)	 For example, if Annual Net Sales of Products in the first Calendar Year of Net Sales equals [***], then
both the first and second Sales Milestone Payments will be made in that year. 

  

	 	(c)	 Each Milestone Payment in the table above will be paid only once. The total potential Milestone Payments
that may be paid under this Section 8.3 is $35,000,000. 

  

	 	(d)	 Each Milestone Payment will be deemed earned as of the first achievement of the corresponding sales
milestone, and will be paid within [***] after the relevant sales milestone is achieved. QED will provide Novartis with written notice of the achievement of each Milestone within 15 days after such sales milestone is determined to have been
achieved. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 18 

	8.4	 Royalty Payments. 

 

	 	(a)	 In consideration of the licenses and rights granted to QED hereunder, during the Royalty Term, QED will
make royalty payments to Novartis on Net Sales of Products by QED, its Affiliates and sublicensees, at the rates set forth below: 

  

					
	
Aggregate Net Sales of Product in any Calendar 
Year
during the Royalty Term (in US Dollars)
	  	Royalty Rate	 
	 Portion of Net Sales less than or equal to [***]
	  	 	[***	] 
	 Portion of Net Sales greater than [***] up to [***]
	  	 	[***	] 
	 Portion of Net Sales greater than [***] up to [***]
	  	 	[***	] 
	 Portion of Net Sales greater than [***]
	  	 	[***	] 

  

	 	(b)	 For example, if Net Sales in a Calendar Year are [***], the royalty on such Net Sales will be equal to
[***] (computed as follows: [***]). 

  

	 	(c)	 Royalties will be payable on a
Product-by-Product and country-by-country basis during the Royalty Term for such Product
in such country. Following the expiration of the applicable Royalty Term for a Product in a country, QED licenses under this Agreement with respect to such Product in such country will continue in effect, but will become fully paid-up, royalty-free, transferable, perpetual and irrevocable. For the avoidance of doubt, royalties will be payable only once with respect to the same unit of Product. 

 

	 	(d)	 Within 30 days after each Calendar Quarter during the term of this Agreement following the First
Commercial Sale of a Product, QED will provide to Novartis a Sales & Royalty Report. Novartis will submit an Invoice to QED with respect to the royalty amount shown therein. QED will pay such royalty amount within 30 days after receipt of
the Invoice. 

  

	 	(e)	 Notwithstanding anything to the contrary herein, in the event that, with respect to a Product in a
specified country, if (i) the Royalty Term for such Product in such country continues solely due to clause (b) or clause (c) of the definition of Royalty Term (i.e., there is no Valid Claim of a Patent Right
included in the Novartis Technology covering the Product), or (ii) a Generic Equivalent exists with respect to such Product in the Field in such country in a Calendar Year, then the royalty rates in such country for such Product
will thereafter be reduced to [***] of the amounts set forth in the table above, in the case of clause (ii), solely for as long as such Generic Equivalent continues to be marketed in the relevant country. 

 

	8.5	 Third Party Obligations; Set Off. 

 

	 	(a)	 If QED reasonably determines that, in order to avoid infringement or misappropriation of any Patent Right or Know-How not licensed hereunder that covers the composition of matter or method of use of a Compound or that is reasonably necessary for the research, Development, manufacture, preparation, use or Commercialization
of the Compound or Products, to the extent that QED or any of its Affiliates or sublicensees acquires or licenses rights under a Third Party’s Patent Rights or Know-How, and is required to pay a royalty
or other payments to such Third Party (including in connection with the settlement of a 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 19 

	 	
patent infringement claim), QED will have the right to deduct [***] of the licensing payments actually paid by QED to such Third Party under such license from the royalty due to Novartis under
Section 8.4. 

  

	 	(b)	 In no event will any royalty payment due to Novartis from QED be reduced by more than [***] any Calendar
Quarter through operation of Section 8.4(e) or Section 8.5(a). Any amount that QED is entitled to deduct that is reduced by this limitation will be carried forward and QED may deduct such amount from royalty payments due to Novartis until
the full amount that QED was entitled to deduct is deducted. 

  

	8.6	 Payments. 

  

	 	(a)	 All payments from QED to Novartis will be made by wire transfer in US Dollars to the credit of such bank
account as may be designated by Novartis in this Agreement or in writing to QED. Any payment which falls due on a date which is not a business day in the location from which the payment may be made on the next succeeding business day in such
location. 

  

	 	(b)	 All payments under this Agreement will be payable in US Dollars. When conversion of payments from any
foreign currency is required to be undertaken by QED, the US Dollar equivalent will be calculated using QED’s then-current standard exchange rate methodology as applied in its external reporting. If there is no standard exchange rate
methodology applied by QED in its external reporting in accordance with Accounting Standards, then any amount in a currency other than US Dollars shall be converted to US Dollars using the exchange rate most recently quoted in the Wall Street
Journal in New York as of the last business day of the applicable Calendar Quarter. 

  

	 	(c)	 [***] will pay any and all taxes levied on account of any payments made to it under this Agreement. If
any taxes are required to be withheld by [***], [***] will: (i) deduct such taxes from the payment made to [***]; (ii) timely pay the taxes to the proper taxing authority; (iii) send proof of payment to [***]; and
(iv) reasonably assist [***] in its efforts to obtain a credit for such tax payment. Each Party will reasonably assist the other Party in lawfully claiming exemptions from and/or minimizing such deductions or withholdings under double
taxation laws or similar circumstances. 

  

	 	(d)	 Without limiting any other rights or remedies available to Novartis hereunder, if QED does not pay any
amount due on or before the due date, any such payment shall bear interest at a rate of four percentage points above the six months LIBOR for US Dollars on the date the payment was due or the highest rate permitted by law (whichever is lower),
computed from the date such payment was due until the date QED makes the payment. 

  

	8.7	 Records and Audit Rights. 

 

	 	(a)	 QED will keep, and will cause its Affiliates and sublicensees to keep, complete, true and accurate books
and records in accordance with its Accounting Standards in relation to Net Sales and royalties payable to Novartis hereunder. QED will keep, and will cause its Affiliates and sublicensees to keep, such books and records for at least three years
following the Calendar Quarter to which they pertain. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 20 

	 	(b)	 Novartis may, upon written notice to QED, appoint an internationally-recognized independent accounting
firm (which is reasonably acceptable to QED) (the “Auditor”) to inspect the relevant reports, statements, records or books of accounts (as applicable) of QED or its Affiliates or sublicensees to verify the accuracy of any
Sales & Royalty Report. Before beginning its audit, the Auditor will execute an undertaking reasonably acceptable to QED by which the Auditor will keep confidential all Information reviewed during such audit. The Auditor will have the right
to disclose to Novartis its conclusions regarding any payment owed under this Agreement. 

  

	 	(c)	 QED will, and will cause its Affiliates and sublicensees to make their records available for inspection
by such Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from Novartis. The records will be reviewed solely to verify the accuracy of the
Sales & Royalty Reports. Such inspection right will not be exercised more than once in any Calendar Year and not more frequently than once with respect to records covering any specific period of time. In addition, Novartis will
only be entitled to audit the relevant books and records of QED relating to a Sales & Royalty Report for a period of three Calendar Years after receipt of the applicable Sales & Royalty Report. Novartis will hold in confidence
all Information received and all Information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or if disclosure is required by law, regulation or judicial order.

  

	 	(d)	 The Auditor will provide its audit report and basis for any determination to QED at the time such report
is provided to Novartis, before it is considered final. QED will have the right to request a further determination by such Auditor as to matters which QED disputes within [***] following receipt of such report. QED will provide Novartis and the
Auditor with a reasonably detailed statement of the grounds upon which it disputes any findings in the audit report and the Auditor will undertake to complete such further determination within [***] after the dispute notice is provided, which
determination will be limited to the disputed matters. Any matter that remains unresolved will be resolved in accordance with the dispute resolution procedures contained in Section 15.5. 

 

	 	(e)	 In the event that the final result of the inspection reveals an undisputed underpayment or overpayment
by QED, the underpaid or overpaid amount will be settled promptly. 

  

	 	(f)	 [***] will pay for any such audits, as well as its own expenses associated with enforcing its rights
with respect to any payments hereunder, except that in the event there is any upward adjustment in aggregate amounts payable for any Calendar Quarter shown by such audit of [***]. 

 

	8.8	 No Projections. Novartis and QED acknowledge that nothing in this Agreement will be construed as
representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 21 

	 	
that have otherwise been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Novartis in the event such Milestones or Net Sales levels are
achieved. QED MAKES NO REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.

  

	9.	 INTELLECTUAL PROPERTY. 

 

	9.1	 Inventions and Know-How. All inventions, whether or not reduced
to practice, and know-how arising from QED’s activities under this Agreement, including any Patent Rights covering such inventions that arise after the Effective Date, will be owned by QED.

  

	9.2	 Ownership of Results and Data. All data and results arising from QED’s activities under this
Agreement, including but not limited to Development, clinical and regulatory data and Information generated for regulatory purposes relating to a Product will be owned by QED. 

 

	9.3	 Patent Prosecution. QED will have the right to control Prosecution and Maintenance of the Novartis
Patents on Exhibit B-1 at QED’s expense. Novartis will have the initial right to control Prosecution and Maintenance of the Novartis Patents on Exhibit
B-2 and Novartis Additional Patents at Novartis’ expense, using counsel reasonably acceptable to QED. Novartis will keep QED informed of important issues relating to the Prosecution and Maintenance of
the Novartis Patents on Exhibit B-2, and will furnish to QED copies of documents relevant to such Prosecution and Maintenance in sufficient time, but no later than 14 days, prior to the filing of such
document to allow for review and comment by QED and Novartis will reasonably consider all of such comments. Novartis will notify QED of any decision not to continue to pay the expenses of Prosecution and Maintenance of any Novartis Patent on
Exhibit B-2 or any Novartis Additional Patent that has been identified in writing by QED pursuant to Section 2.1(c) (or to otherwise abandon their prosecution or maintenance), which notice must be
delivered at least 60 days prior to any payment due date or the relevant action’s due date. In such event, QED, at its sole discretion and expense, shall have the right to continue Prosecution and Maintenance of such Novartis Patent on
Exhibit B-2 or such Novartis Additional Patents (as applicable) in such country. If QED undertakes such Prosecution and Maintenance, (a) Novartis will provide QED all reasonable assistance
and cooperation in relation thereto, including providing any necessary powers of attorney and any other required documents or instruments; and (b) with respect to Novartis Additional Patents, such Patent Rights shall be thereafter be
deemed to be Novartis Patents and deemed to be included in Exhibit B-1. 

  

	9.4	 Third Party Infringement. 

 

	 	(a)	 Each Party will promptly notify the other of any infringement in the Field by a Third Party of any of
the Novartis Patents or misappropriation of any Novartis Know-How in the Field of which it becomes aware, including any filing of an Abbreviated New Drug Application in the United States or such similar filing
under Applicable Law in jurisdictions other than the United States. Each Party shall provide the other Party with all available evidence supporting such infringement, suspected infringement, unauthorized use or misappropriation or suspected
unauthorized use or misappropriation (collectively, “Third Party Infringement”). 

  
 CONFIDENTIAL - 22 

	 	(b)	 QED will have the first right to bring and control any legal action in connection with the Third Party
Infringement relating to any Novartis Patent set forth on Exhibit B-1 in the Field at its own expense as it reasonably determines appropriate, and Novartis will have the right, at its own expense, to be
represented in any such action by counsel of its own choice. If QED fails to bring an action or proceeding with respect to, or to terminate, infringement of any Novartis Patent set forth on Exhibit B-1
(i) within [***] following the notice of alleged infringement (or [***] after QED receives the relevant ANDA notification), or (ii) prior to [***] before the time limit, if any, set forth in the appropriate laws and regulations
for the filing of such actions, whichever comes first, Novartis will have the right to bring and control any such action at its own expense and by counsel of its own choice, and QED will have the right, at its own expense, to be represented in any
such action by counsel of its own choice; provided, however, that if QED notifies Novartis in writing prior to [***] before such time limit for the filing of any such action that QED intends to file such action before the time limit, then QED
will be obligated to file such action before the time limit, and Novartis will not have the right to bring and control such action. Novartis will have the first right to bring and control any legal action in connection with the Third Party
Infringement relating to any Novartis Patent set forth on Exhibit B-2 in the Field at its own expense as it reasonably determines appropriate, and QED will have the right, at its own expense, to be
represented in any such action by counsel of its own choice. If Novartis fails to bring an action or proceeding with respect to, or to terminate, infringement of any Novartis Patent set forth on Exhibit
B-2 (i) within [***] following the notice of alleged infringement (or [***] after Novartis receives the relevant ANDA notification), or (ii) prior to [***] before the time
limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, QED will have the right to bring and control any such action at its own expense and by counsel of its own choice, and Novartis
will have the right, at its own expense, to be represented in any such action by counsel of its own choice; provided, however, that if Novartis notifies QED in writing prior to [***] before such time limit for the filing of any such action
that Novartis intends to file such action before the time limit, then Novartis will be obligated to file such action before the time limit, and QED will not have the right to bring and control such action. 

 

	 	(c)	 At the request of the Party controlling the Third Party Infringement claim, the other Party will provide
assistance in connection therewith, including by executing reasonably appropriate documents, access to such Party’s premises and employees, cooperating reasonably in discovery and joining as a party to the action if required.

  

	 	(d)	 In connection with any such proceeding, neither Party will enter into any settlement admitting the
invalidity of, or otherwise impairing such Party’s rights in, the Novartis Technology without the prior written consent of the other Party, which will not be unreasonably withheld or delayed. 

 

	 	(e)	 Any recoveries resulting from such an action relating to a Third Party Infringement will be first
applied against payment of each Party’s costs and expenses in connection therewith. In the event that QED brought such action, any remainder will be retained by QED; provided, however, any such amount

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 23 

	 	
will be considered Net Sales hereunder and will be subject to a royalties and sales milestones (as applicable) to Novartis under this Agreement. In the event that Novartis brought such action,
the remainder will be retained by Novartis. 

  

	9.5	 Third Party Patent Invalidity Claim. If a Third Party at any time asserts a claim that any Novartis
Patent on Exhibit B-1 is invalid or otherwise unenforceable (an “Invalidity Claim”), whether as a defense in an infringement action brought by a Party pursuant to Section 9.4, in a
declaratory judgment action or any patent office proceeding anywhere in the world (e.g., inter-partes review or European opposition) relating to the Field, QED shall have the first right, but not the obligation, to defend such Invalidity
Claim and Novartis shall cooperate with QED in preparing and formulating a response to such Invalidity Claim. If QED does not defend an Invalidity Claim brought against a Novartis Patent on Exhibit B-1,
Novartis may defend such Invalidity Claim and the coordination provisions of Section 9.4(c) will apply to such Invalidity Claim, mutatis mutandis as they apply to Third Party Infringement suits. If a Third Party at any time asserts an
Invalidity Claim against any on Exhibit B-2, whether as a defense in an infringement action brought by a Party pursuant to Section 9.4, in a declaratory judgment action or any patent office
proceeding anywhere in the world (e.g., inter-partes review or European opposition) relating to the Field, Novartis shall have the first right, but not the obligation, to defend such Invalidity Claim and QED shall cooperate with Novartis in
preparing and formulating a response to such Invalidity Claim. If Novartis does not defend an Invalidity Claim brought against a Novartis Patent on Exhibit B-2, QED may defend such Invalidity Claim and
the coordination provisions of Section 9.4(c) will apply to such Invalidity Claim, mutatis mutandis as they apply to Third Party Infringement suits. No Party may, without the consent of each other Party, settle or compromise any
Invalidity Claim in any manner which would (a) have an adverse effect on such other Party’s rights or obligations hereunder or (b) be an admission of liability on behalf of the other Party (provided,
however, that the Party initiating such suit may settle such suit without such consent if such settlement involves only the receipt of money from, or the payment of money to, such Third Party and the Party settling such suit makes all such
payments to such Third Party). To the extent such Invalidity Claim is raised as a defense in an infringement action brought by a Party pursuant to Section 9.4, the expense provisions of Section 9.4 will apply and counsel to the Party
controlling the infringement action shall act as the ministerial liaison with the court. 

  

	9.6	 QED Patent Invalidity Claim. The Parties have determined the value of the Novartis Technology based on
their understanding of the validity and enforceability of the relevant Patent Rights and Know-How. If QED at any time asserts an Invalidity Claim in a declaratory judgment action or any patent office
proceeding anywhere in the world and such challenge does not result in a material diminution of the scope of the relevant Novartis Patent, then the terms of this Agreement shall continue in full force and effect, [***]. 

 

	9.7	 Defense of Infringement Claims of Licensed IP. If any Third Party asserts a claim, demand, action, suit
or proceeding against a Party (or any of its Affiliates), alleging that any Product or the use or practice of the Novartis Technology infringes, misappropriates or violates the intellectual property rights of any Person (any such claim, demand,
action, suit or proceeding being referred to as an “Infringement Claim”), the Party first having notice of the Infringement Claim shall promptly notify the other Party thereof in writing specifying the facts, to the extent known, in
reasonable detail and the following shall apply: 

  

	 	(a)	 in the case of any such Infringement Claim against either Party individually or against both Novartis
and QED, in each case, with respect to the Product in the 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 24 

	 	
Field in the Territory, QED shall assume control of the defense of such Infringement Claim. Novartis, upon request of QED and if required by Applicable Law, agrees to join in any such litigation
QED’s expense, and in any event to reasonably cooperate with QED at QED’s expense. Novartis will have the right to consult with QED concerning such Infringement Claim and to participate in and be represented by independent counsel in any
litigation in which QED is a party, at its own expense. QED shall not have the right to settle any Infringement Claim without the written consent of Novartis; and 

 

	 	(b)	 during the period in which such Infringement Claim is pending and following the resolution thereof, QED
shall bear all costs incurred in connection therewith (including litigation costs, attorneys fees, costs of settlement) including damage awards, and any other payment resulting therefrom. If QED is required to obtain a license from any unaffiliated
third party or parties under any patent or other intellectual property right of such third party or parties, QED shall further be solely responsible for any costs, fees, royalties, damages or other payments associated with such license.

  

	9.8	 Trademarks. QED will have the right to brand the Products using QED related trademarks and any other
trademarks and trade names it determines appropriate for the Products, which may vary by country or within a country (“Product Marks”). QED will own all rights in the Product Marks and register and maintain the Product Marks in the
countries and regions it determines reasonably necessary. 

  

	9.9	 Patent Extensions. 

 

	 	(a)	 If requested by QED, Novartis will cooperate in obtaining patent term restoration (under but not limited
to the Drug Price Competition and Patent Term Restoration Act), supplemental protection certificates or their equivalents, and patent term extensions with respect to the Novartis Patents on Exhibit B-1
in any country and/or region where applicable. Novartis will provide all reasonable assistance requested by QED, including permitting QED to proceed with applications for such in the name of Novartis, if deemed appropriate by QED, and executing
documents and providing any relevant information to QED. 

  

	 	(b)	 As between the Parties, QED will in its sole discretion determine which, if any, Novartis Patents on
Exhibit B-1, it will apply to extend; provided, however, that QED will give Novartis [***] notice before doing so and reasonably consider any input from Novartis with respect to the
extension of any Novartis Patents. 

  

	10.	 CONFIDENTIALITY 

 

	10.1	 Duty of Confidence. 

 

	 	(a)	 Subject to the other provisions of this Section 10, all Information disclosed by a Party or its
Affiliates under this Agreement will be maintained in confidence and otherwise safeguarded by the recipient Party. The recipient Party may only use the Information for the purposes of this Agreement and pursuant to the rights granted to the
recipient Party under this Agreement. Subject to the other provisions of this Section 10, each Party will hold as confidential such Information of the other Party or its Affiliates in the same manner and with the

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 25 

	 	
same protection as such recipient Party maintains its own confidential information. Subject to the other provisions of this Section 10, a recipient Party may only disclose Information of the
other Party to employees, agents, contractors, consultants and advisers of the Party and its Affiliates and sublicensees and to Third Parties to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this
Agreement; provided that such Persons are bound to maintain the confidentiality of the Information in a manner consistent with the confidentiality provisions of this Agreement. 

 

	 	(b)	 With respect to Novartis’ obligations under this Section 10, all Novartis Know-How, to the extent relating to the Compound and Products in the Field, will be considered Information of QED during the Term of the Agreement and Novartis will maintain in confidence and otherwise safeguard
such Novartis Know-How as such in accordance with this Section 10 (it being understood that the exception in Section 10.2(b) will not apply to Novartis with respect to Novartis Know-How). 

  

	10.2	 Exceptions. The obligations under this Section 10 will not apply to any information to the extent
the recipient Party can demonstrate by competent evidence that such information: 

  

	 	(a)	 is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of
the public domain through no breach of this Agreement by the recipient Party or its Affiliates; 

  

	 	(b)	 was known to, or was otherwise in the possession of, the recipient Party or its Affiliates prior to the
time of disclosure by the disclosing Party or any of its Affiliates; 

  

	 	(c)	 is disclosed to the recipient Party or an Affiliate on a
non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the disclosing Party or any of its Affiliates; or 

 

	 	(d)	 is independently developed by or on behalf of the recipient Party or its Affiliates, as evidenced by its
written records, without reference to the Information disclosed by the disclosing Party or its Affiliates under this Agreement. 

Specific aspects or details of Information will not be deemed to be within the public domain or in the possession of the recipient Party merely
because the Information is embraced by more general information in the public domain or in the possession of the recipient Party. Further, any combination of Information will not be considered in the public domain or in the possession of the
recipient Party merely because individual elements of such Information are in the public domain or in the possession of the recipient Party unless the combination and its principles are in the public domain or in the possession of the recipient
Party. 
  

	10.3	 Authorized Disclosures. 

 

	 	(a)	 On or following the Effective Date, QED shall issue the press release set forth on Exhibit G.
Neither Party shall issue any other press release, trade announcement or make any other public announcement or statement with regard 

  
 CONFIDENTIAL - 26 

	 	
to the transactions contemplated by this Agreement without the other Parties’ prior written consent; provided, however, that information previously disclosed in the press release set
forth on Exhibit G may be further disclosed without restriction. Where consent is forthcoming, the Parties will consult with each other regarding the content of any such press release or other announcement. The aforementioned restriction
shall not apply to announcements required by any Regulatory Authority, security exchanges as required by applicable; provided that in such event the Parties shall coordinate the wording and QED shall take into consideration any requests of
Novartis. 

  

	 	(b)	 In addition to disclosures allowed under Section 10.1 and 10.2, either Party may disclose
Information belonging to the other Party or its Affiliates to the extent such disclosure is necessary in the following instances: (i) filing or prosecuting Patent Rights as permitted by this Agreement; (ii) in connection with
Regulatory Filings for Products; (iii) prosecuting or defending litigation as permitted by this Agreement; (iv) complying with applicable court orders, governmental regulations, or the inquiries of Regulatory
Authorities; (v) in connection with an offering of securities or securities law disclosure requirements if counsel determines that such disclosure is required; or (vi) to the extent otherwise necessary or appropriate in
connection with exercising the license and other rights granted to it hereunder. 

  

	 	(c)	 In addition, QED and its Affiliates and sublicensees may disclose Information of Novartis to Third
Parties as may be necessary or useful in connection with the Development, manufacture or Commercialization of the Compound and/or Product(s) as permitted by this Agreement, including in connection with subcontracting transactions.

  

	 	(d)	 In addition, either Party may disclose the terms of this Agreement and Information pertaining to
Products in connection with an assignment or potential assignment of this Agreement, a loan, financing or investment transaction, or an acquisition, merger, consolidation or similar transaction (or for such Persons to determine their interest in
performing such activities or entering into such transactions), in each case on the condition that any Third Parties to whom such disclosures are made agree to be bound by confidentiality and non-use
obligations no less rigorous than those contained in this Agreement (but which obligations may be of shorter duration for Third Parties). 

  

	 	(e)	 In the event the recipient Party is required to disclose Information of the disclosing Party by law or
in connection with bona fide legal process, such disclosure will not be a breach of this Agreement; provided that the recipient Party (i) informs the disclosing Party as soon as reasonably practicable of the required
disclosure; (ii) limits the disclosure to the required purpose; and (iii) at the disclosing Party’s request and expense, assists in an attempt to object to or limit the required disclosure or to otherwise receive
“confidential” or “trade secret” treatment with respect to relevant portions of such disclosure. 

  

	10.4	 Ongoing Obligation for Confidentiality. Upon early termination of this Agreement for any reason, each
Party and its Affiliates will immediately return to the other Party or destroy any Information disclosed by the other Party, except for one copy which may be retained in its confidential files for archive purposes. 

  
 CONFIDENTIAL - 27 

	11.	 TERM AND TERMINATION 

 

	11.1	 Term. The term of this Agreement will commence upon the Effective Date and continue on a Product-by-Product and country-by-country basis until the expiry of the Royalty Term for such
Product in such country, unless earlier terminated as permitted by this Agreement. 

  

	11.2	 Termination for Cause. If either Novartis or QED is in material breach of any material obligation
hereunder, the non-breaching Party may give written notice to the breaching Party specifying the claimed particulars of such breach, and in the event such material breach is not cured within [***] after such
notice, the non-breaching Party will have the right (but not the obligation) thereafter to terminate this Agreement immediately by giving written notice to the breaching Party to such effect; provided,
however, that if such breach is capable of being cured but cannot be cured within such [***] period and the breaching Party initiates actions to cure such breach within such period and thereafter diligently pursues such actions, the breaching
Party will have an additional [***] (or such longer period agreed upon by the Parties) to cure such breach. Any termination by any Party under this Section and the effects of termination provided herein will be without prejudice to any damages or
other legal or equitable remedies to which it may be entitled. 

  

	11.3	 Insolvency. If an Insolvency Event occurs, (a) QED will give immediate (not longer than
three business days’) notice to Novartis of such occurrence, and (b) Novartis will have the right to immediately terminate this Agreement by written notice to QED.  

 

	11.4	 Termination by QED Without Cause. QED may terminate this Agreement without cause at any time after the
Effective Date in its entirety or on a Product-by-Product or country-by-country basis at
any time on [***] prior written notice. 

  

	11.5	 Rights in Bankruptcy. The Parties acknowledge that this Agreement constitutes an executory contract
under Section 365 of the Code for the license of “intellectual property” as defined under Section 101 of the Code and constitutes a license of “intellectual property” for purposes of any similar laws in any other
country. The Parties further acknowledge that QED, as licensee of such rights under this Agreement, will retain and may fully exercise all of its protections, rights and elections under the Code, including, but not limited to, Section 365(n) of
the Code, and any similar laws in any other country. In the event of the commencement of a bankruptcy proceeding by or against Novartis under the Code and any similar laws in any other country, QED will be entitled to a complete duplicate of (or
complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it (a) upon any such commencement of a
bankruptcy proceeding upon its written request therefor, unless Novartis elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above, following the rejection of this Agreement
by or on behalf of Novartis upon written request therefor by QED. All rights, powers and remedies of QED provided for in this Section 11.5 are in addition to and not in substitution for any and all other rights, powers and remedies now or
hereafter existing at law or in equity (including, without limitation, under the Code and any similar laws in any other country). 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 28 

	12.	 EFFECT OF TERMINATION 

 

	12.1	 Termination by QED for Cause. Upon termination of this Agreement by QED pursuant to Section 11.2:

  

	 	(a)	 the licenses and other rights granted by Novartis to QED under the Novartis Technology will terminate
and QED shall not have any rights to use or exercise any rights under the Novartis Technology; and 

  

	 	(b)	 except as set forth in this Section and in Section 12.3, the rights and obligations of the Parties
hereunder will terminate as of the date of such termination. 

  

	12.2	 Termination by Novartis for Cause or by QED Without Cause. Upon termination of this Agreement by
Novartis pursuant to Section 11.2 or Section 11.3 or by QED pursuant to Section 11.4: 

  

	 	(a)	 all licenses and other rights granted by Novartis to QED under the Novartis Technology will terminate
and QED shall not have any rights to use or exercise any rights under the Novartis Technology; 

  

	 	(b)	 at Novartis’ written request, which must be delivered to QED not later than 60 days after receipt
of QED’s or Novartis’ (as applicable) notice of termination, the following provisions shall apply: 

  

	 	(i)	 within [***] after receipt of such notice, QED will provide to Novartis a fair and accurate summary
report of the status of the Development, manufacture and Commercialization of the Compound and Products in the Field in each country through the effective date of termination; 

 

	 	(ii)	 QED will grant, and hereby does grant (effective on delivery of the notice), and will cause its
Affiliates to, and subject to Section 2.2, its sublicensees to, grant to Novartis and its Affiliates, solely for the Development, manufacture and Commercialization of Products in the Field, a perpetual, irrevocable, exclusive, worldwide, fully paid-up license (subject to the remainder of this Section 12.2(b)(ii)), with the right to grant sublicenses, under all Patent Rights and Know-How Controlled by QED and
its Affiliates and sublicensees (subject to Section 2.2) as of the effective date of termination, that are specifically related to, and actually used and applied as of the date of such termination in the Development, manufacture and
Commercialization of Products in the Field, to Develop, manufacture and Commercialize Products in the Field; provided that with respect to any Patent Rights and Know-How that is Controlled by QED and its
Affiliates and sublicensees (subject to Section 2.2) pursuant to an agreement with a Third Party, Novartis will pay all amounts due under any such agreement as a result of Novartis’ exercise of the rights granted thereunder;

  

	 	(iii)	 to the extent permitted by Applicable Law, QED will, and will cause its Affiliates to, and subject to
Section 2.2, its sublicensees to, promptly transfer to Novartis or its designee, solely for the Development, manufacture and Commercialization of Products in the Field, all right, title, and interest in and to all preclinical and clinical data,
and all other supporting data, including 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 29 

	 	
pharmacology, toxicology, chemistry and biology data, and documented technical and other information or materials Controlled by QED and its Affiliates and sublicensees (subject to
Section 2.2) to the extent related solely to the Development, manufacture and Commercialization of Products in the Field; provided that QED may retain a single copy of such items for its records as required by Applicable Law;

  

	 	(iv)	 to the extent permitted by Applicable Law, QED will, and will cause its Affiliates to, and subject to
Section 2.2, its sublicensees to, promptly transfer to Novartis or its designee all Regulatory Filings, Regulatory Approvals and Pricing Reimbursement Approvals, the contents of any global safety database, records of all interactions with
Regulatory Authorities, in each case to the extent related solely to Products in the Field, that QED and its Affiliates and sublicensees (subject to Section 2.2) Control as of the effective date of such termination; provided, however,
that if QED is restricted under Applicable Law from transferring ownership of any of the foregoing items to Novartis or its designee, QED will grant, and hereby does grant, to Novartis (or its designee) a right of reference or use to such item. QED
will take all permitted actions reasonably necessary to effect such transfer or grant of right of reference or use to Novartis or its designee; 

  

	 	(v)	 to the extent reasonably requested by Novartis, QED will use Commercially Reasonable Efforts to transfer
to Novartis any license agreements or other contracts between QED or any of its Affiliates and any Third Party that are solely related to the Products in the Field (including, as applicable, clinical trial and manufacturing agreements), to the
extent such agreements are in effect as of the effective date of termination and such assignment or transfer is permitted at no cost or expense to QED, and to facilitate introductions of Novartis to the applicable subcontractors, licensors,
manufacturing vendors, clinical trial sites, clinical trial investigators and the like; 

  

	 	(vi)	 Novartis will have the right to purchase from QED all of the inventory of the Products held by QED and
its Affiliates as of the effective date of termination at a price equal to QED’s actual manufacturing cost, determined in accordance with Accounting Standards, but only if such Products meet the applicable release specifications;

  

	 	(vii)	 for a period of six months following the delivery of such notice, QED will provide such assistance as
may be reasonably necessary to transfer manufacturing documents and materials that are Controlled by QED and its Affiliates (or their subcontractor(s)) and actually used and applied as of the date of such termination in the manufacture of Products,
and cooperate with Novartis in reasonable respects to transfer to Novartis, or Novartis’ designated contract manufacturer, the manufacturing technologies (including all relevant Know-How) that are used in
the manufacture of the Products. Novartis shall reimburse QED for such assistance at QED’s standard rates; 

  

	 	(viii)	 Novartis will thereafter indemnify, defend and hold QED and the QED Indemnitees harmless in the manner
forth in Section 14.2(a) as if Novartis were QED and the QED Indemnitees were the Novartis Indemnitees, mutatis mutandis for all claims arising after the effective date of such termination, and QED’s indemnification
obligations under that Section 14.2(a) shall thereupon cease for claims arising after the effective date of such termination; and 

  
 CONFIDENTIAL - 30 

	 	(ix)	 if Novartis exercises the right provided in this Section 12.2(b), Novartis will pay to QED, in
consideration of the rights granted to Novartis, an amount to be negotiated by the Parties, taking into account the relative contribution of the Parties to the Development of the Product and the Product’s potential commercial value given its
state of development; provided, however, that if the Parties cannot agree upon the financial terms within three months after the date of Novartis’ notice, (I) the Parties will refer the matter to arbitration before a mutually
acceptable independent arbitrator, who shall be experienced in the pharmaceutical business; (II) each Party will submit its final proposed terms to the other Party at least 30 days prior to submission to the independent
arbitrator; (III) the independent arbitrator will select between the two sets of terms (i.e., the independent arbitrator will select the more suitable set of terms submitted by the Parties, and will not propose a third set of
terms), and shall render his or her opinion within 30 days after the final arbitration hearing; and (IV) the decision of the arbitrator shall be final and binding on the Parties, and shall not be subject to the dispute resolution
provisions set forth in Section 15.5; and 

  

	 	(c)	 except as set forth in this Section and in Section 12.3, the rights and obligations of the Parties
hereunder will terminate as of the date of such termination; 

  

	12.3	 Survival. Expiration or termination of this Agreement will not relieve the Parties of any obligation
accruing prior to such expiration or termination. Without limiting the foregoing, the provisions of Article 1, 2.2, 8.7 (for the time period specified therein), 9.1, 9.2, 10, 11, 12, 14, and 15 will survive expiration or termination of this
Agreement. The provisions of Article 10 (Confidentiality) will survive the termination or expiration of this Agreement for a period of ten years. 

  

	12.4	 Termination Not Sole Remedy. Termination is not the sole remedy under this Agreement and, whether or not
termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein. For the avoidance of doubt, nothing in this Agreement shall obligate a
Party to terminate this Agreement in the event that the other Party breaches any obligation of this Agreement, and failure to terminate this Agreement shall not prohibit or modify the recovery of damages pursuant to Section 15.5.

  

	13.	 REPRESENTATIONS, WARRANTIES AND COVENANTS 

 

	13.1	 Representations and Warranties by Each Party. Each Party represents and warrants to the other as of the
Effective Date that: 

  

	 	(a)	 it is a corporation duly organized, validly existing, and in good standing under the laws of its
jurisdiction of formation; 

  

	 	(b)	 it has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken
all corporate action required by law and its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement; 

  
 CONFIDENTIAL - 31 

	 	(c)	 this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its
terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles and public
policy constraints (including those pertaining to limitations and/or exclusions of liability, competition laws, penalties and jurisdictional issues including conflicts of laws); 

 

	 	(d)	 all consents, approvals and authorizations from all governmental authorities or other Third Parties
required to be obtained by such Party in connection with this Agreement have been obtained; 

  

	 	(e)	 the execution and delivery of this Agreement and all other instruments and documents required to be
executed pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not and will not (i) conflict with or result in a breach of any provision of its organizational documents;
(ii) result in a breach of any agreement to which it is a party; or (iii) violate any law; and 

  

	 	(f)	 neither such Party nor, to the actual knowledge of such Party, any employee, agent or subcontractor of
such Party involved or to be involved in the Development or manufacture of the Compound or the Products has been debarred under Subsection (a) or (b) of Section 306 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 335a).

  

	13.2	 Representations and Warranties by QED. QED represents and warrants to Novartis as of the Effective Date
that the fair market value of the exclusive pharmaceutical patent license granted pursuant to Section 2.1 of this Agreement is less than [***] as determined in accordance with the requirements of 16 C.F.R. s. 801.10(c)(3).

  

	13.3	 Covenants by QED. QED covenants that: 

 

	 	(a)	 no Person who is known by QED (a) to have been debarred under Subsection (a) or (b) of
Section 306 of said Act, or (b) to be on any of the FDA clinical investigator enforcement lists will be employed by or on behalf of QED or its Affiliates or otherwise participate in the performance of any activities hereunder;

  

	 	(b)	 QED will maintain, general liability insurance with limits not less than those reasonably suited to
address claims that could reasonably arise from the Development and Commercialization of pharmaceutical products (and in any event with combined limits of not less than [***] per occurrence and [***] per accident for bodily injury, including death,
and property damage). At Novartis’ written request, QED will provide Novartis with evidence of QED’s insurance. QED will name Novartis as an additional insured party under such insurance policy, and will provide to Novartis at least 30
days prior written notice of any change or cancellation to QED’s insurance program; and 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 32 

	 	(c)	 QED will conduct its Development, manufacturing, and Commercialization activities relating to the
Compound and/or Product(s) in accordance with Applicable Law (including data privacy laws, current international regulatory standards, including, as applicable, GMP, GLP, GCP, and other rules, regulations and requirements), and will cause any
collaborators and sublicensees to comply with such Applicable Laws. 

  

	13.4	 Representations and Warranties by Novartis. Novartis represents and warrants to QED as of the Effective
Date that: 

  

	 	(a)	 Exhibit B sets forth a true, complete and correct list of all Patent Rights Controlled by
Novartis or its Affiliates as of the Effective Date that claim the Compound or the Products, or use, formulations or manufacture thereof in the Field, or are necessary for the research, Development, manufacture, preparation, use or Commercialization
of the Compound or Products; 

  

	 	(b)	 Exhibit C sets forth a true, complete and correct list of all
Know-How Controlled by Novartis or its Affiliates as of the Effective Date that relates to the Compound or the Products, or use, formulations or manufacture thereof in the Field, or is necessary for the
research, Development, manufacture, preparation, use or Commercialization of the Compound or Products; 

  

	 	(c)	 Novartis is the sole and exclusive owner, or exclusive licensee of all of the rights, title and interest
in and to all Novartis Technology free from Encumbrances (other than [***]) that would interfere with QED’s rights under this Agreement; 

  

	 	(d)	 Exhibit F sets forth a true, complete, and correct list of all Regulatory Filings (including
Transferred INDs) Controlled by Novartis or its Affiliates relating to the Compound or Products. 

  

	 	(e)	 Novartis has the right to grant to QED the licenses under the Novartis Technology that it purports to
grant hereunder; 

  

	 	(f)	 Novartis has the right to use and disclose and to enable QED to use and disclose (in each case under
appropriate conditions of confidentiality) the Novartis Know-How free from encumbrances; 

  

	 	(g)	 Novartis has filed and prosecuted patent applications within the Novartis Patents in good faith and
complied with all duties of disclosure with respect thereto; 

  

	 	(h)	 Novartis has not granted to any Third Party, including any academic organization or agency, any license,
option or other rights to research, Develop, manufacture, use or Commercialize the Compound or the Products in the Field other than [***]; 

  

	 	(i)	 No Third Party has any license, option or other rights or interest in or to the Novartis Technology
other than [***]; 

  

	 	(j)	 Novartis has not received, nor is aware, of any claims or allegations (including threatened interference
actions or oppositions) alleging that the (1) research, Development, registration, manufacture, use or Commercialization of the 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 33 

	 	
Compound or Products infringes the Patent Rights or misappropriates the know-how of any Third Party, (2) that a Third Party has any right or
interest in or to the Novartis Technology, or (3) that any of the Novartis Patents are invalid or unenforceable; 

  

	 	(k)	 To the knowledge of the Novartis associates responsible for such matters, there are no facts that could
form the basis for the invalidation or unenforceability of the Novartis Patents; 

  

	 	(l)	 Novartis has not initiated or been involved in any proceedings or Claims in which it alleges that any
Third Party is or was infringing or misappropriating any Novartis Technology relating the Compound or the Products; 

  

	 	(m)	 To Novartis’ knowledge, there are no activities by Third Parties that would constitute infringement
or misappropriation of the Novartis Technology (in the case of pending claims, evaluating them as if issued); 

  

	 	(n)	 the knowledge of the Novartis associates responsible for such matters, Novartis has taken precautions,
consistent with its usual business practice, to preserve the confidentiality of the Novartis Know-How; 

  

	 	(o)	 Novartis has not entered into a government funding relationship that would result in rights to the
Compound, Products or any Novartis Patents or Novartis Additional Patents” residing in the US Government, National Institutes of Health, National Institute for Drug Abuse or other agency, and the licenses granted hereunder are not subject to
overriding obligations to the US Government as set forth in 35 USC §§ 200 to 204, as amended, or any similar obligations under the laws of any other country; and 

 

	 	(p)	 Novartis has not entered into any agreement with any Third Party that is in conflict with the rights
granted to QED under this Agreement, and has not taken any action that would in any way prevent it from granting the rights granted to QED under this Agreement, or that would otherwise materially conflict with or adversely affect the rights granted
to QED under this Agreement. 

  

	13.5	 Covenants of Novartis. Novartis covenants that: 

 

	 	(a)	 it will not grant any interest in the Novartis Technology that is inconsistent with the terms and
conditions of this Agreement; 

  

	 	(b)	 it shall not enter into any agreement with any Third Party that is in conflict with the rights granted
to QED under this Agreement, and shall not take any action that would in any way prevent it from granting the rights granted to QED under this Agreement, or that would otherwise materially conflict with or adversely affect the rights granted to
Licensee under this Agreement; 

  

	 	(c)	 if, at any time after execution of this Agreement, it becomes aware that it or any employee, agent or
subcontractor of Novartis who participated in the Development or manufacture of a Compound or Product is on, or is being added to the FDA Debarment List or to any of the FDA clinical investigator enforcement lists ,will it will provide written
notice of this to QED within five days of its becoming aware of this fact; and 

  
 CONFIDENTIAL - 34 

	 	(d)	 The BGJ398 Materials provided to QED hereunder have been manufactured in accordance with Applicable Law,
including GMP at the time and in the location of manufacture, and will not have been produced in violation of any applicable provision of the United States Fair Labor Standards Act, as amended. 

 

	13.6	 No Other Warranties. Except as expressly provided in this Article 13, (and, with respect to the BGJ398
Material, except as expressly provided in Section 6.2), the Novartis Technology is licensed hereunder “as is”. Nothing in this Agreement shall be construed as a representation made or warranty given by Novartis that it will be
successful in prosecuting any Novartis Patents or Novartis Additional Patents, that any patents will issue based on pending applications or that any such pending applications or patents issued thereon will be valid. EXCEPT AS EXPRESSLY STATED IN
THIS SECTION 13, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF NOVARTIS OR NOVARTIS; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY
OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 

 

	14.	 INDEMNIFICATION; LIABILITY 

 

	14.1	 Indemnification by Novartis. Novartis will indemnify and hold QED, its Affiliates, and their respective
officers, directors and employees (“QED Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 

 

	 	(a)	 the breach of any of the obligations, covenants, warranties or representations made by Novartis to QED
under this Agreement; 

  

	 	(b)	 the infringement or misappropriation of any Third Party’s intellectual property rights by
Novartis’ research and Development activities with respect to the Compound or Products; 

  

	 	(c)	 any activities conducted by Novartis or its Affiliates or licensees with respect to the Compound or
Products on or prior to the Effective Date; 

  

	 	(d)	 the research, development, manufacture, sale, commercialization or other exploitation of the metabolite
of the Compound [***], or any product incorporating or comprising the metabolite; by Novartis, any of its Affiliates or licensees or sublicensees; or 

  

	 	(e)	 the research, development, manufacture, sale, commercialization or other exploitation of the Compound or
any Product by [***]; 

 provided, however, that Novartis will not be obliged to so indemnify, defend and hold
harmless the QED Indemnitees for any Claims for which QED has an obligation to indemnify Novartis Indemnitees pursuant to Section 14.2 or to the extent that such Claims arise from the breach, negligence or willful misconduct of QED or the QED
Indemnitees. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 35 

	14.2	 Indemnification by QED. QED will indemnify and hold Novartis, its Affiliates, and their respective
officers, directors and employees (“Novartis Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 

 

	 	(a)	 actions by QED, its Affiliates and sublicensees, and their respective employees, agents and
subcontractors, in connection with the Development, manufacture or Commercialization of the Compound or Products, including, for the avoidance of doubt, all product liability claims (whether arising during Development or Commercialization) relating
to any Compound or Product (whether pursuant to design defect, manufacturing defect, failure to notify, or otherwise); or 

  

	 	(b)	 the breach of any of the obligations, covenants, warranties, or representations made by QED to Novartis
under this Agreement; 

 provided, however, that QED will not be obliged to so indemnify, defend and hold harmless
the Novartis Indemnitees for any Claims for which Novartis has an obligation to indemnify QED Indemnitees pursuant to Section 14.1 or to the extent that such Claims arise from the breach, negligence or willful misconduct of Novartis or the
Novartis Indemnitees. 
  

	14.3	 Indemnification Procedure. 

 

	 	(a)	 For the avoidance of doubt, all indemnification claims in respect of a QED Indemnitee or Novartis
Indemnitee will be made solely by QED or Novartis, respectively. 

  

	 	(b)	 A Party seeking indemnification hereunder (“Indemnified Party”) will notify the other
Party (“Indemnifying Party”) in writing reasonably promptly after the assertion against the Indemnified Party of any Claim or fact in respect of which the Indemnified Party intends to base a claim for indemnification hereunder
(“Indemnification Claim Notice”), but the failure or delay to so notify the Indemnifying Party will not relieve the Indemnifying Party of any obligation or liability that it may have to the Indemnified Party, except to the extent
that the Indemnifying Party demonstrates that its ability to defend or resolve such Claim is adversely affected thereby. The Indemnification Claim Notice will contain a description of the claim and the nature and amount of the Claim (to the extent
that the nature and amount of such Claim is known at such time). Upon the request of the Indemnifying Party, the Indemnified Party will furnish promptly to the Indemnifying Party copies of all correspondence, communications and official documents
(including court documents) received or sent in respect of such Claim. 

  

	 	(c)	 Subject to the provisions of Sections (d) and (e) below, the Indemnifying Party will have the
right, upon written notice given to the Indemnified Party within 30 days after receipt of the Indemnification Claim Notice to assume the defense and handling of such Claim, at the Indemnifying Party’s sole expense, in which case the provisions
of Section 14.3(d) below will govern. The assumption of the defense of a Claim by the Indemnifying Party will not be construed as acknowledgement that the Indemnifying Party is liable to indemnify any indemnitee in respect of the Claim, nor
will it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party’s claim for indemnification. In the event that it is ultimately decided that

  
 CONFIDENTIAL - 36 

	 	
the Indemnifying Party is not obligated to indemnify or hold an Indemnitee harmless from and against the Claim, the Indemnified Party will reimburse the Indemnifying Party for any and all costs
and expenses (including attorneys’ fees and costs of suit) and any losses incurred by the Indemnifying Party in its defense of the Claim. If the Indemnifying Party does not give written notice to the Indemnified Party, within 30 days after
receipt of the Indemnification Claim Notice, of the Indemnifying Party’s election to assume the defense and handling of such Claim, the provisions of Section 14.3(e) below will govern. 

 

	 	(d)	 Upon assumption of the defense of a Claim by the Indemnifying Party: (i) the Indemnifying
Party will have the right to and will assume sole control and responsibility for dealing with the Claim; (ii) the Indemnifying Party may, at its own cost, appoint as counsel in connection with conducting the defense and handling of such
Claim any law firm or counsel reasonably selected by the Indemnifying Party; (iii) the Indemnifying Party will keep the Indemnified Party informed of the status of such Claim; and (iv) the Indemnifying Party will have the
right to settle the Claim on any terms the Indemnifying Party chooses; provided, however, that it will not, without the prior written consent of the Indemnified Party, agree to a settlement of any Claim which could lead to liability or create
any financial or other obligation on the part of the Indemnified Party for which the Indemnified Party is not entitled to indemnification hereunder or which admits any wrongdoing or responsibility for the claim on behalf of the Indemnified Party.
The Indemnified Party will cooperate with the Indemnifying Party and will be entitled to participate in, but not control, the defense of such Claim with its own counsel and at its own expense. In particular, the Indemnified Party will furnish such
records, information and testimony, provide witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation will include access during normal
business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Claim, and making the Indemnified Party, the Indemnitees and its and their employees and
agents available on a mutually convenient basis to provide additional information and explanation of any records or information provided. 

  

	 	(e)	 If the Indemnifying Party does not give written notice to the Indemnified Party as set forth in
Section 14.3(c) or fails to conduct the defense and handling of any Claim in good faith after having assumed such, the Indemnified Party may, at the Indemnifying Party’s expense, select counsel reasonably acceptable to the Indemnifying
Party in connection with conducting the defense and handling of such Claim and defend or handle such Claim in such manner as it may deem appropriate. In such event, the Indemnified Party will keep the Indemnifying Party timely apprised of the status
of such Claim and will not settle such Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld. If the Indemnified Party defends or handles such Claim, the Indemnifying Party will cooperate
with the Indemnified Party, at the Indemnified Party’s request but at no expense to the Indemnified Party, and will be entitled to participate in the defense and handling of such Claim with its own counsel and at its own expense.

  
 CONFIDENTIAL - 37 

	14.4	 Mitigation of Loss. Each Indemnified Party will take and will procure that its Affiliates take all such
reasonable steps and action as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Section 14. Nothing in this Agreement will or will be deemed to relieve
any Party of any common law or other duty to mitigate any losses incurred by it. 

  

	14.5	 Special, Indirect and Other Losses. NO PARTY NOR ANY OF SUCH PARTY’S AFFILIATES SHALL BE LIABLE
IN CONTRACT, TORT, NEGLIGENCE BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT ANY SUCH
DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS SECTION 14. 

  

	15.	 GENERAL PROVISIONS 

 

	15.1	 Assignment. No Party may assign its rights and obligations under this Agreement without the other
Party’s prior written consent, except that either Party may (i) assign its rights and obligations under this Agreement or any part hereof to one or more of its Affiliates; or (ii) assign this Agreement in its entirety to
a successor to all or substantially all of its business or assets to which this Agreement relates. Any permitted assignee will assume all obligations of its assignor under this Agreement and the corresponding obligations under the Ancillary
Agreement (or related to the assigned portion in case of a partial assignment). Any attempted assignment in contravention of the foregoing will be void. Subject to the terms of this Agreement, this Agreement will be binding upon and inure to the
benefit of the Parties and their respective successors, heirs and permitted assigns. For clarity, (1) if QED is involved in a change of control with a Third Party, then: (a) the Patent Rights,
Know-How and data controlled by such Third Party (or any Affiliate thereof, excluding QED as a result of such transaction) existing as of the date of closing of such change of control (if such Third Party
becomes the assignee of this Agreement); or (b) the Patent Rights, Know-How and data controlled by such Third Party (if such Third Party remains an Affiliate of QED), in each case, will not be
considered “Controlled” by QED or its Affiliates, unless QED or its Third Party acquirer actually uses or applies any such Patent Rights, Know-How and data to manufacture, Develop or Commercialize
the Compound or a Product (which such Patent Rights or Know-How will be considered “Controlled” by QED or its Affiliates, as applicable, for purposes of this Agreement). Any assignment or attempted
assignment by either Party in violation of the terms of this Section 15.1 will be null, void, and of no legal effect. 

  

	15.2	 Extension to Affiliates. QED will have the right to extend the rights, immunities and obligations
granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement will apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to
QED. QED will remain primarily liable for any acts or omissions of its Affiliates. 

  

	15.3	 Severability. Should one or more of the provisions of this Agreement become void or unenforceable as a
matter of law, then this Agreement will be construed as if such provision were not contained herein and the remainder of this Agreement will be in full force and effect, and the Parties will use their commercially reasonable efforts to substitute
for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties. 

  
 CONFIDENTIAL - 38 

	15.4	 Governing Law and Jurisdiction. This Agreement will be governed by and construed under the laws of
the Commonwealth of Massachusetts, USA, without giving effect to the conflicts of laws provision thereof. The United Nations Convention on Contracts for the International Sale of Goods (1980) will not apply to the interpretation of this
Agreement. 

  

	15.5	 Dispute Resolution. 

 

	 	(a)	 In the event of a dispute under this Agreement, the Parties will refer the dispute to the Alliance
Managers for discussion and resolution. If the Alliance Managers are unable to resolve such a dispute within 30 days of the dispute being referred to them, either Party may require that the Parties forward the matter to the Senior Officers (or
designees with similar authority to resolve such dispute), who will attempt in good faith to resolve such dispute. If the Senior Officers cannot resolve such dispute within [***] of the matter being referred to them, either Party will be free to
initiate the arbitration proceeding outlined in Section 15.5(b) to resolve the matter. 

  

	 	(b)	 Any unresolved disputes between the Parties relating to, arising out of or in any way connected with
this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, whether before or after termination of this Agreement, will be resolved by final and binding arbitration. Whenever a Party decides to
institute arbitration proceedings, it will give written notice to that effect to the other Party. Arbitration will be held in [***], in accordance with the commercial arbitration rules of the International Chamber of Commerce
(“ICC”). The arbitration will be conducted by a panel of [***] arbitrators appointed in accordance with ICC rules; provided that each Party will within [***] after the institution of the arbitration proceedings appoint [***],
and each arbitrator will have significant experience in the biopharmaceutical industry. If the [***] in accordance with ICC rules. The arbitrators will render their opinion within [***] of the final arbitration hearing. No arbitrator (nor the panel
of arbitrators) will have the power to award punitive damages or to award costs and expenses of the proceeding or reasonable attorney’s fees to any Party under this Agreement and such award is expressly prohibited. Decisions of the panel of
arbitrators will be final and binding on the Parties. Judgment on the award so rendered may be entered in any court of competent jurisdiction. 

  

	 	(c)	 Notwithstanding Section 15.5(b), any dispute, controversy or claim relating to the scope, validity,
enforceability or infringement of any Patent Right covering the manufacture, use, importation, offer for sale or sale of any Compound or Product or of any trademark rights relating to any Product shall be submitted to a court of competent
jurisdiction in the country in which such Patent Right or trademark rights were granted or arose. 

  

	15.6	 Force Majeure. In the event that either Party is prevented from performing its obligations under this
Agreement as a result of any contingency beyond its reasonable control (“Force Majeure”), including but not limited to, any actions of governmental authorities or agencies, war, hostilities between nations, civil commotions, riots,
national industry strikes, lockouts, sabotage, shortages in supplies, energy shortages, fire, floods and acts of nature 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 39 

	 	
such as typhoons, hurricanes, earthquakes, or tsunamis, the Party so affected will not be responsible to the other Party for any delay or failure of performance of its obligations hereunder, for
so long as Force Majeure prevents such performance. In the event of Force Majeure, the Party immediately affected thereby will give prompt written notice to the other Party specifying the Force Majeure event complained of, and will use commercially
reasonable efforts to resume performance of its obligations. Notwithstanding the foregoing, if such a Force Majeure induced delay or failure of performance continues for a period of more than three consecutive months, either Party may terminate this
Agreement upon written notice to the other Party. 

  

	15.7	 Waivers and Amendments. The failure of any Party to assert a right hereunder or to insist upon
compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver will be effective unless it has been given
in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party. 

 

	15.8	 Relationship of the Parties. Nothing contained in this Agreement will be deemed to constitute a
partnership, joint venture, or legal entity of any type between Novartis and QED, or to constitute one as the agent of the other. Moreover, each Party will not construe this Agreement, or any of the transactions contemplated hereby, as a partnership
for any tax purposes. Each Party will act solely as an independent contractor, and nothing in this Agreement will be construed to give any Party the power or authority to act for, bind, or commit the other. 

 

	15.9	 Notices. All notices, consents, waivers, and other communications under this Agreement must be in
writing and will be deemed to have been duly given when: (a) delivered by hand (with written confirmation of receipt); or (b) when received by the addressee, if sent by an internationally recognized overnight delivery service
(receipt requested), in each case to the appropriate addresses set forth below (or to such other addresses as a Party may designate by notice): 

If to QED: 
 QED 

421 Kipling Street 
 Palo Alto,
CA 94301 USA 
 Attn: Chief Executive Officer 

with a required copy to: 

Goodwin Procter 
 Three
Embarcadero Center 
 28th Floor 

San Francisco, CA 94111 

Attn: Maggie L. Wong, Esq. 

  
 CONFIDENTIAL - 40 

 If to Novartis: 

Novartis International Pharmaceutical Ltd 

Lichtstrasse 35 
 CH-4056 Basel 
 Switzerland 

with a required copy to: 

Novartis Institutes for BioMedical Research, Inc. 

250 Massachusetts Avenue 

Cambridge, MA 02139 USA 

Attn: General Counsel 
  

	15.10	 Further Assurances. QED and Novartis will execute, acknowledge and deliver any and all such other
documents and take any such other action as may be reasonably necessary to carry out the intent and purposes of this Agreement. 

  

	15.11	 Compliance with Law. Each Party will perform its obligations under this Agreement in accordance with all
Applicable Laws. No Party will, or will be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any Applicable Law. 

 

	15.12	 No Third Party Beneficiary Rights. The provisions of this Agreement are for the sole benefit of the
Parties and their successors and permitted assigns, and they will not be construed as conferring any rights to any Third Party (including any third party beneficiary rights). 

 

	15.13	 Expenses. Except as otherwise expressly provided in this Agreement, each Party will pay the fees and
expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement. 

 

	15.14	 Entire Agreement. This Agreement, together with its Exhibits and schedules, sets forth the entire
agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter, including the Prior Confidentiality
Agreement. In the event of any conflict between a substantive provision of this Agreement and any Exhibit or schedule hereto, the substantive provisions of this Agreement will prevail. 

 

	15.15	 Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed
an original, but all of which together will constitute one and the same instrument. Signatures provided by facsimile transmission or in Adobe Portable Document Format (.pdf) sent by electronic mail shall be deemed to be original signatures.

  

	15.16	 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each will
be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 

  
 CONFIDENTIAL - 41 

 License Agreement - Signature Page 

IN WITNESS WHEREOF, the Parties, intending to be bound, have caused this Agreement to be executed by their duly authorized
representatives. 
  

									
	NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.	 		 	QED THERAPEUTICS, INC.
					
	By:	 	 /s/ Simone Pfirter
	 		 	By:	 	 /s/ Neil Kumar

	Name:	 	 Simone Pfirter
	 		 	Name:	 	 Neil Kumar

	Title:	 	 Authorized Signatory
	 		 	Title:	 	 President

					
	By:	 	 /s/ Lars Windhorn
	 		 		 	
	Name:	 	 Lars Windhorn
	 		 		 	
	Title:	 	 Authorized Signatory
	 		 		 	

  
 CONFIDENTIAL - 42 

 EXHIBIT A 

COMPOUND 

Exhibit A-1 - [***] 

[***] 
 Laboratory codes 

[***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 43 

 EXHIBIT B 

NOVARTIS PATENTS 
 Exhibit B-1 
 [***] 

Exhibit B-2 

[***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 44 

 EXHIBIT C 

NOVARTIS KNOW-HOW 

1 Regulatory Documentation 
 Source: Novartis Regulatory
documentum archive 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 45 

 EXHIBIT D 

DRUG SUBSTANCE INVENTORY 
 [***] 

DRUG PRODUCT INVENTORY – manufactured under GMP 

[***] 
 Drug Substance and Drug Product Stability Programs:

 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 46 

 EXHIBIT E 

INVESTMENT DOCUMENTS 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 47 

 EXHIBIT F 

[***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 48 

 EXHIBIT G 

PRESS RELEASE 
 BridgeBio Pharma
Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing 

PALO ALTO, Calif., Jan. XX, 2018 — BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective
inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million. 

FGFR has been implicated as a driver mutation across multiple oncologies – including roughly one out of every five cases of cholangiocarcinoma and
urothelial carcinoma – and in multiple forms of pediatric skeletal dysplasias, namely achondroplasia, which affects one out of every 20,000 live births. 

Infigratinib is currently in a Phase 2 clinical trial for patients with chemotherapyrefractory bile duct cancer (cholangiocarcinoma) containing FGFR2 fusions.
Early clinical results, recently published in the Journal of Clinical Oncology, demonstrated that the compound showed meaningful activity in this population. 

“We are committed to moving this compound forward in late-stage development and further proving the strong efficacy in cancer that has already been
demonstrated across multiple trials,” said Daniel Hoth, M.D., QED’s chief medical officer, who has devoted over three decades to drug development, including time as chief of the Investigational Drug Branch of the National Cancer Institute
(NCI). 
 Cholangiocarcinoma affects approximately 6,000 to 8,000 patients a year in the United States. Treatment options are limited, and survival rates
vary depending on whether cholangiocarcinoma is found on the bile duct branches within the liver versus those outside of the liver. 
 “Despite immense
strides in studying potential drugs in cholangiocarcinoma, there remains significant need to provide options to these patients,” said Stacie Lindsey, president of the Cholangiocarcinoma Foundation. “The patients and caregivers we work with
are very hopeful given data already generated with infigratinib, and we are excited that the passionate team at BridgeBio and QED are working to advance this drug.” 

BridgeBio co-founder and investor Frank McCormick, Ph.D., head of the NCI’s Ras initiative and former CSO and co-founder of Onyx Pharmaceuticals, remarked “Infigratinib embodies the crux of what we set out to do at BridgeBio: develop targeted therapies for genetically-driven tumors and monogenic disorders.” 

  
 CONFIDENTIAL - 49 

 In addition to its clinical data in FGFR-driven cancer, infigratinib has demonstrated potential in skeletal
dysplasias, including achondroplasia. In the early work published in the Journal of Clinical Investigation, researchers demonstrated that low doses of infigratinib corrected pathological hallmarks of achondroplasia in mouse models. 

Neil Kumar, Ph.D., chief executive officer of BridgeBio, noted that with infigratinib, “We have a late-stage, targeted oncology compound that has
demonstrated clear efficacy in the clinic. With the same molecule, we have a potential best-in-class therapy to treat achondroplasia, a monogenic pediatric condition
that can have devastating associated health problems, at its source.” 
 While specific terms of the deal have not been disclosed, BridgeBio has
committed $65 million in financing to QED, which is inclusive of a substantial upfront payment to Novartis as well as equity in QED. Novartis will also receive additional payments upon the realization of development and sales milestones as well
as royalties. 
 About BridgeBio Pharma 
 BridgeBio is a
clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of
early stage science into medicines that treat disease at its source. Founded in 2015 by a team of industry veterans, the company has built a robust portfolio of fifteen transformative assets, each housed in its own subsidiary, ranging from pre-clinical to late stage development in multiple therapeutic areas including oncology, cardiology, neurology, dermatology and endocrinology. The company’s focus on scientific excellence and rapid execution
aims to translate today’s discoveries into tomorrow’s medicines. 
 About QED Therapeutics 

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is
infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is
also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders. 

BridgeBio Pharma Contact: 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

CONFIDENTIAL - 50EX-10.11

 Exhibit 10.11 

 
  

 

 

	 	[***]	 Certain information in this document has been omitted from this exhibit because it is both (i) not
material and (ii) would be competitively harmful if publicly disclosed. 

 ASSET PURCHASE AGREEMENT

 between 

ALEXION PHARMA HOLDING UNLIMITED COMPANY, 

ORIGIN BIOSCIENCES, INC., 

and 
 BRIDGEBIO PHARMA,
LLC (SOLELY FOR THE PURPOSES OF SECTION 6.14) 
 DATED AS OF June 7, 2018 

 
  

 

 Table of Contents 

 

							
	 	  	 	  	Page	 
	 ARTICLE I. DEFINITIONS AND TERMS
	  	 	1	 
			
	 Section 1.01
	  	 Definitions
	  	 	1	 
	 Section 1.02
	  	 Other Definitional Provisions
	  	 	11	 
		
	 ARTICLE II. PURCHASE AND SALE
	  	 	11	 
			
	 Section 2.01
	  	 Purchase and Sale of Assets
	  	 	11	 
	 Section 2.02
	  	 Matters Related to Purchased Assets
	  	 	12	 
	 Section 2.03
	  	 Excluded Assets
	  	 	13	 
	 Section 2.04
	  	 Assumption of Certain Obligations
	  	 	14	 
	 Section 2.05
	  	 Retained Liabilities
	  	 	14	 
	 Section 2.06
	  	 Purchase Price
	  	 	15	 
	 Section 2.07
	  	 Priority Review Voucher
	  	 	15	 
	 Section 2.08
	  	 Milestone Payments
	  	 	16	 
	 Section 2.09
	  	 Royalties
	  	 	17	 
	 Section 2.10
	  	 Audits
	  	 	18	 
	 Section 2.11
	  	 Allocation of Purchase Price
	  	 	18	 
	 Section 2.12
	  	 Transfer Taxes
	  	 	18	 
	 Section 2.13
	  	 Risk of Loss; Casualty and Condemnation
	  	 	19	 
	 Section 2.14
	  	 Certain Costs
	  	 	19	 
	 Section 2.15
	  	 Withholding
	  	 	19	 
		
	 ARTICLE III. CLOSING
	  	 	19	 
			
	 Section 3.01
	  	 Closing
	  	 	19	 
		
	 ARTICLE IV. REPRESENTATIONS AND WARRANTIES OF SELLER
	  	 	20	 
			
	 Section 4.01
	  	 Organization
	  	 	20	 
	 Section 4.02
	  	 Authority; Binding Effect
	  	 	20	 
	 Section 4.03
	  	 Non-Contravention
	  	 	20	 
	 Section 4.04
	  	 Governmental Authorization
	  	 	21	 
	 Section 4.05
	  	 No Litigation
	  	 	21	 
	 Section 4.06
	  	 Compliance with Laws
	  	 	21	 
	 Section 4.07
	  	 Contracts
	  	 	21	 
	 Section 4.08
	  	 Intellectual Property
	  	 	23	 
	 Section 4.09
	  	 Brokers
	  	 	25	 
	 Section 4.10
	  	 Purchased Assets
	  	 	25	 
	 Section 4.11
	  	 Inventories
	  	 	26	 
	 Section 4.12
	  	 Tax Representations
	  	 	26	 
	 Section 4.13
	  	 Regulatory Matters
	  	 	27	 
	 Section 4.14
	  	 Disclosure
	  	 	28	 
	 Section 4.15
	  	 Exclusivity of Representations
	  	 	28	 

  
 i 

							
	
ARTICLE V. REPRESENTATIONS AND WARRANTIES OF PURCHASER
	  	 	28	 
			
	 Section 5.01
	  	 Organization
	  	 	28	 
	 Section 5.02
	  	 Authority; Binding Effect
	  	 	28	 
	 Section 5.03
	  	 Non-Contravention
	  	 	29	 
	 Section 5.04
	  	 Governmental Authorization
	  	 	29	 
	 Section 5.05
	  	 Brokers
	  	 	29	 
	 Section 5.06
	  	 Financial Capability
	  	 	29	 
	 Section 5.07
	  	 Solvency
	  	 	30	 
	 Section 5.08
	  	 Exclusivity of Representations
	  	 	30	 
		
	 ARTICLE VI. COVENANTS
	  	 	30	 
			
	 Section 6.01
	  	 Conduct of Business
	  	 	30	 
	 Section 6.02
	  	 Condition of the Purchased Assets
	  	 	32	 
	 Section 6.03
	  	 Publicity
	  	 	33	 
	 Section 6.04
	  	 Books and Records; Regulatory Information
	  	 	33	 
	 Section 6.05
	  	 Further Assurances; Transition Plan
	  	 	33	 
	 Section 6.06
	  	 Bulk Transfer Laws
	  	 	35	 
	 Section 6.07
	  	 Non-Competition
	  	 	35	 
	 Section 6.08
	  	 Insurance
	  	 	35	 
	 Section 6.09
	  	 Diligence
	  	 	35	 
	 Section 6.10
	  	 Clinical Trials and Product Supply
	  	 	36	 
	 Section 6.11
	  	 Payments from Third Parties
	  	 	36	 
	 Section 6.12
	  	 Tax Matters
	  	 	36	 
	 Section 6.13
	  	 Confidentiality
	  	 	37	 
	 Section 6.14
	  	 Guarantee
	  	 	37	 
		
	 ARTICLE VII. CLOSING CONDITIONS
	  	 	38	 
			
	 Section 7.01
	  	 Conditions Precedent to Purchaser’s Obligations on the Closing Date
	  	 	38	 
	 Section 7.02
	  	 Conditions Precedent to Seller’s Obligations on the Closing Date
	  	 	39	 
		
	 ARTICLE VIII. INDEMNIFICATION
	  	 	39	 
			
	 Section 8.01
	  	 Indemnification by Seller
	  	 	39	 
	 Section 8.02
	  	 Indemnification by Purchaser
	  	 	40	 
	 Section 8.03
	  	 Notice of Claims
	  	 	41	 
	 Section 8.04
	  	 Third Party Claims
	  	 	41	 
	 Section 8.05
	  	 Expiration
	  	 	42	 
	 Section 8.06
	  	 Certain Limitations
	  	 	43	 
	 Section 8.07
	  	 Materiality
	  	 	44	 
	 Section 8.08
	  	 Sole Remedy/Waiver
	  	 	44	 
	 Section 8.09
	  	 Indemnity Payments
	  	 	44	 
	 Section 8.10
	  	 Tax Treatment of Indemnity Payments
	  	 	45	 
	 Section 8.11
	  	 No Consequential Damages
	  	 	45	 

  
 ii 

							
	 ARTICLE IX. TERMINATION
	  	 	45	 
			
	 Section 9.01
	  	 Termination
	  	 	45	 
	 Section 9.02
	  	 Effect of Termination
	  	 	46	 
		
	 ARTICLE X. MISCELLANEOUS
	  	 	47	 
			
	 Section 10.01
	  	 Notices
	  	 	47	 
	 Section 10.02
	  	 Amendment; Waiver
	  	 	48	 
	 Section 10.03
	  	 Assignment
	  	 	48	 
	 Section 10.04
	  	 Entire Agreement
	  	 	48	 
	 Section 10.05
	  	 Fulfillment of Obligations
	  	 	49	 
	 Section 10.06
	  	 Parties in Interest
	  	 	49	 
	 Section 10.07
	  	 Expenses
	  	 	49	 
	 Section 10.08
	  	 Schedules
	  	 	49	 
	 Section 10.09
	  	 Governing Law; Jurisdiction; No Jury Trial; Specific Performance
	  	 	49	 
	 Section 10.10
	  	 Counterparts
	  	 	50	 
	 Section 10.11
	  	 Headings
	  	 	50	 
	 Section 10.12
	  	 Severability
	  	 	50	 

  

			
	 SCHEDULES
	  	
		
	 2.01(b)
	  	 Transferred Patents

	 2.01(c)
	  	 Transferred Trademarks

	 2.01(d)
	  	 Transferred Copyrights

	 2.01(e)
	  	 Transferred Internet Domain Names

	 2.01(f)
	  	 Transferred Governmental Authorizations

	 2.01(i)
	  	 Transferred Contracts

	 7.01(f)
	  	 Consents

		
	 EXHIBITS
	  	
	 A
	  	 Seller Closing Deliverables

	 B
	  	 Purchaser Closing Deliverables

	 C
	  	 Form of Seller’s Officer’s Certificate

	 D
	  	 Form of Bill of Sale and Assignment and Assumption

	 E
	  	 Form of Patent Assignment

	 F
	  	 Form of Purchaser’s Officer’s Certificate

	 G
	  	 Form of Purchaser’s Secretary’s Certificate

  
 iii 

 ASSET PURCHASE AGREEMENT 

This Asset Purchase Agreement, dated as of June 7, 2018 (the “Effective Date”), by and between Alexion Pharma Holding
Unlimited Company, an unlimited liability company incorporated under the laws of Ireland (“Seller”), Origin Biosciences, Inc., a Delaware corporation (“Purchaser”) and BridgeBio Pharma, LLC, a Delaware limited
liability company (“BridgeBio”) (solely for the purposes of Section 6.14). 
 W
I T N E S S E T H: 
 WHEREAS, Seller, directly and indirectly through
certain of its Affiliates (as defined below), is in the business of researching, developing, manufacturing or having made, marketing, distributing and selling, as the case may be, products (including pharmaceutical drugs) for use in health care; and

 WHEREAS, Seller desires to sell (or to cause to be sold), and Purchaser desires to purchase, the Purchased Assets (as defined below), and
Purchaser is willing to assume the Assumed Liabilities (as defined below), in each case, on the terms and subject to the conditions set forth herein; 

NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, the Parties
hereby agree as follows: 
 ARTICLE I. 

DEFINITIONS AND TERMS 

Section 1.01    Definitions. As used in this Agreement, the following terms shall have
the meanings set forth or as referenced below: 
 “Accounts Receivable” means all accounts receivable, notes receivable and
other indebtedness due and owed by any Third Party to Seller or its Affiliates as of the end of the day immediately prior to the Closing Date, including all trade accounts receivable representing amounts receivable in respect of goods shipped,
products sold or services rendered prior to the day immediately prior to the Closing Date and the full benefit of any security for such accounts or debts. 

“Action” means any proceedings, investigations, audits, claims, arbitrations, litigations, inquiries, demands, actions, suits
and causes of action, whether class, individual or otherwise in nature, and whether in law or in equity by or before a Governmental Authority. 

“Affiliate” means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under
common control with, such Person at any time during the period for which the determination of affiliation is being made. For purposes of this definition, “control” of a Person means the power, direct or indirect, to direct or cause the
direction of the management and policies of such Person whether by contract or otherwise and, in any event and, without limitation of the previous sentence, any Person owning more than fifty percent (50%) or more of the voting securities of another
Person shall be deemed to control that Person. Notwithstanding the foregoing, the Parties acknowledge and agree that: (a) BridgeBio 

  
 1 

 
shall not be deemed an Affiliate of Purchaser; and (b) any other subsidiary of BridgeBio shall not be deemed an Affiliate of Purchaser unless such company directly or indirectly, controls,
is controlled by, or is under common control with Purchaser without regard to their respective relationships with BridgeBio. 

“Agreement” means this Asset Purchase Agreement, including all Schedules and Exhibits attached hereto, as the same may be
amended, modified or supplemented from time to time in accordance with the terms hereof. 
 “ALXN1101 Molecule” means (a)
[***] and (b) [***]. 
 “Apportioned Obligations” has the meaning set forth in Section 6.12(b).

 “Assumed Liabilities” has the meaning set forth in Section 2.04. 

“Basket” has the meaning set forth in Section 8.06(a). 

“Bill of Sale and Assignment and Assumption” has the meaning set forth in Exhibit A. 

“BridgeBio” has the meaning set forth in the Preamble of this Agreement. 

“Business” means the research, development (including regulatory activities), use, manufacture and commercialization of the
ALXN1101 Molecule or any Products as conducted or contemplated to be conducted by Seller, the Divesting Entities or their Affiliates as of the Effective Date. 

“Business Day” means any day other than a Saturday, a Sunday or a day on which banks in New York City, New York and San
Francisco California are authorized or obligated by law or executive order to close. 
 “Calendar Quarter” means the
respective periods of three (3) consecutive calendar months ending March 31, June 30, September 30 and December 31. 

“Calendar Year” shall mean a period of twelve (12) consecutive months corresponding to the calendar year commencing on
the first day of January, except that the first Calendar Year following the Closing Date shall commence on the Closing Date and end on December 31 of the year in which the Closing Date occurs. 

“Claim” has the meaning set forth in Section 8.03. 

“Claims Period” has the meaning set forth in Section 8.05. 

“Closing” means the consummation of the Transactions pursuant to the terms of this Agreement. 

“Closing Date” has the meaning set forth in Section 3.01(a). 

“Closing Legal Impediment” has the meaning set forth in Section 7.01(c). 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 2 

 “Code” means the U.S. Internal Revenue Code of 1986, as amended. 

“Combination Product” means a product that includes a Product and at least one additional active ingredient (whether co-formulated or co-packaged) other than a Product. 

“Commercialize” means, solely for the purposes of Section 6.09, any and all activities directed to
the promotion, marketing, distribution or sale (and offer for sale or import or export for sale) for a Product. 
 “Commercially
Reasonable Efforts” means, [***]. 
 “Confidentiality Agreement” means that certain letter agreement dated
August 15, 2017, between Alexion Pharmaceuticals, Inc. and BridgeBio. 
 “Confidential Information” has the meaning
set forth in Section 6.13. 
 “Contract” means any written legally binding contract, agreement or
other legally binding commitment. 
 “Copyrights” means all copyrights or other works of authorship (whether or not
copyrightable), and all applications, registrations and renewals in connection therewith, and all moral rights and data, databases and database rights. 

“Data Room” means the electronic data room containing documents and materials relating to the Purchased Assets. 

“Development Milestone Events” has the meaning set forth in Section 2.08(a). 

“Development Milestone Payments” has the meaning set forth in Section 2.08(a). 

“Divesting Entities” means, collectively, all Affiliates of Seller that have any right, title or interest in, to or under the
Purchased Assets. 
 “Drug Access Obligations” has the meaning set forth in Section 10.09(d).

 “Effective Date” has the meaning set forth in the Preamble of this Agreement. 

“EMA” means the European Medicines Agency, and any successor agency having substantially the same functions and jurisdiction.

 “European Union” or “EU” means the European Union, as its membership may be constituted from time to
time, and any successor thereto, and which, as of the date of this Agreement, consists of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and United Kingdom. 
 “Excluded
Assets” has the meaning set forth in Section 2.03. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 3 

 “FDA” means the United States Food and Drug Administration, and any
successor agency having substantially the same functions and jurisdiction. 
 “First Commercial Sale” means, with respect
to any Product, the first sale for use or consumption of such Product by Purchaser, one of Purchaser’s Affiliates or a licensee of Purchaser or one of Purchaser’s Affiliates to a Third Party in any country after such Product has been
granted Regulatory Approval in such country. 
 “Forward-Looking Statements” has the meaning set forth in
Section 6.02(d). 
 “Fraud” means, with respect to any Party, common law fraud, as interpreted
under the laws and by the courts of the State of Delaware; provided that Fraud shall only be deemed to exist if such Party had the specific intent to deceive and mislead the other Party. 

“Fundamental Representations” shall mean any representations and warranties contained in [***]. 

“GAAP” means accounting principles and practices generally accepted in the United States, as in effect on the Effective Date.

 “Governmental Authority” means any supranational, national, federal, provincial, state or local judicial (including any
arbitration panel), legislative, executive or regulatory authority, agency, commission, body or instrumentality with competent jurisdiction, including the FDA, or quasi-governmental, self-regulatory organization, commission, body, authority or
agency. 
 “Governmental Authorizations” means all licenses, permits and other authorizations, consents and approvals
(including NDAs and MAAs, if any) of any Governmental Authority. 
 “Governmental Order” means any order, writ, judgment,
injunction, decree, stipulation, determination or award entered by or with any Governmental Authority. 
 “Guaranteed
Obligations” has the meaning set forth in Section 6.14. 
 “IND” means an
Investigational New Drug Application filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations (or its successor regulation) with respect to a Product, or the equivalent application or filing filed with any
equivalent agency or Governmental Authority outside the United States of America (including any supra-national agency such as the EMA), and all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect to
the foregoing. 
 “Indemnified Party” has the meaning set forth in Section 8.03. 

“Indemnifying Party” has the meaning set forth in Section 8.03. 

“Indication” means a specific disease or condition experienced by a specific human patient population. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 4 

 “Intellectual Property” means all Patent Rights, Trademarks, Internet
Domain Name Registrations, Copyrights and Know-How and all other intellectual property and all copies and tangible embodiments or descriptions of any of the foregoing (in whatever form or medium) and all
goodwill associated with, and all rights related to or otherwise associated with, any of the foregoing in any jurisdiction in the world (including all rights to collect royalties, products and proceeds in connection with any of the foregoing, and to
sue and bring other claims for past, present and future infringement, misappropriation or other violation of any of the foregoing, and to recover damages (including attorneys’ fees and expenses) and lost profits in connection therewith). 

“Internet Domain Name Registrations” means all IP addresses identified via a name format, and all goodwill associated with,
and all rights related to or otherwise associated with the foregoing, including all generic top-level domains (gTLDs) and country code top-level domains (ccTLDs). 

“Inventories” means all inventories of finished goods, packaging, raw materials, components and work-in-process, used in or relating to a Product, to the extent owned by Seller or any Divesting Entity as of the Closing Date. 

“IRS” means the U.S. Internal Revenue Service. 

“Judgment” means any judgment, order, writ, injunction, legally binding agreement, stipulation or decree from a Governmental
Authority. 
 “Know-How” means any data, results, and information of any type
whatsoever, whether tangible or intangible and regardless of the form or medium, including any know-how, trade secrets, expertise, knowledge, practices, techniques, concepts, methodologies, methods, processes,
protocols, designs, ideas, inventions (whether or not patentable or reduced to practice), improvements, industrial designs and models, discoveries, developments, unpublished patent applications, specifications, formulations, formulae, materials or
compositions of matter of any type or kind (patentable or otherwise), assays, screens, software, algorithms, models, data, databases, database rights, chemistry, manufacturing and control (CMC) information and data, lab notebooks, patent data,
stability, technology, test data and results (including pharmacological, biological, chemical, biochemical, toxicological, pre-clinical and clinical test data), analytical and quality control data, results or
descriptions, studies and procedures, development, manufacturing and distribution costs, information contained in submissions to and information from regulatory authorities, and marketing and other reports. 

“Knowledge of Seller” means the actual knowledge of Eric Watsky and Karen-Leigh Edwards after reasonable inquiry. 

“Laws” means any federal, state, provincial, foreign or local law, common law, statute, ordinance, rule, regulation, code of
any Governmental Authority or any Governmental Order. 
 “Liabilities” means any and all debts, liabilities, costs,
guarantees, commitments, assessments, expenses, claims, losses, damages, deficiencies and obligations, whether accrued or fixed, accrued or not accrued, due or to become due, direct or indirect, whenever or however arising (including whether arising
out of any contract, common law or tort based on negligence or strict liability). 

  
 5 

 “Lien” means, with respect to any property or asset, any lien, security
interest, mortgage, pledge, assessment, restriction, adverse claim, levy, charge, encumbrance or other similar claim of any kind, character or description, whether of record or not, or any contract to give any of the foregoing, in respect of such
property or asset. 
 “Losses” means losses, liabilities, damages, expenses, penalties, assessments, interest, awards,
fines, fees, suits, actions, causes of action, judgments, Taxes and awards directly incurred or suffered (and, if applicable, reasonable consultants’ and attorneys’ fees associated therewith) including any such fees and expenses incurred
in connection with investigating, defending against or settling any of the foregoing and the reasonable costs and expenses of enforcing the indemnification rights of the Indemnified Party hereunder. 

“MAA” means an EU marketing authorization application. 

“Material Adverse Effect” means, with respect to Seller, any change, effect, event, circumstance, occurrence or state of
facts that is or would reasonably be expected (a) to have a material adverse effect on the Purchased Assets, taken as a whole, or (b) to have a material adverse effect on the ability of Seller to perform its obligations under
this Agreement and to consummate the Transactions, provided that none of the following changes, effects, events, circumstances, occurrences or states of facts shall be deemed, either alone or in combination, to constitute a Material Adverse
Effect, or be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect: (i) changes or effects in the general business, economic, social, political or legal conditions or the
securities, syndicated loan, credit or financial markets; (ii) changes or proposed changes in applicable Law or GAAP (or any applicable accounting standards in any jurisdiction outside the United States) or the enforcement thereof;
(iii) changes to Law that generally affect the industries in which the Seller or its Affiliates operate; (iv) changes or effects that arise out of or are attributable to the commencement, occurrence, continuation or intensification of any
war, sabotage, armed hostilities or acts of terrorism; (v) earthquakes, hurricanes or other natural disasters; (vi) changes or effects that arise out of or are attributable to the negotiation, execution, announcement or pendency of the
Transactions; (vii) currency fluctuations; or (viii) any action or inaction Seller is required to take or refrain from taking under this Agreement. 

“Milestone Events” has the meaning set forth in Section 2.08(b). 

“Milestone Payments” has the meaning set forth in Section 2.08(b). 

“Net Sales” means [***]. 

“Non-assigned Asset” has the meaning set forth in
Section 2.02(a). 
 “Outside Date” means July 21, 2018. 

“Party” means Seller or Purchaser individually, as the context so requires, and the term “Parties” means,
collectively, Seller and Purchaser. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 6 

 “Patent Assignment” has the meaning set forth in Exhibit A. 

“Patent Rights” means all (a) issued patents; (b) pending patent applications and any related patent applications
filed in the future claiming priority thereto, including all provisional applications, non-provisional applications, international (PCT) applications, substitutions, continuations, continuations in part,
divisions, renewals, and all patents granted thereon or issuing therefrom; (c) all patents of addition, reissues, re-examinations and extensions or restorations by existing or future extension or
restoration mechanisms, including supplementary protection certificates or the equivalent thereof; (d) registration patents, inventor’s certificates or confirmation patents; (e) all inventions disclosed in each such patent or patent
application, and all rights and priorities in any of the foregoing; and (f) any form of government-issued right substantially similar to any of the foregoing, in each case in any country or patent examining or granting jurisdiction. 

“Permitted Liens” means (a) all Liens approved in writing by Purchaser as Permitted Liens; (b) statutory Liens
arising out of operation of Law with respect to a Liability incurred in the ordinary course of business and which is not delinquent; (c) Liens for Taxes not yet due, payable, delinquent or subject to penalties for nonpayment, or which are being
contested in good faith through appropriate proceedings; and (d) mechanics’, materialmens’, carriers’, workmens’, warehousemens’, repairmens’, landlords’ or other like Liens and security obligations that are
incurred in the ordinary course of business and are not delinquent. 
 “Person” means an individual, a limited liability
company, a joint venture, a corporation, a partnership, an association, a trust, a division or an operating group of any of the foregoing or any other entity or organization. 

“Post-Closing Apportioned Period” has the meaning set forth in Section 6.12(b) 

“Pre-Closing Apportioned Period” has the meaning set forth in
Section 6.12(b). 
 “Priority Review Voucher” means a voucher issued by the FDA that entitles the
holder of such voucher to priority review of, and action upon, an NDA by the FDA not later than six (6) months after the filing of such application to the FDA. 

“Product” means any pharmaceutical product containing the ALXN1101 Molecule. 

“PRV Sale” has the meaning set forth in Section 2.07(a). 

“Purchase Price” means an aggregate amount equal to the sum of: (i) the Upfront Payment plus (ii) all
Royalty Payments that are actually earned by Seller plus (iii) all Milestone Payments that are actually earned by Seller. 

“Purchased Assets” has the meaning set forth in Section 2.01. 

“Purchaser” has the meaning set forth in the Preamble of this Agreement. 

“Purchaser Indemnitees” has the meaning set forth in Section 8.01(a). 

  
 7 

 “Purchaser Material Adverse Effect” means, with respect to Purchaser, any
change, effect, event, circumstance, occurrence or state of facts that is or would reasonably be expected to have a material adverse effect on the ability of Purchaser to perform its obligations under this Agreement and to consummate the
Transactions, provided that none of the following changes, effects, events, circumstances, occurrences or states of facts shall be deemed, either alone or in combination, to constitute a Purchaser Material Adverse Effect, or be taken into
account in determining whether there has been or would reasonably be expected to be a Purchaser Material Adverse Effect: (i) [***]; (ii) [***]; (iii) [***]; (iv) [***]; (v) [***]; (vi) [***]; (vii) changes or effects that
arise out of or are attributable to the negotiation, execution, announcement or pendency of the Transactions; or (viii) any action or inaction Purchaser is required to take or refrain from taking under this Agreement. 

“Purchaser Transfer Letter to FDA” means the letter(s) from Purchaser to the FDA, duly executed by Purchaser, notifying the
FDA of the transfer of the rights to the appropriate Transferred Governmental Authorizations to Purchaser in the United States. 

“Regulatory Approval” means the approval of the applicable Governmental Authority necessary for the marketing and sale of a
Product, including any separate pricing and/or reimbursement approvals that may be required. 
 “Regulatory Exclusivity”
means any exclusive marketing rights or data exclusivity rights conferred by a Governmental Authority, or otherwise by Law, with respect to a Product other than Patent Rights. 

“Regulatory Information” means (a) any applications, filings, submissions, approvals, minutes of meetings or telephone
conversations or correspondence between Seller or any of the Divesting Entities or any of their Affiliates and any Governmental Authority, that relate to the Business or the Purchased Assets, including, all INDs, establishment license applications,
drug master files, applications for designation as an “Orphan Product” under the Orphan Drug Act, for “Fast Track” status under Section 506 of the FFDCA (21 U.S.C. § 356), for “Breakthrough Therapy” status
under Section 506 of the FFDCA (21 U.S.C. § 356), as a “rare pediatric disease” under Section 529 of the FFDCA (21 U.S.C. 360ff) or for a Special Protocol Assessment under Section 505(b)(5)(B) and (C) of the FFDCA
(21 U.S.C. § 355(b)(5)(B) and (C)), manufacturing approvals, technical, medical, and scientific licenses, and pre-clinical, clinical and non-clinical study
authorization applications or notifications), all amendments, supplements, supporting files, data, studies, and reports relating thereto (in hard and electronic form); and (b) all technical and other information contained therein, and all
correspondence with the FDA and other Governmental Authority relating to the foregoing, that, in each case, are in the possession of or controlled by, or held by or for Seller, the Divesting Entities or their Affiliates, whether generated, filed or
held by or for Seller, the Divesting Entities or their Affiliates. 
 “Representatives” means, with respect to either
Party, such Party’s Affiliates and their respective parents, directors, officers, employees, attorneys, accountants, representatives, financial advisors, lenders, consultants, advisors and other agents. 

“Retained Liabilities” has the meaning set forth in Section 2.05. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 8 

 “Retained Taxes” means (i) all Taxes of Seller, the Divesting Entities
or any of their respective Affiliates, or for which Seller, the Divesting Entities or any of their respective Affiliates is otherwise liable, for any taxable period, (ii) all Taxes relating to the Excluded Assets or Retained Liabilities for any
taxable period; and (iii) all Taxes relating to the Purchased Assets or the Assumed Liabilities for any taxable period ending on or prior to the Closing Date and, with respect to any taxable period beginning before and ending after the Closing
Date, for the portion of such taxable period ending on the Closing Date, except as provided in Section 6.12(b). 

“Royalty Payments” has the meaning set forth in Section 2.09. 

“Royalty Term” has the meaning set forth in Section 2.09. 

“Sales Milestone Events” has the meaning set forth in Section 2.08(b). 

“Sales Milestone Payments” has the meaning set forth in Section 2.08(b). 

“Scheduled Intellectual Property” has the meaning set forth in Section 4.08(a) 

“SEC” has the meaning set forth in Section 6.03. 

“Seller” has the meaning set forth in the Preamble of this Agreement. 

“Seller Indemnitees” has the meaning set forth in Section 8.02(a). 

“Seller Transfer Letter to FDA” means the letter(s) from Seller to the FDA, duly executed by Seller (or any Affiliate of
Seller, as applicable), notifying the FDA of the transfer of the rights to the appropriate Transferred Governmental Authorizations to Purchaser in the United States. 

“Services Agreement” means the [***]. 

“Solvent” has the meaning set forth in Section 5.07. 

“Tax Contest” has the meaning set forth in Section 8.04(b). 

“Tax Return” means any return, report, declaration, information return, statement or other document filed or required to be
filed with any Taxing Authority in connection with the determination, assessment or collection of any Tax or the administration of any Laws relating to any Tax. 

“Taxes” means all taxes, including income, gross revenue, excise, property, sales or use, value added, profits, license,
withholding (with respect to compensation or otherwise), payroll, employment, net worth, capital gains, transfer, stamp, social security, occupation and franchise taxes, imposed by any Taxing Authority, and including any interest, penalties and
additions attributable thereto. 
 “Taxing Authority” means any Governmental Authority, exercising any authority to impose,
regulate or administer the imposition of Taxes. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 9 

 “Third Party” means any Person other than Purchaser, Seller and each of
their respective Affiliates. 
 “Third Party Claim” has the meaning set forth in Section 8.03.

 “Third Party Claim Notice” has the meaning set forth in Section 8.03. 

“Trademarks” means all trademarks, service marks, designs, trade dress, logos, slogans, trade names, business names,
corporate names and all other indicia of origin, together with all translations, adaptations, derivations and combinations thereof, and all social media handles associated therewith and all applications for registration, registrations and renewals
of any of the foregoing and all goodwill associated therewith. 
 “Transactions” means, collectively, the transactions
contemplated by this Agreement, including the purchase and sale of the Purchased Assets and the assumption of the Assumed Liabilities. 

“Transfer Letters to FDA” means the Purchaser Transfer Letter to FDA and the Seller Transfer Letter to FDA. 

“Transfer Taxes” means any federal, state, county, local, foreign and other sales, use, transfer, value added, conveyance,
documentary transfer, stamp duty, recording or other similar Tax, fee or charge imposed in connection with the Transactions or the recording of any sale, transfer or assignment of property (or any interest therein) effected pursuant to this
Agreement. 
 “Transferred Books and Records” has the meaning set forth in Section 2.01(g). 

“Transferred Contracts” has the meaning set forth in Section 2.01(h). 

“Transferred Copyrights” has the meaning set forth in Section 2.01(d). 

“Transferred Governmental Authorizations” has the meaning set forth in Section 2.01(f). 

 “Transferred Intellectual Property” means the Transferred Patents, Transferred Trademarks, Transferred Copyrights and
Transferred Internet Domain Names. 
 “Transferred Internet Domain Names” has the meaning set forth in
Section 2.01(e). 
 “Transferred Patents” has the meaning set forth in
Section 2.01(b). 
 “Transferred Trademarks” has the meaning set forth in
Section 2.01(c). 
 “Upfront Payment” has the meaning set forth in
Section 2.06. 
 “Valid Claim” means a claim (a) of any issued, unexpired U.S. or foreign
Patent Right, which will not, in the country of issuance, have been rejected, revoked, nor held invalid or 

  
 10 

 
unenforceable by a Governmental Authority of competent jurisdiction in an unappealed (within the time allowed for appeal) or final, unappealable decision, or (b) of any U.S. or foreign
patent application within a Patent Right, which will not, in the country in question, have been cancelled, withdrawn, abandoned or finally rejected by a Judgment from which no appeal may be taken, nor been pending for more than [***]. 

Section 1.02    Other Definitional Provisions. 

(a)    The words “hereof”, “herein”, “hereto” and
“hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement. 

(b)    The terms defined in the singular have a comparable meaning when used in the plural, and vice versa.

 (c)    The terms “U.S. Dollars” and “$” mean lawful currency of the
United States. 
 (d)    The terms “include,” “includes” and “including”
means “including, without limitation.” 
 (e)    The words “will” and
“shall” have the same meaning. 
 (f)    When a reference is made in this Agreement to an
Article, a Section, an Exhibit or a Schedule, such reference shall be to an Article or a Section of, or an Exhibit or a Schedule to, this Agreement unless otherwise indicated. 

(g)    Time periods based on a number of days within or following which any payment is to be made or act is
to be done shall be calculated by excluding the day on which the period commences and including the day on which the period ends and, if applicable, by extending the period to the next Business Day following if the last day of the period is not a
Business Day. 
 (h)    The term “United States” shall refer to the United States of
America and its territories, including Puerto Rico. 
 ARTICLE II. 

PURCHASE AND SALE 

Section 2.01    Purchase and Sale of Assets. Upon the terms and subject to the conditions
set forth herein, at the Closing, Seller shall, and shall cause the Divesting Entities to, sell, convey, assign and transfer to Purchaser, and Purchaser shall purchase, acquire and accept from Seller and the Divesting Entities, free and clear of all
Liens (other than Permitted Liens), all of Seller’s and the Divesting Entities’ right title and interest in, to and under the assets, properties, goodwill and business of every kind and description and wherever located, whether tangible or
intangible, real or personal set forth below (collectively, the “Purchased Assets”):  

(a)    the Inventories; 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 11 

 (b)    all Patent Rights set forth on Schedule
2.01(b) (the “Transferred Patents”); 
 (c)    all active Trademark registrations
and Trademark applications and all material unregistered Trademarks set forth on Schedule 2.01(c) (the “Transferred Trademarks”); 

(d)    all active Copyright registrations set forth on Schedule 2.01(d) (the “Transferred
Copyrights”); 
 (e)    all active Internet Domain Name Registrations, together with all
renewals thereof and all goodwill associated therewith, set forth on Schedule 2.01(e) (the “Transferred Internet Domain Names”); 

(f)    all right and interest in all Governmental Authorizations set forth on Schedule 2.01(f)
(collectively, the “Transferred Governmental Authorizations”); 
 (g)    subject to
Section 6.04, all books and records (or portions of books and records), including laboratory notebooks and other records, pre-clinical and clinical studies lists, files (excluding
patent prosecution files), documents, correspondence, studies, reports, data (including all pharmacological, pre-clinical, clinical, analytical, quality control and manufacturing data (including batch records
and technical reports)) and other printed, written or electronic materials (in all cases, in any form or medium) that relate to, or that arise out of, the conduct of the Business or the Purchased Assets and in the possession or control of Seller or
any of its Affiliates (the foregoing records and documents, collectively the “Transferred Books and Records”); 

(h)    all proprietary rights to the information, data and work product proprietary to Seller, the
Divesting Entities or any of their Affiliates related exclusively to the research and development activities and pre-clinical and clinical trials conducted or being conducted in connection with the ALXN1101
Molecule or any Products; 
 (i)    all Contracts set forth on Schedule 2.01(i) (collectively, the
“Transferred Contracts”); and 
 (j)    all claims, counterclaims, defenses, causes of
action, rights under express or implied warranties, rights of recovery, rights of set-off, rights of subrogation and all other rights of any kind against any Third Party, to the extent relating to any Assumed
Liabilities or the ALXN1101 Molecule, any Products, or any Purchased Assets. 

Section 2.02    Matters Related to Purchased Assets. 

(a)    Notwithstanding anything in this Agreement to the contrary, this Agreement shall not constitute an
agreement to assign or transfer any Purchased Asset to the extent that such Purchased Asset is not assignable or transferable without the consent of any Person, other than Seller, Purchaser or any of their respective Affiliates, to the extent that
such consent shall not have been given prior to the Closing (each, a “Non-assigned Asset”); provided that, subject to Section 6.05, Seller shall use, both
prior to and for [***] after the Closing, commercially reasonable efforts to obtain, and Purchaser shall 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 12 

 
use its commercially reasonable efforts to assist and cooperate with Seller in connection therewith, all necessary consents to the assignment and transfer of each
Non-assigned Asset; provided, further, that, subject to Section 6.05, none of Seller, Purchaser or any of their respective Affiliates shall be required to pay money to
any Third Party, commence any litigation or offer or grant any accommodation (financial or otherwise) to any Third Party in connection with such efforts. With respect to any Non-assigned Asset, for a period
beginning on the Closing Date and ending on the earlier of (i) [***] and (ii) the date that is [***] months after the Closing Date, Seller shall, and shall cause the Divesting Entities to, cooperate in any lawful and reasonable arrangement
reasonably proposed by Purchaser under which Purchaser will obtain the economic claims, rights and benefits under the Non-Assigned Asset or related claim, right or benefit with respect to which the consent has
not been obtained in accordance with this Agreement; [***]. Such reasonable arrangement may include (A) the subcontracting, sublicensing or subleasing to Purchaser of any and all rights of Seller or any of its Affiliates against the other party
to a Third Party agreement arising out of a breach or cancellation thereof by the other party, and (B) the enforcement by Seller or any of its Affiliates of such rights. 

(b)    Seller provides no assurances to Purchaser that any consent, authorization, approval or waiver of a
Third Party contemplated by this Section 2.02 will be granted. Subject to compliance by Seller with the provisions of this Section 2.02, the Parties acknowledge and agree that neither Seller nor
its Affiliates shall be obligated to obtain any such authorization, approval, consent or waiver hereunder and neither (i) the failure to so actually obtain any such authorization, approval, consent or waiver in connection with the consummation
of the Transactions in and of itself nor (ii) any default or termination or Action commenced or threatened by or on behalf of any Person to the extent arising out of any such failure to so actually obtain any such authorization, approval,
consent or waiver in connection with the consummation of the Transactions in and of itself shall (to the extent that the necessity of such authorization, approval, consent or waiver was disclosed on the Schedules) be deemed (A) a breach of any
representation, warranty or covenant of Seller contained in this Agreement or (B) to cause any condition to Purchaser’s obligations to close the Transactions to be deemed not satisfied. 

Section 2.03    Excluded Assets. Notwithstanding anything to the contrary contained in
Section 2.01 or elsewhere in this Agreement, the following (collectively, the “Excluded Assets”): shall not be part of the sale and purchase contemplated hereunder and are excluded from the Purchased
Assets, and shall remain the property of Seller or its Affiliates after the Closing: 
 (a)    all cash
and cash equivalents of Seller and any of its Affiliates; 
 (b)    all Accounts Receivable; 

(c)    all Contracts other than the Transferred Contracts; 

(d)    all Governmental Authorizations of Seller or any of its Affiliates other than the Transferred
Governmental Authorizations; 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 13 

 (e)    all intellectual property of Seller or any of its
Affiliates other than the Transferred Intellectual Property; 
 (f)    all of the following: (A) any
records to the extent related to any Excluded Asset or Retained Liability, (B) any original tax records to the extent related to Taxes that constitute Retained Taxes (provided, however, that such Tax records shall be provided to Purchaser upon
Purchaser’s reasonable request), (C) any records of Seller or its Affiliates other than the Transferred Books and Records, (D) any attorney work product, attorney-client communications and other items protected by attorney-client or
similar privilege and (E) any documents that were received from Third Parties in connection with their proposed acquisition of the Purchased Assets or that were prepared by Seller or any of its Affiliates in connection therewith; 

(g)    all rights and claims of Seller or any of its Affiliates to the extent relating to any Excluded
Asset or any Retained Liability, including any such items arising under insurance policies and all guarantees, warranties, indemnities and similar rights in favor of Seller and its Affiliates in respect of any Excluded Asset or any Retained
Liability; 
 (h)    any refund or credit of Taxes to the extent attributable to any Retained Taxes; 

(i)    all rights of Seller and its Affiliates under this Agreement and the other agreements and
instruments executed and delivered in connection with this Agreement; 
 (j)    all land, buildings,
improvements and fixtures thereon owned or leased by Seller or any of its Affiliates; and 
 (k)    all
tangible personal property and other fixed assets and interests therein, including all equipment, furnishings, furniture and fixtures, owned or leased by Seller or any of its Affiliates, including the tangible personal property and other fixed
assets and interests therein, and any warranty rights applicable to such tangible personal property, fixed assets and equipment. 

Section 2.04    Assumption of Certain Obligations. Purchaser agrees, effective at the
Closing, to assume and to timely satisfy and discharge all Liabilities of Seller and its Affiliates, in each case other than the Retained Liabilities, solely to the extent arising out of or relating to the Purchased Assets after the Closing (all of
the foregoing Liabilities being collectively referred to hereinafter as the “Assumed Liabilities”). 

Section 2.05    Retained Liabilities. Notwithstanding any other provision of this
Agreement, Purchaser shall not assume any Liability of Seller and its Affiliates other than the Assumed Liabilities, each of which shall be retained and paid, performed and discharged when due by Seller and its Affiliates including but not limited
to those set forth below (such Liabilities being collectively referred to hereinafter as the “Retained Liabilities”): 

(a)    all Liabilities to the extent arising out of or related to any Excluded Asset; 

  
 14 

 (b)    all Accounts Payable, accrued expenses and other
current liabilities to the extent arising out of services or goods provided prior to the Closing (whether or not yet billed an due); 

(c)    all Liabilities of Seller and its Affiliates relating to any present or former employees, officers,
directors, retirees, independent contractors or consultants of Seller and its Affiliates, including any Liabilities associated with any claims for wages or other benefits, bonuses, accrued vacation, workers’ compensation, severance, retention,
termination or other payments; 
 (d)    all Liabilities of Seller and its Affiliates arising out of or
relating to the Purchased Assets, including any Retained Taxes, solely to the extent arising out of or relating to any actions or occurrence prior to the Closing; and 

(e)    any royalty or other similar payment related to the ALXN1101 Molecule to the extent incurred prior
to the Closing Date. 
 Section 2.06    Purchase Price. In consideration of the sale
and transfer of the Purchased Assets, Purchaser agrees to pay to Seller at the Closing, on behalf of Seller and each Divesting Entity, $1,000,000 (the “Upfront Payment”), exclusive of any Transfer Taxes, and to assume, satisfy and
discharge when due all Assumed Liabilities. The Upfront Payment shall be paid in immediately available funds by wire transfer on the Closing Date, in accordance with written instructions given by Seller to Purchaser not less than two
(2) Business Days prior to the Closing Date, in cash in U.S. Dollars. 

Section 2.07    Priority Review Voucher. 

(a)    If Purchaser or one of its Affiliates or licensees receives a Priority Review Voucher from the FDA
in respect of a Product and Purchaser, its Affiliate or licensee transfer the right to use such Priority Review Voucher to a Third Party in exchange for consideration (a “PRV Sale”), Purchaser shall, within [***] days following such
PRV Sale, pay to Seller in cash an amount equal to [***] percent ([***]%) of the gross proceeds that are directly attributable to such PRV Sale. 

(b)    If Purchaser or one of its Affiliates or licensees receives a Priority Review Voucher from the FDA
in respect of a Product and Purchaser, its Affiliate or licensee does not consummate a PRV Sale on or before the one hundred eightieth (180th) day following the receipt of such Priority Review Voucher, Purchaser shall, within [***] Business Days
following such date, pay to Seller $18,750,000. If, following such payment, Purchaser or one of its Affiliates or licensees consummates a PRV Sale, any amounts paid to Seller pursuant to this Section 2.07(b) shall be offset
against any amounts due pursuant to Section 2.07(a). 
 (c)    Purchaser’s
payment obligations set forth in this Section 2.07 are payable without interest and only with respect to the first Priority Review Voucher received by Purchaser or one of its Affiliates or licensees. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 15 

 Section 2.08    Milestone Payments.

 (a)    Development Milestone Payments. Purchaser shall make the following one-time payments to Seller (the “Development Milestone Payments”) after the achievement following the Closing Date by or on behalf of Purchaser of the applicable event set forth below by the first
Product (collectively, the “Development Milestone Events”). 
  

			
	 Development Milestone Event
	  	 Development Milestone Payment

	 [***]
	  	[***]
	 [***]
	  	[***]

 (b)    Sales Milestones. Purchaser shall make the following one-time payments to Seller (the “Sales Milestone Payments”, together with the Development Milestone Payments, the “Milestone Payments”) after the achievement following the Closing
Date by or on behalf of Purchaser of the applicable event set forth below by the first Product (collectively, the “Sales Milestone Events”, together with the Development Milestone Events, the “Milestone Events”).

  

			
	 Sales Milestone Event
	  	Sales Milestone Payment
	 Occurrence of [***] of such first Product in [***]
	  	[***]
	 Occurrence of [***] of such first Product in [***]
	  	[***]
	 First occurrence of [***]
	  	[***]
	 First occurrence of [***]
	  	[***]

 (c)    Purchaser shall notify Seller in writing as soon as reasonably
possible following the achievement of a Milestone Event. Purchaser shall pay to Seller the corresponding Milestone Payment within [***] days after achievement of the applicable Milestone Event. Each Milestone Payment shall be payable only once and
without interest, and no amounts shall be due for subsequent or repeated achievements of any Milestone Event (whether by the same Product or a different Product). In accordance with the foregoing, the maximum total Milestone Payments payable by
Purchaser to Seller under this Section 2.08 for all Products would be Twenty Million Dollars ($20,000,000). The Milestone Payments shall be non-refundable. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 16 

 Section 2.09    Royalties. 

(a)    Purchaser shall pay the following royalties to Seller (the “Royalty Payments”) as
set forth in the table below. The Royalty Payments shall be payable to Seller, on a Product-by-Product and country-by-country basis, until the last to occur of (i) the last to expire Valid Claim of a Transferred Patent that covers the composition of matter of such Product in such country, (ii) the
expiration of Regulatory Exclusivity granted by the applicable Governmental Authority for such Product in such country, and (iii) the [***] anniversary of the First Commercial Sale of such Product in such country (the “Royalty
Term”). The Royalty Payments shall be non-refundable. The Royalty Payments shall be payable to Seller within [***] days after the end of each Calendar Quarter. If the manufacture, use or sale of any
Product is covered by more than one of the Transferred Patents, multiple royalties shall not be due.  
  

					
	 Net Sales Tranche
	  	Royalty Rate for such
Portion of Net Sales	 	Royalty Rate Floor
	For that portion of aggregate Net Sales of all Products on a worldwide basis per Calendar Year of [***]	  	[***]	 	[***]
	For that portion of aggregate Net Sales of all Products on a worldwide basis per Calendar Year of [***]	  	[***]	 	[***]
	For that portion of aggregate Net Sales of all Products on a worldwide basis per Calendar Year of [***]	  	[***]	 	[***]
	For that portion of aggregate Net Sales of all Products on a worldwide basis per Calendar Year of greater than or equal to [***]	  	[***]	 	[***]

 (b)    Adjustments. Notwithstanding anything in
Section 2.09(a) to the contrary, 
 (i)    if at any time during the Royalty
Term for a given Product in a particular country, there is both (A) no Valid Claim of any Transferred Patent covering the composition of matter of such Product in such country and (B) no Regulatory Exclusivity in respect of such Product in
such country, the applicable royalty rate contemplated by Section 2.09(a) shall be reduced by [***] of the otherwise applicable royalty rate; 

(ii)    if at any time during the Royalty Term for a given Product in a particular country, there is no
Valid Claim of any Transferred Patent covering the composition of matter of such Product in such country but there is Regulatory Exclusivity in respect of such Product in such country, the applicable royalty rate contemplated by
Section 2.09(a) shall be reduced by [***] of the otherwise applicable royalty rate; and 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 17 

 (iii)    Purchaser will have the right to reduce the
royalties payable to Seller pursuant to Section 2.09(a) by an amount equal to [***] of any royalty payments paid by Purchaser or its Affiliates or its licensees or sublicensees of rights to any Product to any Third Party to
license any Patent Rights that are necessary to develop, manufacture, use, sell or otherwise commercialize the Products. 

(c)    Minimum Floor. In no event will any reductions under
Section 2.09(b)(i), Section 2.09(b)(ii) and Section 2.09(b)(iii) for any Product in any given Calendar Quarter during the Royalty Term reduce (x) the royalty rate
during such period to an amount that is less than the applicable royalty rate floor set forth in the table included in Section 2.09(a), or (y) the Royalty Payments due by Purchaser by more than [***] of the amount that
otherwise would have been due and payable to Seller in such Calendar Quarter for such Product but for the reductions set forth in Section 2.09(b)(i), Section 2.09(b)(ii) and
Section 2.09(b)(iii). 
 Section 2.10    Audits. Upon the
written request of Seller, Purchaser and/or its Affiliates as applicable, shall permit an independent certified public accounting firm of nationally recognized standing selected by Seller and reasonably acceptable to Purchaser, to have access during
normal business hours to such of the records of Purchaser as may be reasonably necessary for the sole purpose of verifying the basis and accuracy of payments made and other obligations under Section 2.07, Section 2.08 and
Section 2.09. Seller shall treat all financial information subject to review under this Section 2.10 in accordance with the confidentiality and non-use provisions of this Agreement, and
shall cause its accounting firm to enter into an acceptable confidentiality agreement with Purchaser obligating it to retain all such information in confidence pursuant to such confidentiality agreement. [***] The result of the audit shall, in the
absence of manifest error, be final and binding on the Parties. 

Section 2.11    Allocation of Purchase Price. Within [***] days after the Closing Date,
Purchaser shall prepare and deliver to Seller a statement allocating the purchase price (including the assumed liabilities) for Tax purposes, as finally determined in accordance with this Section 2.11. The Parties covenant and agree (a) to
report for Tax purposes the allocation of the purchase price (including assumed liabilities) among the Purchased Assets in a manner entirely consistent with such allocation, (b) that the Parties will cooperate with each other in connection with
the preparation, execution and filing of all Tax Returns related to such allocation and will take no position inconsistent with such allocation in the filing of any Tax Return, except upon a final determination by an applicable Taxing Authority and
(c) that the Parties will use commercially reasonable efforts to advise each other regarding the existence of any Tax audit, controversy or litigation related to such allocation. 

Section 2.12    Transfer Taxes. 

(a)    All Transfer Taxes payable in connection with the transfer of the Purchased Assets to Purchaser
under this Agreement and the Transactions shall be borne 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 18 

 
and paid solely by [***] when due in compliance with applicable Transfer Tax Laws; provided that, if [***] determines that it is required by applicable Law to pay any Transfer Taxes, then
[***] shall pay such Transfer Taxes, and [***] shall, subject to receipt of satisfactory evidence of payment thereof, promptly reimburse [***] in U.S. Dollars. 

(b)    Purchaser and Seller shall cooperate in making and timely filing all Tax Returns as may be required
to comply with the provisions of applicable Transfer Tax Laws. 
 Section 2.13    Risk of
Loss; Casualty and Condemnation. Prior to the Closing, any loss or damage to the Purchased Assets from fire, casualty or otherwise shall be the sole responsibility of Seller. At the Closing, title to the Purchased Assets will be
transferred to Purchaser and Purchaser will thereafter bear any risk of such loss or damage. 

Section 2.14    Certain Costs. All costs and fees associated with (a) removing and
moving any Purchased Asset to a location designated in writing by Purchaser and (b) transferring to Purchaser or one of its Affiliates the Transferred Patents and the Transferred Governmental Authorizations conveyed to Purchaser hereunder shall
be borne and paid [***]; provided that if any such amount shall be incurred by Seller or Purchaser, the other Party shall, subject to receipt of satisfactory evidence of the payment thereof, promptly reimburse the other Party for the amount
of such costs and expenses. 
 Section 2.15    Withholding. Purchaser shall be entitled
to deduct and withhold from any amounts otherwise payable to Seller under this Agreement such amounts as Purchaser, in its reasonable judgment, determines must be deducted and withheld with respect to the making of such payment under the Code, or
any applicable provisions of U.S. federal, state, or local or foreign Tax Law; provided, that prior to withholding, Purchaser shall use commercially reasonable efforts to provide prior notice to Seller to allow Seller an opportunity to
provide the appropriate withholding certificate to prevent or minimize such withholding. Such amounts so deducted and withheld shall be treated for all purposes of this Agreement as having been paid to Seller in respect of which such deduction
and withholding was made by Purchaser. 
 ARTICLE III. 

CLOSING 

Section 3.01    Closing. 

(a)    The Closing shall take place no later than three (3) Business Days after the satisfaction or
waiver of the conditions precedent to Closing specified in ARTICLE VII (other than those conditions that, by their nature, cannot be satisfied until the Closing Date) at the offices of Ropes & Gray LLP, Prudential Tower, 800 Boylston
St., Boston, Massachusetts (including any Persons connected by remote access to the Closing) or at such time and place as the Parties may mutually agree in writing. The date on which the Closing occurs is referred to as the “Closing
Date.” The Closing shall be deemed to occur and be effective as of 5 p.m. Boston time on the Closing Date. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 19 

 (b)    At the Closing, Seller shall deliver, or cause to
be delivered, to Purchaser the instruments and documents set forth on Exhibit A. 
 (c)    At the
Closing, Purchaser shall deliver to Seller (i) the Upfront Payment, by wire transfer in accordance with Section 2.06 and (ii) the instruments and documents set forth on Exhibit B. 

ARTICLE IV. 

REPRESENTATIONS AND WARRANTIES OF SELLER 

As of the Effective Date, Seller hereby represents and warrants to Purchaser as follows: 

Section 4.01    Organization. Seller is an unlimited liability company duly organized,
validly existing and in good standing under the Laws of Ireland. Each Divesting Entity is duly organized, validly existing and, where applicable, in good standing under the Laws of the jurisdiction of its organization. Seller and each Divesting
Entity is authorized to do business under the Laws of all jurisdictions in which it is required to be so authorized, except as would not, individually or in the aggregate, have a Material Adverse Effect. 

Section 4.02    Authority; Binding Effect. 

(a)    Seller and each Divesting Entity has all requisite corporate, limited liability company or other
similar organizational power and authority to own and operate its properties and assets and to carry on its business as it is now being conducted and as it is related to the Purchased Assets. Seller has all requisite corporate, limited liability
company or other similar organizational power and authority to execute and deliver this Agreement, and to carry out, or to cause to be carried out, the Transactions. The execution and delivery by Seller of this Agreement, and the performance by
Seller and each Divesting Entity of its obligations hereunder and thereunder, have been duly authorized by all requisite corporate action on the part of Seller and such Divesting Entity. 

(b)    This Agreement has been duly executed and delivered by Seller and, assuming the valid execution and
delivery by Purchaser, constitutes a legal, valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance,
moratorium or similar Laws affecting creditors’ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). 

Section 4.03    Non-Contravention. The execution,
delivery and performance of this Agreement by Seller, and the consummation of the Transactions, do not and will not (a) violate any provision of the certificate of incorporation or bylaws of Seller and the comparable organizational documents of
any Divesting Entity; (b) subject to obtaining the consents set forth in Schedule 4.03, materially conflict with, or result in the breach of, constitute a default under, or result in the termination, cancellation or acceleration (whether
after the giving of notice or the lapse of time or both) of any right or obligation of Seller or any Divesting Entity 

  
 20 

 
under any Transferred Contract; (c) assuming compliance with the matters set forth in Section 4.04 and Section 5.03, violate or result in a breach of,
or constitute a default under any Law or other restriction of any Governmental Authority to which the Purchased Assets, Seller or any Divesting Entity is subject; or (d) result in the creation of any Liens (other than Permitted Liens) upon the
Purchased Assets, except, with respect to clauses (b) and (c), for any violations, breaches, conflicts, defaults, losses, Liens, terminations, cancellations or accelerations that would not, individually or in the aggregate, reasonably be
expected to be material to the Purchased Assets. 
 Section 4.04    Governmental
Authorization. Except as set forth on Schedule 4.04, and other than the Transfer Letters to FDA, comparable documents required to transfer all other Transferred Governmental Authorizations and the Patent Assignment, the execution and
delivery of this Agreement by Seller, and the consummation of the Transactions, do not require any consent or approval of, or any notice to or other filing with, any Governmental Authority, except for consents, approvals, notices and filings the
failure of which to obtain would not, individually or in the aggregate, be material to the Purchased Assets. 

Section 4.05    No Litigation. There are no Actions pending or, to the Knowledge of
Seller, threatened in writing against Seller or any Divesting Entity with respect to the Purchased Assets. This Section 4.05 does not relate to intellectual property, which is the subject of
Section 4.08. 
 Section 4.06    Compliance with Laws. 

(a)    Seller and each Divesting Entity is and has been in compliance in all material respects with all
Laws applicable to the ownership of the Purchased Assets; and 
 (b)    Seller and each Divesting Entity
possesses, and is and has been in compliance in all material respects with, all Governmental Authorizations necessary for the conduct of its business as it is currently conducted in respect of ALXN1101 and the other Purchased Assets. 

(c)    Seller and each Divesting Entity has not received any notice of proceedings relating to the
revocation or modification of, or non-compliance with, any Governmental Authorizations which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a
Material Adverse Effect. 
 Section 4.07    Contracts. 

(a)    Schedule 4.07 sets forth each Transferred Contract that is or contains: 

(i)    a covenant by Seller, any Divesting Entities or any of their Affiliates not to compete or other
covenant restricting the research, development, product design, manufacturing, production, distribution, marketing, sale, commercialization or other similar activities relating to the ALXN1101 Molecule or any Product that materially impairs such
activities as the Business is currently conducted; 

  
 21 

 (ii)    (A) a continuing contract for the future
purchase of materials, supplies or equipment (other than purchase contracts and orders for inventory in the ordinary course of business consistent with past practice) or (B) a management, service, consulting or other similar type of Contract
(other than contracts for services in the ordinary course of business), in any such case which has an aggregate future liability to any person in excess of [***] and is not terminable by Seller, any Divesting Entities or any of their Affiliates, as
applicable, by notice of not more than [***] days for a cost of less than [***]; 
 (iii)    any
(A) Contract pursuant to which (1) Seller, any of the Divesting Entities or any of their Affiliates is granted by any other person any license or other right to use, or a covenant not to sue with respect to, or is assigned by any person,
any Intellectual Property that relates to the ALXN1101 Molecule, any Product, or otherwise relates to the Business (other than shrink wrap agreements for off-the-shelf
software with a replacement cost and/or annual license fees of less than [***]), (2) Seller, any of the Divesting Entities or any of their Affiliates grants to any other person, any license or other right to use, or a covenant not to sue with
respect to, or assigns to any person, any Intellectual Property that relates to the ALXN1101 Molecule, any Product, or otherwise to the Business, or (3) any research or pre-clinical or clinical
development activities are conducted with respect to the ALXN1101 Molecule, a Product or any Transferred Intellectual Property, and (B) any other agreement (including any option) relating in whole or in part to any Transferred Intellectual
Property; 
 (iv)    any arrangement, agreement or other Contract with any academic institution, research
center or Governmental Authority (or any person working for or on behalf of any of the foregoing) that relates to the ALXN1101 Molecule, any Product, the Business or any Purchased Assets, including for the development or other creation of any
Transferred Intellectual Property; or 
 (v)    any other agreement, contract, lease, license, commitment
or instrument to which Seller, any of the Divesting Entities or any of their Affiliates is a party and by or to which the Business, the ALXN1101 Molecule, any Product or any of the Purchased Assets is bound or subject which has an aggregate future
liability to any person in excess of [***] and is not terminable by Seller, such Divesting Entity or such Affiliate, as applicable, by notice of not more than [***] days for a cost of less than [***]. 

(b)    Seller has made available to Purchaser true and complete copies of all Transferred Contracts.
(a) Each Transferred Contract is valid and binding on Seller or the Divesting Entity that is a party thereto and, to the Knowledge of Seller, the other party thereto, and is in full force and effect in accordance with its terms, subject to
bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law),
and (b) neither Seller nor any Divesting Entity or, to the Knowledge of Seller, any other party thereto is in material breach of, or material default under, any Transferred Contract, and no event has occurred that, with the giving of notice or
lapse of time or both, would constitute a material breach or material default thereunder. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 22 

 Section 4.08    Intellectual Property.

 (a)    Schedule 4.08(a) sets forth a complete and accurate list of all (i) Patent Rights,
(ii) active Trademark registrations and applications for registration of any Trademarks, and (iii) active registered Copyrights, in each case included in the Transferred Intellectual Property, and specifies as to each such item:
(A) the current owner(s) (including any co-owner) thereof (and, if the owner is not Seller or one of the Divesting Entities, the corresponding license agreement pursuant to which Seller and/or any of the
Divesting Entities has the right to use such Intellectual Property), (B) the jurisdiction of each application and/or registration or issuance, (C) the issuance, serial, application and/or registration number, and (D) the date of issuance,
application or registration (collectively, the “Scheduled Intellectual Property”). The Scheduled Intellectual Property is subsisting and in full force and effect, and all required actions and payments in respect of the Scheduled
Intellectual Property have been taken or made in a timely manner (including, as applicable, with respect to the payment of filing, examination and maintenance fees, proofs of working or use, disclosure requirements, timely post-registration filing
of affidavits of use and incontestability and renewal applications) and no filings, responses or other actions are required to be taken, and no renewal, maintenance or other fees are due, during the ninety (90) day period following the Closing
Date. 
 (b)    As of the Effective Date, to there is no objection or claim being asserted by any Person
or threatened in writing, with respect to the ownership, validity, enforceability or use of any of the Transferred Intellectual Property (including any opposition, cancellation, interference, reissue, reexamination or other similar proceeding). 

(c)    On the Effective Date, Seller or one or more of the Divesting Entities is and, at the Closing,
Seller or one or more of the Divesting Entities will be, the sole and exclusive owner of all right, title and interest in and to, or the holder of a valid and enforceable right or license pursuant to a written license agreement set forth in
Schedule 4.07(a)(iii)(A)(1), the Transferred Intellectual Property, free and clear of all Liens, including any royalty payment or other obligations or contractual limitations (other than pursuant to the terms of any agreement set forth in
Schedule 4.08(c)). The consummation of the transactions contemplated hereby will not conflict with, alter or impair any such rights of Seller or such Divesting Entities in or to any of the Transferred Intellectual Property (including not
causing any supplemental payments of any kind to be due to any Person as a result of the Closing ), and the Transferred Intellectual Property shall be solely and exclusively owned or available for use by Purchaser immediately after the Closing on
terms and conditions identical to those under which Seller or such Divesting Entities owned and/or used the Transferred Intellectual Property immediately prior to the Closing. 

  
 23 

 (d)    Neither Seller nor any of the Divesting Entities
nor any of their Affiliates owns or otherwise possesses, any right, title or interest in or to any Patent Rights or other Intellectual Property that relate to the ALXN1101 Molecule or any Products, including any that relates to the exercise of any
Transferred Patents, or that would be necessary for the research, development, use, manufacture, commercialization and/or other exploitation of the ALXN1101 Molecule or any Products, and not included in the Purchased Assets. 

(e)    (i) There have been no claims asserted since [***], and, as of the Effective Date, there are no
claims pending or threatened, by Seller or any of the Divesting Entities or any of their Affiliates against any Person, and (ii) neither Seller nor any of the Divesting Entities nor any of their Affiliates has sent since [***] any written
notice to any Person, in each case of (i) and (ii) regarding any actual or potential infringement, dilution, misappropriation or other unauthorized use of any Transferred Intellectual Property by such Person. To the Knowledge of Seller, no
Person has infringed, misappropriated or otherwise violated any Transferred Intellectual Property. 

(f)    To the Knowledge of Seller, the conduct of the Business, including the research, development,
manufacture and commercialization of ALXN1101 Molecule or Products by or on behalf of Seller, the Divesting Entities, or their Affiliates or licensees, has not infringed, misappropriated or otherwise violated, and will not constitute an
infringement, misappropriation or otherwise violation of the Intellectual Property rights of any other Person. (i) There have been no adverse Third Party actions or claims against Seller or any of the Divesting Entities or any of their
Affiliates by any Person in any court, arbitration or by or before any Governmental Authority since [***], and, as of the Effective Date, no such actions or claims are pending or, to the Knowledge of Seller, threatened against Seller or any of the
Divesting Entities or any of their Affiliates, and (ii) neither Seller nor any of the Divesting Entities nor any of their Affiliates has received written notice of any such actions or claims, in each case of (i) and (ii), alleging that the
development, manufacture, marketing or sale of the ALXN1101 Molecule or any Products infringes, misappropriates or otherwise violates, the Intellectual Property rights of any other Person. 

(g)    No Transferred Intellectual Property is subject to any outstanding consent, settlement, decree,
order, injunction, judgment or ruling, or any Contract, restricting or otherwise limiting the use, ownership, validity, enforceability, disposition or exploitation thereof. 

(h)    To the Knowledge of Seller, no funding, Intellectual Property, facilities, personnel or other
resources of any Governmental Authority or university or other academic institution or research center or of any other person has been used in connection with the conception, invention, reduction to practice, development or other creation of any
Intellectual Property relating to the ALXN1101 Molecule or Products or otherwise included in the Transferred Intellectual Property, except for any such funding or use of Intellectual Property, facilities, personnel or other resources that has not
resulted and would not result in such Governmental Authority or university or other academic institution or research center obtaining ownership rights or any other similar right, title or interest (including any “march in” rights) in or to
any Intellectual Property relating to the ALXN1101 Molecule or Products or otherwise included in the Transferred Intellectual Property (including any claim or option to any of the foregoing). 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 24 

 (i)    Seller and the Divesting Entities have taken
commercially reasonable steps to protect, maintain and enforce all Transferred Intellectual Property, including the secrecy, confidentiality and value of trade secrets and other confidential information included in the Purchased Assets. Seller and
each of the Divesting Entities have required each of its current and former employees, consultants and independent contractors to enter into valid and enforceable agreements with Seller or such Divesting Entity pursuant to which such person or
entity agreed to maintain and protect the confidential information of Seller or such Divesting Entity and made an assignment to Seller or such Divesting Entity of a present grant of ownership in all Intellectual Property authored, developed or
otherwise created by such person or entity in the course of its employment or other engagement with Seller or such Divesting Entity. 

(j)    Seller and the Divesting Entities are and have been in compliance with (i) all applicable Laws
relating to the privacy of patient medical records and all other personal information and data, including with respect to the collection, storage, use, sharing, transfer, disposition, protection and processing thereof (including in connection with
any clinical trials conducted with respect to the ALXN1101 Molecule or any Product), and (ii) all privacy policies and other related policies, programs and other notices of Seller or any of the Divesting Entities relating to the privacy of
patient medical records and all other personal information and data, in each case to the extent applicable to the Business or the Purchased Assets. Neither Seller nor any of the Divesting Entities has been subject to any security breaches with
respect to any personal information or data, and there have not been any complaints, notices, audits, proceedings, investigations or claims conducted or asserted by any other Person (including any Governmental Authority) regarding any collection or
use of any patient medical records or other personal information or data by or on behalf of Seller or any of the Divesting Entities in connection with the ALXN1101 Molecule, any Products or the conduct of the Business (including in connection with
any clinical trials conducted with respect to the ALXN1101 Molecule or any Product) or any violation of applicable Laws, and neither Seller nor any of the Divesting Entities has received any notices, correspondence or other communications from any
Person alleging any of the foregoing, and to the Knowledge of Seller, there is no reasonable basis for the same and no such claim has been threatened or is currently pending. 

Section 4.09    Brokers. No broker, finder or investment banker is entitled to any
brokerage, finder’s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of Seller or any of the Divesting Entities. 

Section 4.10    Purchased Assets. 

(a)    Seller and the Divesting Entities are the sole owners of the Purchased Assets. Seller and the
Divesting Entities have good and valid title to all the Purchased Assets free and clear of all Liens, except for Permitted Liens. This Section 4.10(a) does not relate to intellectual property, which is the subject of
Section 4.08. 

  
 25 

 (b)    The Purchased Assets constitute all of the
assets, rights or properties (tangible or intangible) owned or controlled by, or in the possession of, Seller, the Divesting Entities or their respective Affiliates that are exclusively related to or necessary for the Business, other than those
assets set forth on Schedule 4.10(b) or any Contract that Purchaser elects to remove from Schedule 2.01(i)(b) in accordance with Section 6.15. This Section 4.10(b) does not relate to
intellectual property, which is the subject of Section 4.08. 

Section 4.11    Inventories. All finished goods included in the Inventories as of such
date consist in all material respects of inventory of a quality sufficient for use in the ordinary course of the business, including being manufactured in all material respects with current Good Manufacturing Practice (cGMP) requirements for the
Products. 
 Section 4.12    Tax Representations. 

(a)    Seller and each of the Divesting Entities has timely filed all material Tax Returns with respect to
the Purchased Assets which are required to be filed under applicable Law, and all such Tax Returns are true, correct and complete in all material respects. 

(b)    All Taxes due and payable by Seller and the Divesting Entities with respect to the Purchased Assets,
whether or not shown or required to be shown on any Tax Return, have been timely paid to the appropriate Taxing Authority and no Taxes are delinquent. 

(c)    There are no Liens for Taxes upon any of the Purchased Assets, other than Permitted Liens. 

(d)    No deficiency for any amount of Tax in respect of the Purchased Assets has been asserted, written or
orally, or assessed by a Taxing Authority against Seller or any of the Divesting Entities, and neither Seller nor any of the Divesting Entities reasonably expects that any such assertion or assessment of Tax liability will be made. 

(e)    There is no Action or any notice of inquiry of any of the foregoing pending against or with respect
to Seller or any of the Divesting Entities regarding Taxes in respect of the Purchased Assets and, to the Knowledge of Seller, no Action or audit has been threatened against or with respect to Seller or any of the Divesting Entities regarding Taxes
in respect of the Purchased Assets. 
 (f)    No claim has ever been made by a Taxing Authority in a
jurisdiction where Seller or any of the Divesting Entities does not file Tax Returns that Seller or any of the Divesting Entities is or may be subject to taxation by that jurisdiction or may be required to file a Tax Return in that jurisdiction.

 (g)    Neither Seller nor any of the Divesting Entities has any obligation for Taxes pursuant to any
Contract that Purchaser is assuming as a result of the Transactions. None of the Contracts that are included in Purchased Assets is treated as a partnership or other entity for any applicable Tax purposes. 

  
 26 

 Section 4.13    Regulatory Matters.

 (a)    The ALXN1101 Molecule has been and is being developed, manufactured, packaged, labeled, stored,
tested and distributed by Seller in material compliance with all applicable requirements under the Federal Food, Drug and Cosmetic Act, Public Health Service Act and their implementing regulations and all comparable state, local and foreign Laws.

 (b)    Except as set forth on Schedule 4.13(b), all nonclinical studies conducted by or on
behalf of Seller and intended to be submitted in support of any Regulatory Approval of the ALXN1101 Molecule have been, and are being, conducted in material compliance with the requirements of Good Laboratory Practice as contained in 21 C.F.R. Part
58 and comparable foreign requirements, as applicable. 
 (c)    All manufacturing operations conducted
in respect of the production of clinical quantities of the ALXN1101 Molecule have been and are being conducted in material compliance with current Good Manufacturing Practices, as promulgated by the FDA under the Federal Food, Drug, and Cosmetic
Act, as amended, 21 C.F.R. Parts 210 and 211, 21 C.F.R. Parts 600-610 and any successor legislation and/or regulations, and comparable foreign Laws, as applicable. 

(d)    All clinical trials conducted by or on behalf of Seller in connection with the ALXN1101 Molecule
have been, and are being, conducted in material compliance with the applicable requirements of Good Clinical Practice, Informed Consent, and all other applicable requirements relating to protection of human subjects specifically contained in 21
C.F.R. Parts 312, 50, 54, 56, and 11 and all applicable Laws, including all comparable foreign Laws. 

(e)    Seller has an investigational new drug application in effect with the FDA and, as required by
applicable Laws, similar foreign Governmental Authorizations in effect with applicable foreign Governmental Authorities for the ALXN1101 Molecule manufactured by synthetic means and not in recombinant form, and has conducted its clinical trial
activities in connection with the ALXN1101 Molecule in accordance with such investigational new drug application and similar foreign authorizations or any amendment or supplement thereto. No clinical trials conducted by or on behalf of Seller in
connection with the ALXN1101 Molecule is, or has been, subject to any clinical hold or suspension. 

(f)    Seller has not used in any capacity the services of any Person debarred under section 306 of the
Federal Food, Drug, and Cosmetic Act or any similar state or foreign Law in connection with any work performed or to be performed on the ALXN1101 Molecule. 

(g)    There has not been, nor, to the Knowledge of Seller, is there currently under consideration by
Seller or any Governmental Authority, any recall, market withdrawal, safety alert, “Dear Doctor” letter, public health notification or other safety communication in respect of the ALXN1101 Molecule, except for such instance which would not
have a Material Adverse Effect. 

  
 27 

 (h)    Except for ordinary course inquires, Seller has
not received, with respect to the ALXN1101 Molecule, any notice or communication from the FDA or any comparable state, local or foreign Governmental Authority alleging noncompliance with any applicable Laws, except for such instances which would not
have a Material Adverse Effect, and Seller is not subject to any enforcement proceedings by the FDA or any comparable state, local or foreign Governmental Authority and, to the Knowledge of Seller, no such proceedings have been threatened. 

(i)    The product registration files and dossiers of Seller in respect of the ALXN1101 Molecule have been
maintained in accordance with all applicable Laws and guidance documents in all material respects. 

Section 4.14    Disclosure. Seller has made available to Purchaser true and complete
copies of all documents requested by Purchaser or listed in the Schedules to this Agreement (including any attachment thereto, such that the contents of such copies comprise the entire agreement between the parties thereto) or in any other
Exhibit or Schedule called for by this Agreement. 
 Section 4.15    Exclusivity
of Representations. The representations and warranties made by Seller in this ARTICLE IV and in any certificate, instrument or other document required to be delivered pursuant to this Agreement by Seller or any of the Divesting Entities
are the exclusive representations and warranties made by Seller with respect to Seller and the Divesting Entities, including the ALXN1101 Molecule and the Purchased Assets. Seller hereby disclaims any other express or implied representations or
warranties with respect to itself or any of the Divesting Entities, including the ALXN1101 Molecule and the Purchased Assets. It is understood that any other materials made available to Purchaser or its Affiliates do not, directly or indirectly, and
shall not be deemed to, directly or indirectly, contain representations or warranties of Seller, the Divesting Entities or their respective Affiliates. 

ARTICLE V. 

REPRESENTATIONS AND WARRANTIES OF PURCHASER 

As of the Effective Date, Purchaser hereby represents and warrants to Seller as follows: 

Section 5.01    Organization. Purchaser is a corporation duly organized, validly existing
and in good standing under the Laws of the State of Delaware. Purchaser is authorized to do business under the Laws of all jurisdictions in which it is required to be so authorized, except as would not reasonably be expected to have a Purchaser
Material Adverse Effect. 
 Section 5.02    Authority; Binding Effect. 

(a)    Purchaser has all requisite power and authority to own and operate its properties and assets, to
carry on its business as it is now being conducted and to execute and deliver this Agreement, and to carry out or cause to be carried out, the Transactions. 

  
 28 

 
The execution and delivery by Purchaser of this Agreement, and the performance by Purchaser of its obligations hereunder and thereunder, have been duly authorized by all requisite corporate
action on the part of Purchaser, including resolutions duly adopted and not subsequently rescinded or modified in any way by the Board of Directors of Purchaser (i) resolving that this Agreement, and the Transactions, are in the best interests
of Purchaser and its shareholders and (ii) approving the execution, delivery and performance of this Agreement by Purchaser. No approval of Purchaser’s equity interest holders is necessary for Purchaser to execute and deliver this
Agreement or perform the Transactions. 
 (b) This Agreement has been duly executed and delivered by Purchaser and, assuming
the valid execution and delivery by Seller, constitutes a legal, valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization,
fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). 

Section 5.03    Non-Contravention. The execution,
delivery and performance by Purchaser of this Agreement, and the consummation of the Transactions, do not and will not (a) violate any provision of the certificate of incorporation, bylaws or other organizational documents of Purchaser;
(b) conflict with, or result in a breach of, constitute a default under or result in the termination, cancellation or acceleration (whether after the giving of notice or the lapse of time or both) of any right or obligation of Purchaser or any
of its Affiliates under, or to a loss of any benefit to which Purchaser or any of its Affiliates is entitled under, any agreement, lease of real estate or license of intellectual property to which Purchaser or any of its Affiliates is a party or to
which its properties or assets are subject; or (c) assuming compliance with the matters set forth in Section 4.04 and Section 5.03, violate or result in a breach of or constitute a default under any Law or other
restriction of any Governmental Authority to which Purchaser is subject, except, with respect to clauses (b) and (c), for any violations, breaches, defaults, conflicts, losses, Liens, terminations, cancellations or accelerations except as would
not reasonably be expected to be material to Purchaser’s ability to consummate the Transactions and to perform its obligations hereunder. 

Section 5.04    Governmental Authorization. The execution and delivery of this Agreement
by Purchaser, and the consummation of the Transactions, do not require any consent or approval of, or any notice to or other filing with, any Governmental Authority, except for consents, approvals, notices and filings the failure of which to obtain
or make would not, reasonably be expected to be material to Purchaser’s ability to consummate the Transactions and to perform its obligations hereunder. 

Section 5.05    Brokers. No broker, finder or investment banker is entitled to any
brokerage, finder’s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of Purchaser or any of its Affiliates. 

Section 5.06    Financial Capability. Purchaser has, or has access to, sufficient cash to
pay the Upfront Payment on the terms and conditions contemplated by this Agreement and to pay its fees and expenses related hereto, and, following the Closing, Purchaser will be able to satisfy its Liabilities as they become due. 

  
 29 

 Section 5.07    Solvency. As of the
Effective Date, after giving effect to all of the Transactions contemplated by this Agreement, including without limitation the payment of the Upfront Payment, and assuming for these purposes the satisfaction of the conditions set forth in
Section 7.01, as of the Effective Date the Purchaser shall be Solvent. For the purposes of this Section 5.07, the term “Solvent” when used with respect to any Person, means that, as of
any date of determination, (a) the “fair saleable value” of the assets of such Person will, as of such date, exceed (i) the value of all “liabilities of such Person, including contingent and other liabilities,” as of
such date, as such quoted terms are generally determined in accordance with applicable federal laws governing determinations of the insolvency of debtors, and (ii) the amount that will be required to pay the probable liabilities of such Person
on its existing debts (including contingent liabilities) as such debts become absolute and matured, (b) such Person will not have, as of such date, unreasonably small capital for the operation of the businesses in which it is engaged or
proposed to be engaged following such date and (c) such Person will be able to pay its liabilities, including contingent and other liabilities, as they mature. 

Section 5.08    Exclusivity of Representations. The representations and warranties made
by Purchaser in this ARTICLE V and in any certificate, instrument or other document required to be delivered pursuant to this Agreement by the Purchaser, are the exclusive representations and warranties made by Purchaser with respect to the
Transaction. It is understood that any other materials made available to Seller or its Affiliates do not, directly or indirectly, and shall not be deemed to, directly or indirectly, contain representations or warranties of the Purchaser. 

ARTICLE VI. 
 COVENANTS

 Section 6.01    Conduct of Business. 

(a)    From the Effective Date to the Closing Date, except as otherwise permitted by this Agreement or
consented to by Purchaser in writing (which consent shall not be unreasonably withheld, conditioned or delayed), Seller shall use (and to cause each Divesting Entity to use) reasonable best efforts to: 

(i)    maintain the condition of the Purchased Assets; 

(ii)    with respect to Transferred Patents that are not subject to the Transferred Contracts, maintain in
effect all Transferred Patents and applications and registrations included in the Transferred Patents, and maintain in effect all registrations and applications for all other registered Intellectual Property constituting the Transferred Intellectual
Property; and 
 (iii)    perform its obligations in all material respects under the Transferred
Contracts. 

  
 30 

 (b)    Seller shall not (and shall cause each Divesting
Entity not to) without the prior written consent of Purchaser (which consent shall not be unreasonably withheld, conditioned or delayed): 

(i)    enter into any transaction or take any action that would reasonably be expected to result in any of
Seller’s representations and warranties in this Agreement or in any of the documents required to be delivered by this Agreement (disregarding any qualification as to materiality) not being true and correct in all material respects; 

(ii)    commence any Action with respect to the Purchased Assets; 

(iii)    pledge, sell, lease, transfer, license, assign or otherwise make subject to a Lien (other than any
Permitted Liens) any interest in any Purchased Asset; 
 (iv)    waive any material claims or rights of
material value that relate exclusively to the Purchased Assets; 
 (v)    transfer, assign, grant any
license or sublicense, or otherwise dispose of any rights under or with respect to any Transferred Intellectual Property; 

(vi)    terminate, modify or amend in any material respect any Transferred Contract or Transferred
Governmental Authorization; 
 (vii)    enter into any Contract related to the Business or any of the
Purchased Assets, or enter into any Contract regarding any clinical trial not ongoing as of the date of this Agreement; 

(viii)    make, or amend, any filings with the FDA, the EMA or any other Governmental Authority performing
functions similar to those performed by the FDA, the EMA or such other Governmental Authority related to the Business or any of the Purchased Assets; 

(ix)    settle any claims, actions, arbitrations, disputes or other proceedings affecting the Purchased
Assets or the Business; or 
 (x)    agree, whether in writing or otherwise, to do any of the foregoing.

 (c)    Notwithstanding the foregoing, nothing herein prevents Seller or any of its Affiliates from
taking actions, including (i) contributions, transfers, assignments and acceptances of assets and liabilities; (ii) the repayment of indebtedness and the extinguishment of Liens; and (iii) the cancellation of any intercompany
contracts and any other agreements that will not constitute Transferred Contracts, in each case in order to facilitate the consummation of the Transactions. 

  
 31 

 Section 6.02    Condition of the Purchased
Assets. 
 (a)    In light of such inspections and investigations, and the representations and
warranties expressly made to Purchaser by Seller in this Agreement and the certificates and other documents delivered pursuant hereto, PURCHASER AGREES THAT THE REPRESENTATIONS AND WARRANTIES GIVEN HEREIN BY SELLER ARE IN LIEU OF, AND PURCHASER
HEREBY EXPRESSLY WAIVES ALL RIGHTS TO, ANY IMPLIED WARRANTIES THAT MAY OTHERWISE BE APPLICABLE BECAUSE OF THE PROVISIONS OF THE UNIFORM COMMERCIAL CODE OR ANY OTHER LAWS, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
PURPOSE. 
 (b)    Except in the event of Fraud, any claims Purchaser may have for breach of
representation or warranty will be based solely on the representations and warranties of Seller or the Divesting Entities expressly set forth in this Agreement and the certificates and other documents delivered pursuant hereto or thereto. 

(c)    Except in the event of Fraud, Purchaser further acknowledges and agrees that neither Seller, its
Affiliate, nor any other Person, has made any representation, warranty or statement, express or implied, regarding Seller, any of the Divesting Entities, the Purchased Assets or the Assumed Liabilities not expressly set forth in this Agreement or
the certificates or other documents delivered pursuant hereto or thereto upon which Purchaser has relied, and neither Seller nor any of its Affiliates or any other Person will have, or be subject to, any liability to Purchaser or any other Person
resulting from the distribution to Purchaser or its Representatives, or Purchaser’s use of, any such information, including confidential memoranda distributed by or on behalf of Seller or any Divesting Entity relating to the ALXN1101 Molecule,
the Purchased Assets or the Assumed Liabilities or any other publication, document or information provided in the Data Room or otherwise provided to Purchaser prior to the Closing Date. 

(d)    Without limiting the representations and warranties of the Seller in ARTICLE IV, Purchaser
acknowledges and agrees that (i) it may have received from Seller various forward-looking statements (including estimates, assumptions, projections, forecasts and plans) regarding the ALXN1101 Molecule and the Purchased Assets (collectively,
the “Forward-Looking Statements”) in connection with Purchaser’s investigation of the Purchased Assets; (ii) there are uncertainties inherent in attempting to make such Forward-Looking Statements; (iii) Purchaser is
familiar with such uncertainties; (iv) Purchaser has made its own investigation, examination and valuation of the Purchased Assets, and has employed outside professionals to assist with such investigation, examination and valuation;
(v) Purchaser is not relying on any Forward-Looking Statement in any manner whatsoever; and (vi) Purchaser has no claim against Seller or any of its Affiliates with respect to the foregoing. Without limiting the representations and
warranties of the Seller in ARTICLE IV, Purchaser further acknowledges and agrees that Seller makes no representation or warranty hereunder with respect to (A) the reasonableness of the assumptions underlying any Forward-Looking
Statement; or (B) any Forward-Looking Statement made in any materials in the Data Room, any supplemental due diligence information provided or made available to Purchaser, any of Purchaser’s discussions with management regarding the
ALXN1101 Molecule or the Purchased Assets, any negotiations leading to this Agreement, or any other circumstance. 

  
 32 

 Section 6.03    Publicity. No Party to
this Agreement shall originate any publicity, news release or other public announcement, written or oral, whether relating to this Agreement or the existence of any arrangement between the Parties, without the prior written consent of the other
Party (whether such other Party is named in such publicity, news release or other public announcement or not), except where such publicity, news release or other public announcement is required by Law or any listing or trading agreement concerning
its publicly traded securities, provided that, in such event, the Party issuing the same shall still be required to consult with the other Party (whether such other Party is named in such publicity, news release or public announcement or not)
at a reasonable time prior to its release to allow the other Party to comment thereon and, after its release, shall provide the other Party with a copy thereof. If Purchaser, based on the advice of its counsel, determines that this Agreement must be
filed with the United States Securities and Exchange Commission (“SEC”) or any other similar Governmental Authority, then Purchaser, prior to making any such filing, shall provide Seller and its counsel with a redacted version of
this Agreement which it intends to file and any draft correspondence with the SEC requesting the confidential treatment by the SEC of those redacted sections of the Agreement, and will give due consideration to any comments provided by Seller or its
counsel and use commercially reasonable efforts to ensure the confidential treatment by the SEC of those sections specified by Seller or its counsel. 

Section 6.04    Books and Records; Regulatory Information. Seller shall use commercially
reasonable efforts to transfer to Purchaser on the Closing Date (or as soon as reasonably practicable after the Closing Date) the Transferred Books and Records and Regulatory Information in the possession or under the control of Seller and its
Affiliates. Seller may transfer copies or originals of the Transferred Books and Records and Regulatory Information at its election. 

Section 6.05    Further Assurances; Transition Plan. 

(a)    From time to time after the Closing, and for no further consideration (other than reimbursement for
expenses incurred in packing or shipping any Purchased Asset), each of the Parties shall, and shall cause its Affiliates to, execute, acknowledge and deliver such assignments, transfers, consents, assumptions and other documents and instruments and
take such other commercially reasonable actions as may reasonably be requested to more effectively assign, convey or transfer to or vest in: (a) Purchaser and its designated Affiliates, all rights, title and interests in, to and under the
Purchased Assets and the Assumed Liabilities contemplated by this Agreement to be transferred or assumed at the Closing and (b) Seller, any rights, title or interests in, to or under any Excluded Asset that may have been transferred to
Purchaser at Closing; provided that the foregoing obligations with respect to the transfer to Purchaser of the Transferred Patents shall terminate [***] months after the Closing Date. Purchaser agrees that, following the Closing, it shall
prepare any such additional instruments or documents necessary to assign, convey or transfer the Transferred Patents and the Transferred Governmental Authorizations [***]. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 33 

 (b) From time to time after the Closing and through December 31, 2018,
and for no additional consideration, Seller shall provide or cause to be provided, access to qualified personnel from Seller or any of its Affiliates familiar with the Business and make such personnel available at Purchaser’s reasonable advance
request to meet and participate in telephone conference calls with personnel from Purchaser or Purchaser’s designee at such times, and in the case of in-person meetings, at such venues, to be agreed upon
by the Parties, as reasonably requested by Purchaser. From time to time after the Closing and through December 31, 2018, Seller shall use commercially reasonable efforts to respond to reasonable document and other information requests related
to the Purchased Assets with copies of such requested materials (or redacted portions thereof), to the extent within Seller’s possession or control; provided that Seller may restrict the foregoing access to the extent that (i) such
restriction is required by applicable Law, (ii) such access or provision of information would reasonably be expected to result in a violation of confidentiality obligations to a third party, (iii) disclosure of any such information would
result in the loss or waiver of the attorney-client privilege or (iv) such information constitutes an Excluded Asset. Notwithstanding the foregoing, personnel from Seller and its Affiliates shall not be obligated to spend more than an aggregate
of [***] hours providing the services required by this Section 6.05(b) during the [***] month-period immediately following the Closing nor more than [***] hours in any subsequent [***] month-period. Seller and Purchaser
shall each designate a transition manager to act as the primary contact person with respect to all matters relating to this Section 6.05. Each Party may replace its transition manager at any time upon written notice to the
other Party. 
 (c)    Following the Closing, and for no additional consideration, Seller shall supply,
or cause to be supplied, to Purchaser the inventory for use in or relating to a Product in the quantities and upon the terms set forth in Schedule 6.05(c), subject to final release of Product in Seller’s sole discretion in accordance
with its quality standards. In no event shall Seller be responsible for providing Purchaser with replacement lots of Product in the event of any manufacturing failure. 

(d)    No later than [***] days after the date hereof, each Party shall prepare and deliver the Transfer
Letters to FDA and, following such submission to FDA, Purchaser, or its Affiliates, shall prepare and deliver comparable documents required to transfer all other Transferred Governmental Authorizations to the applicable Governmental Authorities.
Until each Party executes and delivers to FDA the Transfer Letters to FDA and the ALXN1101 Molecule investigational new drug application is transferred to Purchaser, for no additional consideration, Seller shall continue to act as sponsor, as that
term is defined in 21 C.F.R. § 312.3(b), and Seller shall use, and cause its Affiliates to use, commercially reasonable efforts to continue to: (i) comply with all applicable Laws; (ii) fulfill all other requirements and conditions
pursuant to the ALXN1101 Molecule investigational new drug application or any amendment or supplement thereto, including but not limited to: (1) conducting and monitoring all ongoing clinical trials and studies in respect of the ALXN1101
Molecule that are being conducted by or on behalf of Seller or its Affiliates as of the Closing Date; and (2) submitting all required reports, including investigational new drug safety reports and investigational new drug annual reports; and
(iii) provide the ALNX1101 Molecule for use in the United States in any compassionate 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 34 

 
use or named patients access programs in which Seller or its Affiliates participate. For each of the Transferred Governmental Authorizations required to conduct clinical trials in the applicable
foreign country, until the Transferred Governmental Authorization is effectively transferred to Purchaser, for no additional consideration, Seller shall continue to act as sponsor, or foreign equivalent, in that foreign country, and Seller shall
use, and cause its Affiliates to use, commercially reasonable efforts to continue to: (i) comply with all applicable Laws; (ii) fulfill all other requirements and conditions pursuant to the ALXN1101 Molecule Transferred Governmental
Authorization or any amendment or supplement thereto, including but not limited to: (a) maintaining the Transferred Governmental Authorization; (b) conducting and monitoring all ongoing clinical trials and studies in respect
of the ALXN1101 Molecule that are being conducted by or on behalf of Seller or its Affiliates as of the Closing Date; and (c) submitting all required reports; and (iii) provide the ALNX1101 Molecule for use in the foreign country in
any compassionate use or named patients access programs in which Seller or its Affiliates participate. 

Section 6.06    Bulk Transfer Laws. The Parties hereby waive compliance with the
provisions of applicable bulk sale or bulk transfer Laws or similar Laws that may otherwise be applicable with respect to the sale of any or all of the Purchased Asset. 

Section 6.07    Non-Competition. In connection
with the consideration to be paid by Purchaser to Seller hereunder and as an inducement to Purchaser to enter into this Agreement and consummate the transactions contemplated hereby, from the Closing Date until the [***] anniversary of the Closing
Date, Seller shall not, and shall cause its Affiliates not to, engage or participate (whether as an owner, operator, director, employee, officer, manager, consultant, advisor, representative or otherwise), directly or indirectly anywhere in the
world in any research, development, manufacture, or commercialization of any product with a similar mechanism of action for [***] (the “Restricted Field”); provided, [***]. Subject to the foregoing, Purchaser acknowledges and agrees
that: (a) [***]; and (b) [***]. 
 Section 6.08    Insurance. As of the Closing Date,
the coverage under all insurance policies of Seller and its Affiliates shall continue in force only for the benefit of the Seller and its Affiliates, and not for the benefit of Purchaser or any of its Representatives. As of the Closing Date,
Purchaser agrees to arrange for its own insurance policies (to the extent such policies are obtainable) with respect to the Purchased Assets covering all periods and agrees not to seek, through any means, to benefit from any of Seller’s or its
Affiliates’ insurance policies which may provide coverage for claims relating in any way to the Purchased Assets. For the avoidance of doubt, nothing contained in this Section 6.08 will adversely impact either Party’s rights to
indemnification under ARTICLE VIII. 
 Section 6.09    Diligence. Following the
Closing, Purchaser shall use, and shall cause its Affiliates and licensees to use, Commercially Reasonable Efforts to: [***]. Notwithstanding anything in this Agreement to the contrary, Seller acknowledges and agrees that notwithstanding anything in
this Agreement to the contrary, (A) upon the Closing, Purchaser shall have the right to own, operate, use, license, develop and otherwise commercialize the Products, in any way that Purchaser and its Affiliates deem appropriate, in its sole
discretion, (B) Purchaser has no obligation to own, operate, use, license, develop or otherwise commercialize 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 35 

 
the Product, in order to maximize or expedite the Milestone Payments or the Royalty Payments, (C) Purchaser has the exclusive right to determine the terms and conditions of the development
and commercialization of the Products and any and all sales of the Products, including the determination of whether or not to develop or commercialize the Products or the indications for which the Products may be developed or commercialized,
(D) there is no assurance that Seller will receive any Milestone Payments or Royalty Payments, (E) Purchaser has not promised or projected any amounts to be received by Seller in respect of any Milestone Payments or Royalty Payments, and
Seller has not relied on any statements or information provided by Purchaser with respect to the potential sales or value of the Product and (F) Purchaser owes no fiduciary duty to Seller, and Seller hereby expressly waives any fiduciary duty
of Purchaser to Seller; provided, however, that (I) clauses (A) through (F) shall not apply to Purchaser’s obligations pursuant to Section 6.09(a) and (II) Purchaser shall not take any actions or make
any operational changes with the specific intent to eliminate or otherwise minimize Net Sales or the development of any Product for the specific purposes of avoiding achievement of Milestone Events or the payment of Royalty Payments. 

Section 6.10    Clinical Trials and Product Supply. From and after the Closing, Purchaser
shall, or shall cause its Affiliates to continue to (a) conduct the clinical trials and studies in respect of the ALXN1101 Molecule that are being conducted by or on behalf of Seller or its Affiliates as of the Closing Date and
(b) Purchaser shall, or shall cause its Affiliates, to continue to provide the ALXN1101 Molecule for use in any compassionate use or named patient access programs in which Seller or its Affiliates participate as of the Closing for as long as
indicated, in the medical judgment of the treating physician, for each Person participating in such programs, in each case of subsections (a) and (b), in a manner and quantity substantially consistent with Seller’s current practice. 

Section 6.11    Payments from Third Parties. In the event that, on or after the Closing
Date, either Party shall receive any payments or other funds due to the other pursuant to the terms of this Agreement, then the Party receiving such funds shall promptly forward such funds to the proper Party. The Parties acknowledge and agree that
there is no right of offset regarding such payments and a Party may not withhold funds received from Third Parties for the account of the other Party in the event there is a dispute regarding any other issue under this Agreement. 

Section 6.12    Tax Matters. 

(a)    Tax Deficiencies. Neither Seller nor any of the Divesting Entities shall permit to exist any
Tax deficiencies (including penalties and interest) of any kind assessed against or relating to Seller or any of the Divesting Entities with respect to any taxable periods ending on or before, or including, the Closing Date of a character or nature
that could reasonably be expected to result in Liens (other than Permitted Liens) or claims on any of the Purchased Assets or on Purchaser’s title or use of the Purchased Assets following the Closing or that would reasonably be expected to
result in any claim against Purchaser. 
 (b)    Apportioned Taxes. Subject to
Section 2.12, all real property Taxes, personal property Taxes and similar ad valorem obligations levied with respect to the 

  
 36 

 
Purchased Assets for a taxable period which includes (but does not end on) the Closing Date (collectively, the “Apportioned Obligations”) shall be apportioned between Seller and
Purchaser as of the Closing Date based on the number of days of such taxable period ending on and including the Closing Date (the “Pre-Closing Apportioned Period”) and the number of days of
such taxable period beginning from the day after the Closing Date through the end of such taxable period (the “Post-Closing Apportioned Period”). Seller shall be liable for the proportionate amount of Apportioned Obligations
that is attributable to the Pre-Closing Apportioned Period. Purchaser shall be liable for the proportionate amount of the Apportioned Obligations that is attributable to the Post-Closing Apportioned
Period. 
 Section 6.13    Confidentiality. From and after the Closing Date, Seller and
the Divesting Entities will, and will cause their Affiliates and Representatives to, treat and hold as confidential, and not use or disclose any nonpublic or confidential information relating to the ALXN1101 Molecule, any Products or the Purchased
Assets (collectively, the “Confidential Information”) to any person (including any of their Affiliates); provided, however, that Confidential Information shall not include information which (a) is or becomes generally available
to the public other than as a result of a disclosure by Seller, the Divesting Entities or their Affiliates or any Representatives of the foregoing in violation of this Section 6.13; or (b) is legally required to be
disclosed in accordance with this Section 6.13. In the event that Seller or any Divesting Entity is required by request for information or documents in any legal proceeding, interrogatory, subpoena, civil investigative
demand or similar process or as otherwise required by applicable Law to disclose any Confidential Information, Seller will promptly notify Purchaser of the request so that Purchaser may seek, at its expense, an appropriate protective order or waive
compliance with the provisions of this Section 6.13. If in the absence of a protective order or the receipt of a waiver hereunder Seller or any Divesting Entity is compelled to disclose any Confidential Information to any
Governmental Authority, it may disclose the Confidential Information to the Governmental Authority; provided, however, that Seller or such Divesting Entity shall use its commercially reasonable efforts to obtain, at the request, and at
the expense of Purchaser, an order or other assurance that confidential treatment will be afforded to such portion of the Confidential Information to be disclosed as Purchaser shall designate. 

Section 6.14    Guarantee. BridgeBio guarantees irrevocably, absolutely and
unconditionally and as a primary obligation that Purchaser shall fully, completely and timely pay and perform all of its obligations and discharge all its Liabilities contained in this Agreement (the “Guaranteed Obligations”). This
Section 6.14 is a guaranty of payment and not of collection. There are no conditions precedent to the enforcement of this Section 6.14. The obligations of BridgeBio hereunder shall be continuing,
absolute and unconditional and, without limiting the generality of the foregoing, shall not be released, discharged or otherwise affected by any invalidity, illegality or unenforceability against Purchaser of this Agreement or any agreement executed
by Purchaser pursuant to this Agreement, any change in the corporate existence structure or ownership of Purchaser, or otherwise. This Section 6.14 shall continue to be effective, or be automatically reinstated, as the case
may be, if at any time performance of any of the Guaranteed Obligations is rescinded or must otherwise be restored, returned or rejected by Seller for any reason, including, upon the insolvency, bankruptcy, dissolution, liquidation or reorganization
of Purchaser. 

  
 37 

 Section 6.15    Transferred Contracts
Schedule Updates. After the Effective Date but prior to the Closing Date, Schedule 2.01(i)(b) may be updated from time to time as follows: (i) in the event Purchaser provides notice of such at least [***] Business Days prior to the
Closing Date any Contract listed on Schedule 2.01(i)(b) may be removed therefrom and (ii) in the event Purchaser and Seller shall so agree in writing any Contract not previously contained on Schedule 2.01(i)(a) may be added
thereto. In the event a Contract is removed from Schedule 2.01(i)(b) pursuant to this Section 6.15, such Contract shall no longer be considered a “Transferred Contract” and shall instead be an
“Excluded Asset” and all liabilities with respect thereto shall be considered “Retained Liabilities” hereunder. In the event a Contract is added to Schedule 2.01(i)(a) pursuant to this
Section 6.15, such Contract shall be considered a “Transferred Contract” for all purposes hereunder. For the avoidance of doubt, notwithstanding anything else to the contrary contained herein, any update pursuant
to this Section 6.15 will not be taken into account in determining the truth of any representation or warranty in Article IV hereof. 

ARTICLE VII. 
 CLOSING
CONDITIONS 
 Section 7.01    Conditions Precedent to Purchaser’s Obligations on
the Closing Date. All of the obligations of Purchaser hereunder are subject to fulfillment, prior to or at the Closing, of the following conditions (compliance with which or the occurrence of which may be waived in whole or in part by Purchaser
in writing): 
 (a)    The representations and warranties of Seller contained in this Agreement and in
any certificate delivered by them pursuant hereto, to the extent not qualified by materiality, shall have been true and correct in all material respects as of the date hereof and shall be true and correct in all material respects at and as of the
Closing Date as if made at and as of such date and the representations and warranties of Seller contained in this Agreement and in any certificate or other writing delivered by them pursuant hereto, to the extent qualified by materiality, shall have
been true and correct in all respects as of the date hereof and at and as of the Closing Date as if made at and as of such date. 

(b)    Seller shall have performed and complied in all material respects with all of its covenants and
agreements under this Agreement to be complied with and performed by Seller at or before the Closing. 
 (c) No Law or
Judgment enacted, entered, promulgated, enforced or issued by any Governmental Authority or other legal restraint or prohibition preventing the consummation of any of the Transactions (each, a “Closing Legal Impediment”) shall be in
effect; provided that Purchaser shall have used commercially reasonable efforts to prevent the occurrence or entry of any such Closing Legal Impediment and to remove or appeal as promptly as possible any such Closing Legal Impediment. 

(d)    Since the Effective Date, there shall have been no events or occurrences that have resulted in a
Material Adverse Effect. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 38 

 (e)    Seller shall have signed and delivered, or caused
one or more of its Affiliates, to sign and deliver the instruments and documents set forth on Exhibit A. 

(f)    The consents set forth on Schedule 7.01(f) shall have been obtained. 

(g)    The actions set forth in Section 3.01(b) shall have been completed. 

Section 7.02    Conditions Precedent to Seller’s Obligations on the Closing Date.
All of the obligations of Seller hereunder are subject to the fulfillment, prior to or at the Closing, of the following conditions (compliance with which or the occurrence of which may be waived in whole or in part by Seller in writing): 

(a)    The representations and warranties of Purchaser contained in this Agreement and in any certificate
delivered by them pursuant hereto, to the extent not qualified by materiality, shall have been true and correct in all material respects as of the date hereof and shall be true and correct in all material respects at and as of the Closing Date as if
made at and as of such date and the representations and warranties of Purchaser contained in this Agreement and in any certificate or other writing delivered by them pursuant hereto, to the extent qualified by materiality, shall have been true and
correct in all respects as of the date hereof and at and as of the Closing Date as if made at and as of such date. 

(b)    Purchaser shall have performed and complied in all material respects with all of its covenants and
agreements under this Agreement to be complied with and performed by Purchaser at or before the Closing. 

(c)    No Closing Legal Impediment shall be in effect; provided that Seller shall have used its
commercially reasonable efforts to prevent the occurrence or entry of any such Closing Legal Impediment and to remove or appeal as promptly as possible any such Closing Legal Impediment. 

(d)    Purchaser shall have signed and delivered, or caused one or more of its Affiliates to sign and
deliver, the instruments and documents set forth on Exhibit B. 
 (e)    The actions set forth in
Section 3.01(c) shall have been completed. 
 ARTICLE VIII. 

INDEMNIFICATION 

Section 8.01    Indemnification by Seller. 

(a)    Subject to the provisions of this ARTICLE VIII, Seller agrees, from and after the Closing, to
defend, indemnify and hold harmless Purchaser and its Affiliates and, if applicable, their respective directors, officers, agents, employees, successors and assigns (collectively, the “Purchaser Indemnitees”), from and against any
and all Losses to the extent arising from or relating to (i) any Retained Liability; (ii) any breach by Seller or any Divesting Entity of any of its covenants or agreements contained in this Agreement; (iii) any breach of any warranty
or representation of Seller or any Divesting Entity contained in this Agreement or in any other certificate or document delivered by Seller or any Divesting Entity pursuant to the Transactions or (iv) any Third Party Claim. 

  
 39 

 (b)    Purchaser shall take, and shall cause the other
Purchaser Indemnitees to take, all commercially reasonable steps mitigate any Loss upon becoming aware of any event that would reasonably be expected to, or does, give rise thereto, provided that the foregoing shall not be deemed to limit the
ability of Purchaser and the other Purchaser Indemnitees to incur reasonable costs and expenses in connection therewith. For purposes of calculating or determining the amount of Losses paid, incurred or sustained by a Purchaser Indemnitee, there
shall be deducted from any Losses an amount equal to any third-party insurance, indemnification or contribution payments actually received by such Purchaser Indemnitee in respect of such Losses (net of applicable costs of recovery or collection,
retention, deductible, retroactive premium adjustment, reimbursement or other cost related to such insurance, indemnification or contribution arrangement in respect of Losses thereof); provided, however, that no Purchaser Indemnitee shall
have any obligation to claim, seek or otherwise obtain any such insurance, indemnification or contribution proceeds to which it may be entitled, and the failure of an Purchaser Indemnitee to seek any such proceeds shall not in any way affect or
modify such Purchaser Indemnitee’s rights, or the Seller’s or Divesting Entities’ obligations, under and subject to the terms of this ARTICLE VIII. 

Section 8.02    Indemnification by Purchaser. 

(a)    Subject to the provisions of this ARTICLE VIII, Purchaser agrees, from and after the Closing,
to defend, indemnify and hold harmless Seller and its Affiliates and, if applicable, their respective directors, officers, agents, employees, successors and assigns (collectively, the “Seller Indemnitees”), from and against any and
all Losses to the extent arising from or relating to (i) any Assumed Liability; (ii) any breach by Purchaser of any of its covenants or agreements contained in this Agreement; (iii) any breach of any warranty or representation of
Purchaser contained in this Agreement; (iv) any event occurring on or after the Closing in connection with use, ownership, possession, operation, management, business integration, or transfer of any Purchased Asset on or after the Closing or
(v) any Third Party Claim. 
 (b)    Seller shall take, and shall cause the other Seller Indemnitees
to take, all commercially reasonable steps (including making claims under any applicable insurance policies) to mitigate any Loss upon becoming aware of any event that would reasonably be expected to, or does, give rise thereto, provided that
the foregoing shall not be deemed to limit the ability of Seller and the other Seller Indemnitees to incur reasonable costs and expenses in connection therewith. For purposes of calculating or determining the amount of Losses paid, incurred or
sustained by a Seller Indemnitee, there shall be deducted from any Losses an amount equal to any third-party insurance, indemnification or contribution payments actually received by such Seller Indemnitee in respect of such Losses (net of applicable
costs of recovery or collection, retention, deductible, retroactive premium adjustment, reimbursement or other cost related to such insurance, indemnification or contribution arrangement in respect of Losses thereof). 

  
 40 

 Section 8.03    Notice of Claims. Any
Purchaser Indemnitee or Seller Indemnitee claiming that it has suffered or incurred any Loss for which it may be entitled to indemnification under this ARTICLE VIII (the “Indemnified Party”) shall give prompt written notice
to the Party from whom indemnification is sought (the “Indemnifying Party”) of the matter, action, cause of action, claim, demand, fact or other circumstances upon which a claim for indemnification under this ARTICLE VIII
(each, a “Claim”) may be based, provided, however, that the failure to give such notice shall not affect the indemnification provided hereunder unless the Party who was entitled to receive such notice has been materially
prejudiced by such failure. Such notice shall contain, with respect to each Claim, such facts and information as are then reasonably available with respect to such Claim, including a description of the Losses suffered or incurred by the Indemnified
Party, the amount or estimated amount of such Losses (if known or reasonably capable of estimation) and the method of computation of such Losses, and a reference to the provisions of this Agreement or any other agreement, instrument or certificate
delivered pursuant hereto in respect of which such Loss shall have occurred. If any Claim is based on any Action (in equity or at law) instituted by a Third Party with respect to which the Indemnified Party intends to claim any Loss under this
ARTICLE VIII (a “Third Party Claim”), the Indemnified Party shall promptly notify (the “Third Party Claim Notice”) the Indemnifying Party of such Third Party Claim and offer to tender to the Indemnifying
Party the defense of such Third Party Claim. A failure by the Indemnified Party to give written notice of any Claim or to offer to tender the defense of any Third Party Claim in a timely manner pursuant to this Section 8.03
shall not limit the obligation of the Indemnifying Party under this ARTICLE VIII, except (a) to the extent such Indemnifying Party is actually prejudiced thereby or (b) as provided in Section 8.05. 

Section 8.04    Third Party Claims. 

(a)    The Indemnifying Party shall have the right, but not the obligation, exercisable by written notice
to the Indemnified Party within [***] days of receipt of a Third Party Claim Notice from the Indemnified Party with respect to a Third Party Claim, to assume the conduct and control, at the expense of the Indemnifying Party and through counsel of
its choosing that is reasonably acceptable to the Indemnified Party, of such Third Party Claim. During such [***] day period, the Indemnified Party may not compromise or settle, nor assume the defense of, any Third Party Claim for which it is
seeking indemnification hereunder without the prior written consent of the Indemnifying Party. The Indemnifying Party may compromise or settle any such Third Party Claim; provided that the Indemnifying Party shall give the Indemnified Party
advance written notice of any proposed compromise or settlement and shall not, without the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed), consent to or enter into any
compromise or settlement with respect to such Third Party Claim that (i) commits the Indemnified Party to take, or to forbear to take, any action or (ii) does not provide for a full and complete written release by the applicable Third
Party of the Indemnified Party. The Indemnifying Party shall permit the Indemnified Party to participate in, but not control, the defense of any such Third Party Claim through counsel chosen by the Indemnified Party, provided that the fees
and expenses of such counsel shall be borne solely by the Indemnified Party. If the Indemnifying Party elects not to control or conduct the defense of a Third Party Claim, the Indemnifying Party nevertheless shall have the right to participate in
the defense of 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 41 

 
any Third Party Claim and, [***] to employ counsel of its own choosing for such purpose. The Parties shall cooperate in the defense of any Third Party Claim, with such cooperation to include
(i) the retention and the provision to the Indemnifying Party of records and information that are reasonably relevant to such Third Party Claim and (ii) reasonable access to employees on a mutually convenient basis for providing additional
information and explanation of any material provided hereunder. 
 (b)    Purchaser and Seller agree to
cooperate and to cause their Affiliates to cooperate with each other to the extent reasonably required after the Closing Date in connection with any claims conducted by a Taxing Authority relating to any Taxes with respect to or in relation to any
Purchased Asset for any Tax period ending on or before the Closing Date or, in the case of any Tax period that includes, but does not end on, the Closing Date, the portion of such period ending on the Closing Date (each a “Tax
Contest”). Promptly (but no more than [***] days) after Purchaser or any of its Affiliates receives notice of any Tax Contest, Purchaser shall notify Seller in writing (which notice shall include copies of any notices, correspondence and
any other documents received by Purchaser or its Affiliates with respect to such Tax Contest) of the Tax Contest; provided, that no failure or delay of Purchaser in providing such notice shall reduce or otherwise affect the obligations of
Seller pursuant to this Agreement, except to the extent Seller is materially and adversely prejudiced as a result of such failure or delay. Notwithstanding anything to the contrary, if Seller’s Tax liability or rights to any refunds (or the
liability or rights of the Seller) could be affected by the Tax Contest or if Seller could have an indemnification obligation under this Agreement, Seller shall have the sole right to conduct, control, defend, settle or compromise the defense of the
Tax Contest [***] whether the Tax Contest began before or after the Closing Date; and Purchaser shall provide Seller with all necessary powers of attorney and other necessary documents and assistance to allow Seller to effectively conduct and
control such defense; provided that in the case of any Claims conducted by a Taxing Authority against the Purchaser that is a Tax Contest, the Purchaser shall have the right to control the defense against such Claim except that the Seller
shall have the right to participate in such defense and the Purchaser shall not settle or resolve such Claim without the consent of Seller (which consent shall not be unreasonably withheld, conditioned or delayed). 

Section 8.05    Expiration. If the Closing shall have occurred, all covenants,
agreements, warranties and representations made herein or in any certificate or other document delivered pursuant hereto shall survive the Closing. Notwithstanding the foregoing, all representations, warranties, covenants and agreements made herein
or in any certificate or other document delivered pursuant hereto, and all indemnification obligations under [***] with respect to any such representations, warranties, covenants and agreements, except [***], shall (a) in the case of any such
representations or warranties by the Seller, other than the Fundamental Representations, terminate and expire on, and no action or proceeding seeking damages or other relief for breach of any thereof or for any misrepresentation or inaccuracy with
respect thereto, shall be commenced after, the date that is [***] months after the Closing Date (the “Claims Period”), unless prior to such date a claim for indemnification with respect thereto shall have been made, with reasonable
specificity, by written notice given in accordance with Section 8.03; and (b) in the case of any such covenants or agreements, terminate and expire on, and no action or proceeding seeking damages or other relief for
breach of any thereof shall be commenced 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 42 

 
after, the date that is [***] days after the last date on which such covenant or agreement is to be performed, including for such covenants and agreements in which no date is specified, unless
prior to such date a claim for indemnification with respect thereto shall have been made, with reasonable specificity, by written notice given in accordance with Section 8.03. The Claims Period for Losses arising or
resulting from a breach of any Fundamental Representation will commence at the Closing and continue until [***]. All representations and warranties of Purchaser in this Agreement shall expire upon the end of the Claims Period. Third Party Claims
alleging the occurrence of facts or circumstances that, if true, regardless of the outcome of such defense, would entitle a Purchaser Indemnitee to indemnification pursuant to Section 8.01(a)(iii) shall survive until the
date [***]. It is the express intent of the Parties that, [***]. In the event of any Fraud, with respect to any representations or warranties set forth in this Agreement, such representations and warranties shall survive the Closing and shall remain
in full force and effect until the date that is [***]. If a Claim has been delivered on or prior to the end of the applicable survival period, such the subject matter of such Claim shall survive beyond the applicable survival period until such Claim
has been finally resolved. 
 Section 8.06    Certain Limitations. 

(a)    Notwithstanding the other provisions of this ARTICLE VIII, Seller shall not have any
indemnification obligations for Losses under Section 8.01(a)(iii), other than with respect to Fraud or the Fundamental Representations, unless the aggregate amount of all such Losses exceeds [***], (the
“Basket”) and then Seller shall be required to pay [***]. 
 (b)    Notwithstanding the
other provisions of this ARTICLE VIII, Seller shall not have any indemnification obligations for Losses under Section 8.01(a)(iii), other than with respect to Fraud or the Fundamental Representations, in excess, on a
cumulative basis in respect of all such Claims, an amount equal to [***]. 
 (c)    Except in the event
of Fraud, Seller’s liability under (i) Section 8.01(a)(iii) with respect to Fundamental Representation, (ii) Section 8.01(a)(ii), and (iii) Section 8.01(a)(iv) shall not exceed, on a
cumulative basis in respect of all such Claims, an amount equal to [***]. Notwithstanding anything else contained herein, Seller’s indemnification obligations with respect to [***] shall be [***]. 

(d)    Subject to Section 8.06(e), an Indemnified Party may assert a claim for
indemnification based on or arising out of the same set of facts and circumstances under more than one provision of Section 8.01 or 8.02, as applicable, and an Indemnified Party shall not be foreclosed or limited
from recovering under one or more such applicable provisions an amount of Losses that such Indemnified Party would not be entitled to recover under another applicable provision due to the application of a survival period, basket, or other limitation
on such other applicable provision that differs from, or does not apply to, the first applicable provision. 

(e)    Notwithstanding anything to the contrary set forth herein, no Indemnified Party shall be entitled to
double recovery for any Losses based on or arising out of the same set of facts or circumstances under more than one claim for indemnification regardless of whether such facts or circumstances would give rise to multiple bases for indemnification.

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 43 

 (f)    The amount of any Loss for which indemnification
is provided under Section 8.01 or Section 8.02 shall be net of any amounts actually recovered by the Indemnified Party pursuant to any indemnification by or indemnification agreement with any
nonaffiliated Third Party. If the amount to be netted hereunder from any payment required under Section 8.01 or Section 8.02 is determined after payment by the Indemnifying Party of any amount
otherwise required to be paid to an Indemnified Party pursuant to this ARTICLE VIII, the Indemnified Party shall repay to the Indemnifying Party, promptly after such determination, any amount that the Indemnifying Party would not have had to
pay pursuant to this ARTICLE VIII had such determination been made at the time of such payment. The Indemnifying Party may require, as a condition to the provision of any indemnification hereunder, that the Indemnified Party execute an
undertaking consistent with its obligations set forth in this Section 8.06(f). Purchaser shall promptly assign or subrogate to Seller or its designated Affiliate any claim Purchaser acquired from Seller pursuant to
Section 2.01(j), to the extent such claim may reasonably mitigate any Losses that Seller is liable for pursuant to Section 8.01. 

Section 8.07    Materiality. Notwithstanding anything in this Agreement to the contrary,
for purposes of the parties’ indemnification obligations under this ARTICLE VIII, all of the representations and warranties set forth in this Agreement or any certificate or schedule that are qualified as to “material,”
“materiality,” “material respects,” “Material Adverse Effect”, “Purchaser Material Adverse Effect”, or words of similar import or effect shall be deemed to have been made without any such qualification for
purposes of determining the amount of Losses resulting from, arising out of or relating to any breach of a representation or warranty. 

Section 8.08    Sole Remedy/Waiver. This ARTICLE VIII provides the exclusive means
by which a Party may assert and remedy Claims, and Section 10.09 provides the exclusive means by which a Party may bring actions against the other Party with respect to Claims under this Agreement. Except as set forth in
Section 10.09(c) each Party hereby waives and releases any other remedies or claims that it may have against the other Party (or any of its Affiliates) with respect to the matters arising out of or in connection with this
Agreement or relating to the ALXN1101 Molecule or the Purchased Assets, except that nothing herein shall limit the liability of any Party hereto for Fraud. With respect to any Losses arising under this Agreement, the Parties agree that they shall
only seek such Losses from the other Party and hereby waive the right to seek Losses from or equitable remedies, such as injunctive relief, against any Affiliate of the other Party or any director, officer or employee of thereof (or any of its
Affiliates). 
 Section 8.09    Indemnity Payments. In the event that either Party
agrees to, or is determined to have an obligation to, reimburse the other Party for Losses as provided in this ARTICLE VIII, the Indemnifying Party shall promptly pay such amount to the Indemnified Party in U.S. Dollars via wire transfer of
immediately available funds to the accounts specified in writing by the Indemnified Party. Upon written notice to Seller specifying in reasonable detail the basis therefor, if Seller has not satisfied any indemnification obligation conclusively owed
by it to the Purchaser Indemnitees hereunder, Purchaser may set off the amount to which Purchaser is entitled from Seller against any indemnification obligation conclusively owed by Purchaser to 

  
 44 

 
the Seller Indemnitees hereunder and against any Milestone Payment or Royalty Payments owed to Seller. Neither the exercise of, nor the failure to exercise such right of setoff, will constitute
an election of remedies or limit Purchaser in any manner in the enforcement of any other remedies against Seller that may be available to Purchaser under this Agreement. 

Section 8.10    Tax Treatment of Indemnity Payments. Any indemnity payment under this
Agreement shall be treated as an adjustment to the Upfront Payment for Tax purposes unless otherwise required by applicable Law. 

Section 8.11    No Consequential Damages. NOTWITHSTANDING ANYTHING TO THE CONTRARY
CONTAINED HEREIN, WITH THE EXCEPTION OF RELIEF MANDATED BY STATUTE, (I) NO PARTY TO THIS AGREEMENT SHALL BE LIABLE TO OR OTHERWISE RESPONSIBLE TO THE OTHER PARTY OR ANY AFFILIATE OF THE OTHER PARTY FOR LOST REVENUES OR PROFITS DAMAGES OR
INDIRECT, INCIDENTAL, CONSEQUENTIAL OR MULTIPLIED DAMAGES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF OR ANY LIABILITY RETAINED OR ASSUMED HEREUNDER UNLESS SUCH LOST REVENUES OR PROFITS OR DAMAGES ARE NOT BASED
ON ANY SPECIAL CIRCUMSTANCES OF THE PARTY ENTITLED TO INDEMNIFICATION AND ARE THE NATURAL, PROBABLE AND REASONABLY FORESEEABLE RESULT OF THE EVENT THAT GAVE RISE TO THE CLAIM FOR INDEMNIFICATION AND (II) NO PARTY TO THIS AGREEMENT SHALL BE
LIABLE TO OR OTHERWISE RESPONSIBLE TO THE OTHER PARTY OR ANY AFFILIATE OF THE OTHER PARTY FOR PUNITIVE OR EXEMPLARY DAMAGES; PROVIDED THAT THE FOREGOING SHALL NOT BE CONSTRUED TO PRECLUDE RECOVERY IN RESPECT OF ANY LOSS DIRECTLY INCURRED
OR SUFFERED FROM THIRD PARTY CLAIMS. 
 ARTICLE IX. 

TERMINATION 

Section 9.01    Termination. 

(a)    Mutual Termination. This Agreement may be terminated at any time prior to the Closing by
mutual written agreement of Purchaser and Seller. 
 (b)    Termination by Purchaser. 

(i)    This Agreement may be terminated by Purchaser at any time prior to the Closing, if (A) Seller
shall have failed to comply, in any material respect, with any of Seller’s covenants or agreements contained in this Agreement or (B) any one or more of the representations or warranties of Seller contained in this Agreement shall prove to
have been inaccurate in any material respect, which, in each case, if not cured, would result in a failure of any of the conditions set forth in Section 7.01(a) or Section 7.01(b) to be satisfied,
and such inaccuracy or breach shall not have been cured within [***] Business Days after receipt by the Seller of written notice of such inaccuracy or breach (provided that no such cure period shall be available or applicable to any such
breach that by its nature cannot be cured by the Outside Date). 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 45 

 (ii)    This Agreement may be terminated by Purchaser if
the Closing shall not have occurred on or before the Outside Date; provided that Purchaser may terminate this Agreement pursuant to this Section 9.01(b)(ii) only if at the time of termination Purchaser is not in
material breach of any of its representations, warranties, covenants or agreements contained in this Agreement and Purchaser has satisfied those conditions set forth in Section 7.02 (other than those conditions that by
their terms are to be satisfied by actions taken at the Closing and could have been satisfied or would have been waived assuming a Closing would occur). 

(c)    Termination by Seller. 

(i)    This Agreement may be terminated by Seller at any time prior to the Closing, if (A) Purchaser
shall have failed to comply, in any material respect, with any of Purchaser’s covenants or agreements contained in this Agreement or (B) any one or more of the representations or warranties of Purchaser contained in this Agreement shall
prove to have been inaccurate in any material respect, which, in each case, if not cured, would result in a failure of any of the conditions set forth in Section 7.02(a) or Section 7.02(b) to be
satisfied, and such inaccuracy or breach shall not have been cured within [***] Business Days after receipt by the Purchaser of written notice of such inaccuracy or breach (provided that no such cure period shall be available or applicable to
any such breach that by its nature cannot be cured by the Outside Date). 
 (ii)    This Agreement may be
terminated by Seller if the Closing shall not have occurred on or before the Outside Date; provided that Seller may terminate this Agreement pursuant to this Section 9.01(c)(ii) only if at the time of termination
Seller is not in material breach of any of its representations, warranties, covenants or agreements contained in this Agreement and Seller has satisfied those conditions set forth in Section 7.01 (other than those
conditions that by their terms are to be satisfied by actions taken at the Closing and could have been satisfied or would have been waived assuming a Closing would occur). 

Section 9.02    Effect of Termination. 

(a)    In the event of the termination of this Agreement in accordance with
Section 9.01, this Agreement shall thereafter become void and have no effect, and neither Party shall have any liability to the other Party or to such other Party’s Affiliates or Representatives in respect of this
Agreement, except for the obligations of the Parties contained in this Section 9.02, and in Section 6.03 and ARTICLE X; provided that nothing herein shall limit the liability of any
Party hereto for Fraud whereby the breaching Party both intended to take or fail to take the action giving rise to the breach and had knowledge that such action or inaction would constitute a breach of this Agreement. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 46 

 (b)    In the event this Agreement shall be terminated
in accordance with Section 9.01 and, at such time, a Party is in material breach of or default under any term or provision hereof, such termination shall be without prejudice to, and shall not affect, any and all rights to
damages and other equitable remedies that the other Party may have hereunder. 
 ARTICLE X. 

MISCELLANEOUS 

Section 10.01    Notices. All notices or other communications hereunder shall be deemed
to have been duly given and made if in writing and if served by personal delivery upon the Party for whom it is intended, delivered by registered or certified mail, return receipt requested, or by a national overnight courier service, or sent by
facsimile (provided that notice by facsimile is promptly confirmed by telephone confirmation thereof and receipt is confirmed by the sending facsimile machine), to the Person at the address set forth below, or such other address as may be
designated in writing hereafter, in the same manner, by such Person: 
 to Seller and any Divesting Entity: 

Alexion Pharma Holding Unlimited Company 

c/o Alexion Pharmaceuticals, Inc. 

100 College Street 
 New Haven,
CT 06510 
 Attn: Chief Legal Officer 

with copies to: 

Ropes & Gray LLP 

Prudential Tower 
 800 Boylston
Street 
 Boston, MA 02199-3600 

Telephone:       (617) 235-9705 

Facsimile:        (617) 235-0223 

Attn:                 Zachary R. Blume 

to Purchaser: 
 Origin
Biosciences, Inc. 
 421 Kipling St. 

Palo Alto, CA 94301 
 Telephone:
      (650) 391-9740 
 Attn: Michael Henderson 

Email: [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 47 

 with a copy to: 

Goodwin Procter LLP 
 Three
Embarcadero 
 San Francisco, California 94111 

Attention: Maggie Wong 

Facsimile No.: (415) 733-6071 

E-Mail: [***] 

All notices and other communications under this Agreement shall be deemed to have been received (a) when delivered by hand, if personally delivered;
(b) one (1) Business Day after being sent, if delivered to a national overnight courier service; or (c) one (1) Business Day after being sent, if sent by facsimile, with a telephonic acknowledgment of sending and confirmation of receipt by
the sending facsimile machine. 
 Section 10.02    Amendment; Waiver. Any provision of
this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed (a) in the case of an amendment, by Purchaser and Seller and (b) in the case of a waiver, by the Party against whom the waiver is to
be effective. No failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the
exercise of any other right, power or privilege. 
 Section 10.03    Assignment.
Neither Party to this Agreement may assign any of its rights or obligations under this Agreement, including by sale of stock, operation of Law in connection with a merger or sale of substantially all of the assets, without the prior written consent
of the other Party, except that (a) Seller may, without such consent, assign its rights or obligations to an Affiliate and (b) Purchaser may, without such consent, assign its rights to acquire the Purchased Assets hereunder, in whole or in
part, to one or more of its Affiliates; provided that no such assignment by Purchaser shall relieve Purchaser of any of its obligations hereunder. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any
purported assignment in violation of this Section 10.03 shall be null and void. 

Section 10.04    Entire Agreement. This Agreement, together with the Exhibits and
Schedules expressly contemplated hereby and attached hereto (which are hereby incorporated by reference), and the other agreements and certificates delivered in connection herewith (including the Confidentiality Agreement), contains the entire
agreement between the Parties with respect to the Transactions and supersedes all prior agreements or understandings between the Parties. Other than the Confidentiality Agreement entered into between the Parties, this Agreement is intended to define
the full extent of the legally enforceable undertakings and representations of the Parties, and no promise or representation, written or oral, which is not set forth explicitly in such agreements is intended by either Party to be legally binding.
Each of the Parties acknowledges that, in deciding to enter into this Agreement and to consummate the Transactions, none of them has relied upon any statements or representations, written or oral, other than those explicitly set forth herein or
therein. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 
 48 

 Section 10.05    Fulfillment of
Obligations. Any obligation of a Party to the other Party under this Agreement, which obligation is performed, satisfied or fulfilled by an Affiliate of such Party, shall be deemed to have been performed, satisfied or fulfilled by such Party.

 Section 10.06    Parties in Interest. This Agreement shall inure to the benefit of
and be binding upon the Parties and their respective successors and permitted assigns. Nothing in this Agreement, express or implied, is intended to confer upon any Person other than Purchaser, Seller and the Divesting Entities, or their successors
or permitted assigns, any rights or remedies under or by reason of this Agreement. 

Section 10.07    Expenses. Except as otherwise expressly provided in this Agreement,
whether or not the Transactions are consummated, all costs and expenses incurred in connection with this Agreement and the Transactions shall be borne solely by the Party incurring such expenses. 

Section 10.08    Schedules. The disclosure of any matter in the Schedules to this
Agreement shall be deemed to be a disclosure for the purposes of the Section or subsection of this Agreement to which it corresponds in number and each other Section and subsection of this Agreement to the extent such disclosure is reasonably
apparent on the face thereof to be relevant to such other Section or subsection. The disclosure of any matter in any Schedule to this Agreement shall expressly not be deemed to constitute an admission by any Party, or to otherwise imply, that any
such matter is material for the purposes of this Agreement, could reasonably be expected to have a Material Adverse Effect or a Purchaser Material Adverse Effect, as applicable, or is required to be disclosed under this Agreement. 

Section 10.09    Governing Law; Jurisdiction; No Jury Trial; Specific Performance. 

(a)    This Agreement shall be governed by and construed in accordance with the laws of the State of
Delaware, without regard to the conflicts of law, principles or rules of such state, to the extent such principles or rules are not mandatorily applicable by statute and would permit or require the application of the laws of another jurisdiction.

 (b)    The Parties consent to the exclusive jurisdiction of the Federal and State courts located in
the State of Delaware for the resolution of all disputes or controversies between the Parties. Each of the Parties (i) consents to the exclusive jurisdiction of each such court in any suit, action or proceeding relating to or arising out of
this Agreement or the Transactions; (ii) waives any objection that it may have to the laying of venue in any such suit, action or proceeding in any such court; and (iii) agrees that service of any court paper may be made in such manner as
may be provided under applicable Laws or court rules governing service of process. THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN ANY ACTION DIRECTLY OR INDIRECTLY
ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, ANY RELATED AGREEMENTS OR ANY OF THE TRANSACTIONS. 

  
 49 

 (c)    Purchaser acknowledges and agrees that Seller
would be damaged irreparably in the event that any of Purchaser’s obligations pursuant to Section 6.09 or Section 6.10(b) (the “Drug Access Obligations”) are not performed.
Accordingly, Purchaser agrees that, without posting bond or other undertaking, Seller shall be entitled to an injunction or injunctions to prevent breaches or violations of Section 6.09 or the Drug Access Obligations and to
enforce specifically the obligations under Section 6.09 or the Drug Access Obligations in any action instituted in any court specified in Section 10.09(b) in addition to any other remedy to which
Seller may be entitled, at law or in equity. Purchaser further agrees that, in the event of any action for an injunction or specific performance in respect of Section 6.09 or such Drug Access Obligations, it shall not
assert that a remedy at law would be adequate. 
 Section 10.10    Counterparts. This
Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and together shall constitute one and the same agreement and shall become effective when one or more counterparts have been signed by each of the
Parties and delivered to the other Party, it being understood that both Parties need not sign the same counterpart. This Agreement, following its execution, may be delivered via facsimile or other form of electronic delivery, which shall constitute
delivery of an execution original for all purposes. 
 Section 10.11    Headings. The
heading references herein and the table of contents hereto are for convenience purposes only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 

Section 10.12    Severability. The provisions of this Agreement shall be deemed severable
and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any term or other provision of this Agreement, or the application thereof to any Person or any circumstance,
is invalid, illegal or unenforceable, (a) a suitable and equitable provision shall be substituted therefore in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and
(b) the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity, illegality or unenforceability, nor shall such invalidity, illegality or unenforceability
affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction. 
 [remainder of page
intentionally blank] 

  
 50 

 IN WITNESS WHEREOF, the undersigned have executed or caused this Agreement to be executed as
of the Effective Date. 
  

					
	ALEXION PHARMA HOLDING UNLIMITED COMPANY
		
	By:	 	 /s/ Christopher Brough

		 	Name:	 	Christopher Brough
		 	Title:	 	Director

  
 [Signature Page to Asset
Purchase Agreement] 

 IN WITNESS WHEREOF, the undersigned have executed or caused this Agreement to be executed as
of the Effective Date. 
  

					
	ORIGIN BIOSCIENCES, INC.
		
	By:	 	 /s/ Michael Henderson

		 	Name:	 	Michael Henderson
		 	Title:	 	Chief Executive Officer

  
 [Signature Page to Asset
Purchase Agreement] 

 IN WITNESS WHEREOF, the undersigned have executed or caused this Agreement to be executed as
of the Effective Date. 
  

					
	BRIDGEBIO PHARMA, LLC, solely for the purposes of Section 6.14
		
	By:	 	 /s/ Neil Kumar

		 	Name:	 	Neil Kumar
		 	Title:	 	Chief Executive Officer

  
 [Signature Page to Asset
Purchase Agreement] 

 Exhibit A 

SELLER CLOSING DELIVERABLES 
  

	(a)	 A receipt for payment of the Upfront Payment at Closing; 

 

	(b)	 A certificate in the form attached hereto as Exhibit C, dated the Closing Date and executed by an
authorized officer of Seller, to the effect that each of the conditions specified in Section 7.01(a) and Section 7.01(b) of the Agreement is satisfied in all respects; 

 

	(c)	 An executed bill of sale and assignment and assumption in the form attached hereto as Exhibit D (the
“Bill of Sale and Assignment and Assumption”), dated the Closing Date; 

  

	(d)	 Executed patent assignments in the form attached hereto as Exhibit E (with assignments in recordable
form to be delivered after the Closing) (the “Patent Assignment”), dated the Closing Date; 

  

	(e)	 In the case of (i) Seller and each non-U.S. Divesting Entity, a
properly completed and executed IRS Form W-8BEN-E, establishing that Seller and each such non-U.S. Divesting Entity is eligible
for applicable treaty benefits that reduce or eliminate any withholding in respect of royalty payments and (ii) each Divesting Entity that is a U.S. person (as defined in Section 7701(a)(30) of the Code), a properly completed and executed
IRS Form W-9; and 

  

	(f)	 The executed Seller Transfer Letter to FDA, dated the Closing Date. 

 Exhibit B 

PURCHASER CLOSING DELIVERABLES 
  

	(a)	 A good standing certificate for Purchaser; 

 

	(b)	 A certificate in the form attached hereto as Exhibit F, dated the Closing Date and executed by an
authorized officer of Purchaser, to the effect that each of the conditions specified in Section 7.02(a) and Section 7.02(b) of the Agreement is satisfied in all respects; 

 

	(c)	 A certificate of a Secretary or an Assistant Secretary of Purchaser in the form attached hereto as Exhibit
G enclosing a copy of (i) its certificate of incorporation certified by the Secretary of State of the State of Delaware, (ii) its by-laws and (iii) board of director resolutions authorizing Purchaser to enter into this Agreement
and to consummate the Transactions; 

  

	(d)	 The executed Bill of Sale and Assignment and Assumption, dated the Closing Date; 

 

	(e)	 The executed Patent Assignment, dated the Closing Date; and 

 

	(f)	 The executed Purchaser Transfer Letter to FDA, dated the Closing Date. 

 Schedule 7.01(f) 

Consents 
 1. The Services Agreement. 

 Final Version 

SCHEDULES 
 to the

 ASSET PURCHASE AGREEMENT 

between 
 ALEXION PHARMA
HOLDING UNLIMITED COMPANY, ORIGIN BIOSCIENCES, INC. 
 and 

BRIDGEBIO PHARMA, LLC (SOLELY FOR THE PURPOSES OF SECTION 6.14) 

DATED AS OF JUNE 7, 2018 

Capitalized terms used in the following schedules (these “Schedules”) but not otherwise defined shall have the meanings ascribed to such
terms in that certain Asset Purchase Agreement (the “Agreement”) by and between Alexion Pharma Holding Unlimited Company (the “Seller”), Origin Biosciences, Inc. (the “Purchaser”) and BridgeBio
Pharma, LLC (solely for the purposes of Section 6.14) to which these Schedules are attached. 

 SCHEDULE 2.01(b) 

TRANSFERRED PATENTS 
  

									
	 Patent Ref.
	  	Patent No.	 	Current
Owner(s)	 	Jurisdiction	 	Issuance
Date
	
[                   
 ]
	  	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 SCHEDULE 2.01(c) 

TRANSFERRED TRADEMARKS 
 None. 

 SCHEDULE 2.01(d) 

TRANSFERRED COPYRIGHTS 
 None. 

 SCHEDULE 2.01(e) 

TRANSFERRED INTERNET DOMAIN NAMES 
 None.

 SCHEDULE 2.01(f) 

TRANSFERRED GOVERNMENTAL AUTHORIZATIONS 
  

							
	 Country
	  	Competent Authority	 	Subject	 	Date of Decision
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 SCHEDULE 2.01(i) 

TRANSFERRED CONTRACTS 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 SCHEDULE 6.05(c) 

SUPPLY OF PRODUCT 
 The following
inventory is scheduled for manufacture in the remainder of 2018: 
 [Attached] 

 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 Final Version 

DISCLOSURE SCHEDULES 

to the 
 ASSET PURCHASE
AGREEMENT 
 between 

ALEXION PHARMA HOLDING UNLIMITED 

COMPANY, ORIGIN BIOSCIENCES, INC., 

and 
 BRIDGEBIO PHARMA,
LLC (SOLELY FOR THE PURPOSES OF SECTION 6.14) DATED AS OF 
 June 7, 2018 

Capitalized terms used in the following schedules (these “Schedules”) but not otherwise defined shall have the meanings ascribed to such
terms in that certain Asset Purchase Agreement (the “Agreement”) by and between Alexion Pharma Holding Unlimited Company (the “Seller”), Origin Biosciences, Inc. (the “Purchaser”) and BridgeBio
Pharma, LLC (solely for the purposes of Section 6.14) to which these Schedules are attached. 

 SCHEDULE 4.03 

NON-CONTRAVENTION 

[***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 SCHEDULE 4.04 

GOVERNMENTAL AUTHORIZATION 
 Authorization
concerning Clinical Trial Applications in the following countries: 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 SCHEDULE 4.05 

NO LITIGATION 
 None. 

 SCHEDULE 4.06 

COMPLIANCE WITH LAWS 
 None. 

 SCHEDULE 4.07 

CONTRACTS 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 SCHEDULE 4.08 

INTELLECTUAL PROPERTY 
 None. 

 SCHEDULE 4.09 

BROKERS 
 None. 

 SCHEDULE 4.10 

PURCHASED ASSETS 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 SCHEDULE 4.11 

INVENTORIES 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 SCHEDULE 4.12 

TAX REPRESENTATIONS 
 None. 

 SCHEDULE 4.13 

REGULATORY MATTERS 
 [***] 

 SCHEDULE 6.01 

CONDUCT OF BUSINESS 
 None. 

 Exhibit C 

OFFICER’S CERTIFICATE 

OF 
 ALEXION PHARMA
HOLDING UNLIMITED COMPANY 
 [***] 

This certificate is being delivered pursuant to Section 7.01(e) of that certain Asset Purchase Agreement, by and among Alexion Pharma
Holding Unlimited Company (“Seller”), Origin Biosciences, Inc. (“Purchaser”) and BridgeBio Pharma, LLC (solely for the purposes of Section 6.14) dated as of June 7, 2018 (the “Asset Purchase
Agreement”). All capitalized terms used but not defined herein shall have the meanings assigned to them in the Asset Purchase Agreement, unless they are specifically otherwise defined herein. 

The undersigned, [***], in [***] capacity as [***] of the Seller, and not in [***] personal capacity and without personal liability, hereby
certifies that: 
 1.    The representations and warranties of Seller contained in the Asset Purchase Agreement and in
any certificate delivered by Seller pursuant to the Asset Purchase Agreement, to the extent not qualified by materiality, are true and correct in all material respects as of the Effective Date and are true and correct in all material respects at and
as of the Closing Date as if made at and as of such date and the representations and warranties of Seller contained in the Asset Purchase Agreement and in any certificate or other writing delivered by Seller pursuant to the Asset Purchase Agreement,
to the extent qualified by materiality, are true and correct in all respects as of the Effective Date and at and as of the Closing Date as if made at and as of such date. 

2.    Seller has performed and complied in all material respects with all of its covenants and agreements under the Asset
Purchase Agreement to be complied with and performed by Seller at or before the Closing. 
 [Signatures on following page] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 IN WITNESS WHEREOF, I cause this certificate to be executed as of the date first
written above. 
  

	
	     

	Name:
	Title:

  
 [Signature Page to
Seller’s Officer’s Certificate] 

 Exhibit D 

BILL OF SALE AND ASSIGNMENT AND ASSUMPTION 

This BILL OF SALE AND ASSIGNMENT AND ASSUMPTION (this “Agreement”) is dated as of
[            ], 2018, by and between Alexion Pharma Holding Unlimited Company, [●] [Note to Draft: To be updated to include Divesting Entities.] (collectively, the
“Sellers”) and Origin Biosciences, Inc. (the “Purchaser”). 
 RECITALS 

WHEREAS, pursuant to that certain Asset Purchase Agreement by and among Alexion Pharma Holding Unlimited Company, Purchaser and BridgeBio
Pharma, LLC (solely for the purposes of Section 6.14) dated as of June 7, 2018 (the “Asset Purchase Agreement”), Sellers have agreed to sell, convey, assign and transfer to Purchaser, and Purchaser has agreed to purchase,
acquire and accept from Sellers, Sellers’ right, title and interest in, to and under the Purchased Assets (as defined in the Asset Purchase Agreement), and (b) Sellers have agreed to sell, convey, assign and transfer to Purchaser, and
Purchaser has agreed to accept and assume, the Assumed Liabilities (as defined in the Asset Purchase Agreement). 
 NOW, THEREFORE, in
consideration of the Asset Purchase Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Sellers and the Purchaser agree as follows: 

1.    Definitions. All capitalized terms used but not defined herein shall have the meanings assigned to them in
the Asset Purchase Agreement, unless they are specifically otherwise defined herein. 
 2.    Bill of Sale of
Purchased Assets. In accordance with terms and subject to the conditions of the Asset Purchase Agreement, effective as of the Closing, Sellers hereby do sell, convey, assign and transfer to Purchaser all of Sellers’ right, title, and
interest in, to and under each of the Purchased Assets. 
 3.    Assignment and Assumption. In accordance with
terms and subject to the conditions of the Asset Purchase Agreement, effective as of the Closing, Sellers hereby do sell, convey, assign and transfer to Purchaser all of Sellers’ right, title, interest in, obligations and liabilities, to and
under the Assumed Liabilities at the Closing pursuant to the Asset Purchase Agreement. In accordance with terms and subject to the conditions of the Asset Purchase Agreement, effective as of the Closing, Purchaser hereby accepts the foregoing
assignment and transfer and agrees to accept, assume and undertake, and timely satisfy and discharge when due, Sellers’ obligations, liabilities and responsibilities under or pursuant to such Assumed Liabilities arising from and after the date
hereof as contemplated by the Asset Purchase Agreement. 
 4.    Miscellaneous. This Agreement shall be governed
by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law, principles or rules of such state, to the extent such principles or rules are not mandatorily applicable by statute and would permit or
require the application of the laws of another jurisdiction. 

 5.    Additional Rights and Obligations. This Agreement is made
subject to and with the benefit of the respective provisions of the Asset Purchase Agreement (including, without limitation, the schedules and exhibits thereto). Purchaser and Sellers hereby agree and acknowledge that the execution and delivery of
this Agreement shall not expand, impair, supersede, modify, limit, extend, diminish, amend or in any way affect any of the rights, obligations, agreements, covenants, representations, warranties or indemnities contained in the Asset Purchase
Agreement, which shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the Asset Purchase Agreement and the terms hereof, the terms of the Asset Purchase
Agreement shall govern. 
 6.    Further Assurances. Sellers agree to cooperate with Purchaser and to execute and
deliver such further instruments and documents and, at each Seller’s expense, do all such further acts and things as Purchaser may reasonably be requested to do from time to time by Sellers in order to carry out the provisions and objectives of
this Agreement in accordance with the terms of the Asset Purchase Agreement. 
 [Remainder of page intentionally left blank] 

  
 -2- 

 IN WITNESS WHEREOF, the undersigned have executed, made and entered into this Agreement
under seal as of the date first set forth above. 
  

			
	ALEXION PHARMA HOLDING UNLIMITED COMPANY
		
	By:	 	
                     
                                         
                 

	Name:	 	
	Title:	 	

  
 [Signature Page to Bill
of Sale and Assignment and Assumption] 

 IN WITNESS WHEREOF, the undersigned have executed, made and entered into this Agreement
under seal as of the date first set forth above. 
  

			
	[●]	 	
		
	By:	 	
                     
                                         
          

	Name:	 	
	Title:	 	

  
 [Signature Page to Bill
of Sale and Assignment and Assumption] 

 IN WITNESS WHEREOF, the undersigned have executed, made and entered into this Agreement
under seal as of the date first set forth above. 
  

			
	ORIGIN BIOSCIENCES, INC.
		
	By:	 	
                     
                                         
      

	Name:	 	
	Title:	 	

  
 [Signature Page to Bill
of Sale and Assignment and Assumption] 

 Exhibit E 

PATENT ASSIGNMENT 
 This
PATENT ASSIGNMENT (“Assignment”) is dated as of [            ], 2018, by and between Alexion Pharmaceuticals, Inc. (the “Assignor”) and Origin Biosciences,
Inc. (the “Assignee”). 
 RECITALS 

WHEREAS, pursuant to that certain Asset Purchase Agreement by and among Alexion Pharma Holding Unlimited Company, Assignee and BridgeBio
Pharma, LLC (solely for the purposes of Section 6.14) dated as of June 7, 2018 (the “Asset Purchase Agreement”), Assignor has agreed to assign to the Assignee all of the Assignor’s right, title, and interest in, to
and under the patents listed on Schedule A hereto (collectively, the “Patents”). 
 NOW, THEREFORE, in consideration
of the Asset Purchase Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor and the Assignee agree as follows: 

1.    Assignment. Assignor does hereby sell, assign, convey and transfer to the Assignee or its designee, and to
their respective successors, assigns, or other legal representatives, Assignor’s entire right, title, and interest in and to the Patents, together with the right to claim priority in the United States and before any international conventions
and any other foreign jurisdictions, and continuations, continuations-in-part, divisionals, reissues, reexaminations, extensions, modifications, substitutions, and where
relevant supplementary protection certificates, and the rights to all income, royalties, or payments due or payable as of the effective date of this assignment or thereafter, including, without limitation, all claims for damages by reason of past,
present, or future infringement or other unauthorized use of the Patents with the right to sue for and collect the same for the Assignee’s own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal
representatives. 
 2.    Miscellaneous. This Assignment shall be governed by and construed in accordance with
the laws of the State of Delaware, without regard to the conflicts of law, principles or rules of such state, to the extent such principles or rules are not mandatorily applicable by statute and would permit or require the application of the laws of
another jurisdiction. In the event that any provision of this Assignment shall be construed to conflict with a provision in the Asset Purchase Agreement, the provision in the Asset Purchase Agreement shall control. 

[Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the undersigned have executed, made and entered into this Assignment
under seal as of the date first set forth above. 
  

			
	ASSIGNOR:
	ALEXION PHARMACEUTICALS, INC.
		
	By:	 	
                     
    

	Name:	 	
	Title:	 	

 [Jurisdiction] 

                     [city/county]
                                        ,
ss. 
 On this      day of             , 2018, before me, the
undersigned notary public, 

            Day            Month 

personally appeared
                                         
                                         
                                         
                                         
                , 
 Name (s) of Signer(s) 

proved to me through satisfactory evidence of identification, which 

was/were                        
                                         
                                         
                                         
                                         
                             , 

Description of Evidence of Identity 
 to be the
person(s) whose name(s) is/are signed on the preceding or attached document, and acknowledged to me that he/she/they signed it voluntarily for its stated purpose. 

 

			
	as
                                         
                                    for
	      Title of Office
	
	                                    
                                    , a corporation.
	
	  
 Signature of Notary
Public

 Place Notary Seal and/or Stamp above 

  
 [Signature Page to Patent
Assignment] 

 IN WITNESS WHEREOF, the undersigned have executed, made and entered into this Assignment
under seal as of the date first set forth above. 
  

			
	ASSIGNEE:
	ORIGIN BIOSCIENCES, INC.
		
	By:	 	
                     
        

	Name:	 	
	Title:	 	

 [Jurisdiction] 

                     [city/county]
                                        ,
ss. 
 On this      day of             , 2018, before me, the
undersigned notary public, 
             Day
             Month 
 personally appeared
                                         
                                         
                                         
                                         
            , 
 Name (s) of Signer(s) 

proved to me through satisfactory evidence of identification, which 

was/were                        
                                         
                                         
                                         
                                         
                             , 

Description of Evidence of Identity 
 to be the
person(s) whose name(s) is/are signed on the preceding or attached document, and acknowledged to me that he/she/they signed it voluntarily for its stated purpose. 

 

			
	as
                                         
                    for
	      Title of Office
	
	                                    
                        , a corporation.
	
	  
 Signature of Notary
Public

 Place Notary Seal and/or Stamp above 

  
 [Signature Page to Patent
Assignment] 

 Schedule A 

Patents 
 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 Exhibit F 

OFFICER’S CERTIFICATE 

OF 
 ORIGIN BIOSCIENCES,
INC. 
 [***] 
 This
certificate is being delivered pursuant to Section 7.02(d) of that certain Asset Purchase Agreement, by and among Alexion Pharma Holding Unlimited Company (“Seller”), Origin Biosciences, Inc. (“Purchaser”) and
BridgeBio Pharma, LLC (solely for the purposes of Section 6.14) dated as of June 7, 2018 (the “Asset Purchase Agreement”). All capitalized terms used but not defined herein shall have the meanings assigned to them in the
Asset Purchase Agreement, unless they are specifically otherwise defined herein. 
 The undersigned, Neil Kumar, in his capacity as
President of the Purchaser, and not in his personal capacity and without personal liability, hereby certifies that: 

1.    The representations and warranties of Purchaser contained in the Asset Purchase Agreement and in any certificate
delivered by Purchaser pursuant to the Asset Purchase Agreement, to the extent not qualified by materiality, are true and correct in all material respects as of the Effective Date and are true and correct in all material respects at and as of the
Closing Date as if made at and as of such date and the representations and warranties of Purchaser contained in the Asset Purchase Agreement and in any certificate or other writing delivered by them pursuant to the Asset Purchase Agreement, to the
extent qualified by materiality, are true and correct in all respects as of the Effective Date and at and as of the Closing Date as if made at and as of such date. 

2.    Purchaser has performed and complied in all material respects with all of its covenants and agreements under the
Asset Purchase Agreement to be complied with and performed by Purchaser at or before the Closing. 
 [Signatures on
following page] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 IN WITNESS WHEREOF, I cause this certificate to be executed as of the date first
written above. 
  

			
	  

	Name:	 	Neil Kumar
	Title:	 	President

  
 [Signature Page to
Purchaser’s Officer’s Certificate] 

 Exhibit G 

SECRETARY’S CERTIFICATE 

OF 
 ORIGIN BIOSCIENCES,
INC. 
 [***] 
 This
certificate is being delivered pursuant to Section 7.02(d) of that certain Asset Purchase Agreement, by and among Alexion Pharma Holding Unlimited Company (“Seller”), Origin Biosciences, Inc. (“Purchaser”) and
BridgeBio Pharma, LLC (solely for the purposes of Section 6.14) dated as of June 7, 2018 (the “Asset Purchase Agreement”). All capitalized terms used but not defined herein shall have the meanings assigned to them in the
Asset Purchase Agreement, unless they are specifically otherwise defined herein. 
 The undersigned, being the Secretary of Purchaser,
hereby certifies in its capacity as Secretary and not in its personal capacity and without personal liability, hereby certifies that: 

1.    The undersigned is the Secretary of the Purchaser and as such the undersigned is familiar with the corporate affairs
and records of the Purchaser. 
 2.    Attached hereto as Exhibit A is a true, complete and correct copy of the
Certificate of Incorporation of the Purchaser and all amendments thereto, issued on [***] by the Delaware Secretary of State. There have been no further amendments to said Certificate of Incorporation since the said date, and said Certificate of
Incorporation is in full force and effect as of the date hereof. 
 3.    Attached here to as Exhibit B is a
true, complete and correct copy of the current By-laws of the Purchaser adopted on [***]. There have been no amendments to said By-laws since said date, and said By-laws are in full force and effect as of the date hereof. 
 4.    Attached hereto
as Exhibit C is a true, complete and correct copy of the resolutions of the Board of Directors of the Purchaser effective as of [***] authorizing the Purchaser to enter into the Asset Purchase Agreement and to consummate the Transactions.

 [Signatures on following page] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

 IN WITNESS WHEREOF, I cause this certificate to be executed as of the date first
written above. 
  

			
	ORIGIN BIOSCIENCES, INC.

 
			
		
	By:	 	  

	Name:	 	Michael Henderson
	Title:	 	Secretary

  

  
 [Signature Page to
Purchaser’s Secretary’s Certificate] 

 Exhibit A 

Certificate of Incorporation 

 Exhibit B 

By-laws 

 Exhibit C 

Resolution of the Board of Directors

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]